Studies of the hormonal control of renal function in normal man and in type 1 (insulin-dependent) diabetes mellitus by Eadington, David William
STUDIES OF THE HORMONAL CONTROL OF
RENAL FUNCTION IN NORMAL MAN AND IN TYPE 1
(INSULIN-DEPENDENT) DIABETES MELLITUS.
David William Eadington
BSC(Hons) / MB ChB, MRCP(UK).










CHAPTER ONE: THE CONTROL OF RENAL SODIUM HANDLING. 1
1.1 The Importance of Sodium Balance. 2
1.2 Afferent Mechanisms. 4
1.2.1 Extrarenal Sensors. 5
1.2.1.1 Intrathoracic Volume Receptors. 5
1.2.1.2 Arterial Volume Receptors 6
and Baroreceptors.
1.2.1.3 Central Nervous System 7
Volume Receptors.
1.2.1.4 Hepatoportal Volume Receptors. 8
1.2.2 Intrarenal Sensors. 8
1.3 Efferent Mechanisms. 9
1.3.1 Physical Factors. 9
1.3.1.1 Glomerular Filtration Rate and
Glomerulotubular Balance. 9
1.3.1.2 Peritubular Capillary Forces. 10
1.3.1.3 Renal Nerves. 13
1.3.1.4 Medullary Blood Flow, Interstitial 15
Solute Composition, and Distal
Tubular Reabsorption.
1.3.2 Hormonal Factors. 16
1.3.2.1 Renin-Angiotensin-Aldosterone Axis. 16
1.3.2.1.1 Renin. 18




1.3.2.4 Kallikrein-Kinin System. 33
1.3.2.5 Other Hormonal Factors. 35
1.4 Renal-Body Fluid Feedback Control 36
of Arterial Blood Pressure.
1.5 Renal Autoregulation and Tubuloglomerular 40
Feedback.
1.5.1 Afferent Mechanism. 42
1.5.2 Effector Mechanism. 43
1.5.3 Mediating Mechanisms. 44
1.5.4 Integration of the renal response. 46
ii
CHAPTER TWO: RENAL FUNCTION IN DIABETES MELLITUS. 48
2.1 Natural History of Diabetic Nephropathy. 49
2.2 Renal Haemodynamics in Type 1 Diabetes. 53
2.2.1 Determinants of increased GFR. 54
2.2.2 Mechanisms of GFR elevation. 56
2.2.3 Glomerular Hyperfiltration as an 60
Initiator of Renal Injury ?
2.3 Hypertension and Nephropathy 64
in Diabetes Mellitus.
2.4 Sodium Homeostasis in Diabetes. 68
2.4.1 Exchangeable Sodium. 69
2.4.2 Mechanisms of Sodium Retention. 72
2.4.2.1 Sodium-glucose cotransport. 7 2
2.4.2.2 Insulin 73
2.4.2.3 Physical and hormonal factors. 75
2.5 Cardiovascular Reactivity in Diabetes 77
and Diabetes-Associated Hypertension.
CHAPTER THREE: AIMS AND METHODS. 81
3.1 Aims of The Work. 82
3.2 Ethical Approval. 83
3.3 Experimental Protocols. 83
3.3.1 Experimental changes in RAAS activity: 83
angiotensin II infusion or converting
enzyme inhibition?
3.3.2 Experimental design. 85
3.4 Analytical Methods. 90
3.4.1 Renal Haemodynamics: the concept of 90
• clearance•.
3.4.1.1 Glomerular Filtration Rate. 92
3.4.1.2 Effective Renal Plasma Flow. 94
3.4.2 Hormonal Estimations. 95
3.4.2.1 Plasma Renin Activity. 95




3.4.4 Lithium estimation. 105
3.5 Calculations and Statistical Analyses. 112
iii
CHAPTER FOUR: THE ACTIONS OF EXOGENOUS






CHAPTER FIVE: EFFECT OF LITHIUM ON RESPONSES TO 128
ANGIOTENSIN II IN NORMAL MAN.
5.1 Lithium in Renal Physiology. 129
5.1.1 Protocol. 134
5.2 Results. 135
5.2.1 Hormonal responses. 135
5.2.2 Systemic responses. 135
5.2.3 Renal haemodynamics. 138
5.2.4 Electrolyte excretion. 141
5.2.5 Lithium clearance data. 143
5.3 Discussion. 145
CHAPTER SIX: RENAL RESPONSES TO EXOGENOUS 151




6.2.1 Systemic and hormonal responses. 155
6.2.2 Renal haemodynamics. 158
6.2.3 Sodium excretion. 160
6.3 Discussion. 162
CHAPTER SEVEN: EFFECT OF LITHIUM ON RESPONSES TO 167




7.2.1 Systemic responses. 171
7.2.2 Renal haemodynamics. 172
7.2.3 Sodium and water excretion. 177
7.3 Problems with comparisons between 179
diabetic and control groups
after lithium pretreatment.
iv
7.3.1. Effective renal plasma flow. 179
7.3.2. Glomerular filtration rate. 182
7.3.3. Effective renal vascular resistance. 182
7.3.4. Systemic blood pressure. 184
7.4 Validity of lithium clearance 186
as a tubular marker in diabetes.
7.4.1 Results. 187
7.5 Discussion. 191
CHAPTER EIGHT: RENAL TUBULAR SODIUM HANDLING AND 196




8.2.1 Proximal tubular sodium handling. 200
8.2.2. Distal tubular sodium handling. 203
8.2.3 Renal concentrating capacity 205
and water handling.
8.3 Discussion. 208
CHAPTER NINE: THE EFFECTS OF INSULIN ON RENAL 215




9.3.1 Dextrose utilisation during 221
insulin infusion.
9.3.2 General. 221
9.3.3 Renal haemodynamics. 225
9.3.4 Electrolyte and water excretion. 229
9.3.5 Lithium clearance data. 233
9.4 Discussion. 233
CHAPTER TEN: FINAL DISCUSSION AND CONCLUSIONS. 240
Bibliography. 252
Publications arising from this work. ix
v
UNIVERSITY OF EDINBURGH
ABSTRACT OF THESIS (Regulation 3.5.10)
Name ofCandidate
Address .. 7.^' Lasswade Road, Edinburgh, EH16 6SZ.
M.D. 17th December 1991
Degree Date
, rrrn . Studies of the hormonal control of renal function in normal man and inTitle of Thesis
Type 1 (insulin-dependent) diabetes mellitus.
No. ofwords in the main text of Thesis
Angiotensin II (ANGII) has profound effects on renal
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the effect on renal function of acute changes in
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a reduced suppression of plasma renin activity after
dietary sodium loading compared to control subjects.
The utility of lithium clearance as an indirect
marker of tubular sodium handling was then assessed.
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a blunted proximal antinatriuretic response to ANGII
infusion in IDDM, the severity of this abnormality
correlating with the level of chronic glycaemic control.
The urinary concentrating response to ANGII infusion is
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These results support the hypothesis that increased
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by increased activity of the endogenous intrarenal RAAS.
vi
Acknowledgements.
Many people have helped me to complete the studies
described in this thesis. Most of the work was done
during my tenure of a Lectureship funded through the
University of Edinburgh by the Sir Stanley Davidson
Trust. I am indebted to Dr Charles Swainson and
Professor I.A.D. Bouchier for their personal support,
and for giving me access to the facilities of the Medical
Renal Unit and the Department of Medicine of the Royal
Infirmary. My Adviser Professor M.R. Lee provided
thoughtful and forthright criticism which was always
useful. Dr B.M. Frier and Dr B.F. Clarke kindly
allowed me to study patients under their care in the
Department of Diabetes of the Royal Infirmary. I am
especially grateful to Dr A.T. Lambie for stimulating my
interest in renal physiology, and for valuable
discussions during the preparation of the thesis.
Patricia Swan and Sheena Rowbottom provided expert
technical help with chemical assays. Eileen MacDonald
taught me the practicalities of radioimmunoassay, and
performed many of the hormonal estimations. Mr Neil
Johnston and Mr R.R. Samson did the urinary dopamine
estimations.
Finally and most importantly, none of the work would
have been successful without the enthusiastic cooperation
that I received from all the normal subjects and diabetic
patients who took part in the studies.
vii
DECLARATION.
The studies described in this thesis were performed
while I was working in the Medical Renal Unit of the
Royal Infirmary, Edinburgh, between December 1988 and
October 1991. I received technical assistance which has
already been acknowledged. I was entirely responsible
for the planning and execution of the studies, and for
all the data analysis. The composition of the thesis is
also my own work. This thesis has not previously been






THE CONTROL OF RENAL
SODIUM HANDLING IN NORMAL MAN.
"The kidney presents in the highest
degree the phenomenon of 'sensibility',
the power of reacting to various stimuli
in a direction which is appropriate for
the survival of the organism; a power of
adaptation which almost gives one the




1.1 THE IMPORTANCE OF SODIUM BALANCE.
An appropriately filled extracellular fluid (ECF)
space and an adequate plasma volume delivering oxygen to
cells at an optimal rate and pressure are fundamental
requirements for normal tissue metabolism. The sodium
ion plays a central role in the regulation of ECF volume.
The tonicity of the ECF is maintained within strict
limits, and water equilibrates across cell membranes
according to osmotic gradients, so that ECF volume is
determined by the total osmolar content of the
extracellular fluids. Sodium is actively excluded from
the intracellular space, and sodium salts comprise more
than 90% of the osmolar content of the ECF, making the
ECF sodium content the major determinant of
interstitial fluid and plasma volume. Plasma volume in
health is maintained within narrow limits, and a complex
hierarchy of interacting physical and hormonal systems
has evolved in order to preserve sodium balance.
Disturbance of these mechanisms in disease states leads
to abnormal sodium homeostasis.
Sodium balance exists when dietary sodium intake and
sodium excretion are equal. The preservation of normal
ECF and plasma volume requires the maintenance of
appropriate levels of sodium excretion in the face of
potentially wide variations in sodium intake, and the
pivotal role of the kidney in achieving this has been
recognized for many years (Starling, 1909). Important
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insights into the renal regulation of sodium balance in
humans first came from balance studies (McCance RA, 1935;
Strauss et al, 1958). These showed that when an
individual in balance on a low sodium diet changes to a
diet containing 150 mmol/day, urinary sodium excretion
increases over 3-5 days until sodium output matches the
new input. Attainment of this new steady state involves
small increases in weight, total exchangeable sodium,
plasma volume and venous pressure, changes which are
reversible when sodium intake is reduced. Sodium balance
is therefore normally maintained around a notional 'set
point', arbitrarily defined as the amount of sodium
chloride in the body when an individual is in balance on
zero salt intake (allowing for small obligatory losses in
sweat and faeces) (Hollenberg, 1980). An individual on a
10 mmol sodium diet will thus excrete an extra sodium
load, even if only a small additional amount is given,
while the detection of a sodium deficit will lead to
retention of sodium by the kidney until the 'set point'
is regained and sodium balance restored.
Sodium balance is maintained by a feedback mechanism
with afferent sensing limbs and a range of coordinated
effector responses. Under resting conditions about one
quarter of the cardiac output enters the kidneys, which
each day filter more than 25 mols of sodium (about eight
times the total exchangeable body sodium content).
Against this background of high turnover, small changes
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in the filtered load of sodium or in tubular reabsorption
produce rapid and substantial changes in sodium
excretion.
Understanding of the mechanisms controlling renal
sodium excretion followed the development of methods for
studying renal function first in animals and later in man
(reviewed by Smith, 1951). Newer in vitro techniques
have continued to expand knowledge of the control of
glomerular and tubular haemodynamics, tubular transport,
tubular transport and the electrical events which
accompany it, and the effects of hormones and drugs on
the kidney. However, a problem remaining in such studies
is the identification of those phenomena which are
physiologically relevant, particularly when studies of
normal kidney function are extended to disease states
in which renal sodium handling is abnormal.
Traditional in vivo human renal physiology still
contributes useful information under these circumstances.
1.2 AFFERENT MECHANISMS.
The maintenance of a normal ECF volume is essential,
and volume sensors are present in both the venous and the
arterial circuits, and within the kidney itself, to
provide information on the "effective volume" or
"fullness" of the circulation, ie the relationship of
plasma volume to the capacitance of the vascular space.
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1.2.1 Extrarenal Sensors.
1.2.1.1 Intrathoracic Low Pressure Volume Receptors.
The distensible low pressure venous compartment is
well suited for detection of small changes in circulating
blood volume. A variety of neural receptors which alter
their discharge rate according to changes in mechanical
stretch and in transmural pressure have been found in the
great veins and in the cardiac chambers (Gauer et al,
1970). In the cardiac atria two classes of mechano-
receptor are found, Type A receptors discharging during
atrial systole independently of atrial volume (Arndt et
al, 1971), and Type B receptors which discharge during
atrial filling and are sensitive to changes in atrial
volume (Paintal, 1973). Studies in the conscious dog
show the effectiveness of this volume receptor reflex in
controlling sodium and water excretion (Goetz et al,
1970). Ventricular receptors may also modulate renal
sodium excretion since stimulation of right ventricular
afferent nerves causes a prompt natriuresis (Wennergren
et al, 1976). Juxtapulmonary capillary (J) receptors
have been found in the interstitium of the lung (Paintal,
1973), an ideal situation to detect early interstitial
oedema.
Afferent signals from these receptors travel along
cranial nerves 9 and 10 to hypothalamic and medullary
centres where inputs from volume and osmotic receptors
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can theoretically interact. Evidence that intrathoracic
blood volume does affect sodium excretion comes from
studies utilising manouevres which increase venous return
such as tilting (Hulet and Smith, 1961), zero gravity
(Gauer and Henry, 1976), negative pressure respiration
(Gauer et al, 1954) and head-out water immersion (Epstein
et al, 1978), all of which are accompanied by a
natriuretic response. These experiments, however, do not
prove that the response is mediated by a neural pathway.
The importance of neural afferent input is supported by
the abolition of the natriuresis accompanying volume
expansion after cervical vagotomy (Atkins and Pearce,
1959). However, other workers have not detected any
change in the natriuretic response to volume expansion
after either cardiac denervation or cervical vagotomy
(Knox et al, 1967; Gilmore and Zucker, 1978). It
therefore seems that intrathoracic volume receptors do
exist and may modulate sodium excretion, but other
factors must also operate to sense the effective volume
of the ECF space.
1.2.1.2 Arterial Volume Receptors and Baroreceptors.
The arterial portion of the circulation is smaller
and less distensible than the venous compartment. The
existence of arterial volume receptors was first
suspected after the observation in man that closure of a
traumatic atrio-ventricular fistula increased diastolic
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pressure and caused natriuresis despite a fall in right
atrial pressure and cardiac output, and without any
measurable changes in glomerular filtration rate or renal
blood flow (Epstein et al, 1953). In these
circumstances natriuresis occurs because the kidney
responds more to the increase in effective filling of the
arterial tree than to the decreased filling of the venous
system. The carotid sinus baroreceptor (Guyton et al,
1952) is a likely candidate for the sensor; traction on
the baroreceptor in unanaesthetised rats leads to
natriuresis (Keeler, 1974), while bilateral carotid
ligation is antinatriuretic (Prosnitz, 1977), the reflex
being dependent on an increase in renal sympathetic nerve
activity.
1.2.1.3 Central Nervous System Volume Receptors.
The possibility of intracerebral interaction between
stimuli arising from extracranial 'volume' and osmotic
receptors has been mentioned. Intracranial receptors
monitoring sodium balance also exist; an increase in
cerebrospinal fluid sodium concentration promptly
increases sodium excretion (Passo et al, 1975), as does
infusion of a small amount of hypertonic saline into the
carotid artery (Thornborough et al, 1973). It is not
known if these receptors play a physiological role in
sodium homeostasis.
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1.2.1.4 Hepatoportal Volume Receptors.
The notion that the liver may modulate renal
excretion of salt and water is plausible, since it is
ideally placed to detect changes in sodium absorption
from the gut into the portal vein. Experimental support
for hepatic sensing is provided by the greater
natriuresis seen after infusion of hypertonic saline into
the portal vein than after systemic infusion (Daly et al,
1967), and the larger increment in sodium excretion when
a sodium load is given orally rather than intravenously
(Carey, 1978). These observations have not been
confirmed in all studies (Obika et al, 1981).
1.2.2 Intrarenal Sensors.
The initial evidence for a separate intrarenal
volume sensor came from studies of the isolated perfused
kidney preparation, in which an increase in perfusion
pressure suppressed renal renin and angiotensin II
formation (Tobian et al, 1959). The demonstration of
this relationship in the non-filtering kidney established
the existence of a renal afferent arteriolar baroreceptor
located in the juxtaglomerular apparatus (Blaine et al,
1970). Intrarenal mechanoreceptors that sense changes in
subcapsular and interstitial pressure have also been
identified (Burnett and Knox, 1980).
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1.3 EFFERENT MECHANISMS.
The kidney responds to physical, neural and hormonal
stimuli, and urinary sodium output is the net result of
the combined activities of each input. The physiological
importance of a particular mechanism under different
conditions, and its interaction with other systems, is
frequently not clear.
1.3.1 PHYSICAL FACTORS.
1.3.1.1 Glomerular Filtration Rate and
Glomerulotubular Balance.
During ECF volume expansion whole kidney glomerular
filtration rate increases (Osgood et al, 1978), but the
natriuresis of volume expansion persists when the
filtered load of sodium is held constant or even reduced
(DeWardener et al, 1961). However if glomerular
filtration rate, and hence the filtered load of sodium,
is increased by manoeuvres other than volume expansion
there is little if any change in fractional sodium
excretion (Lindheimer et al, 1967). The occurrence of
these proportional changes in the tubular reabsorption of
sodium which maintain constancy of sodium excretion in
the face of alterations in glomerular filtration rate,
glomerulotubular balance, was suspected many years
(Walker et al, 1941) before its confirmation (Giebisch et
al, 1964). The phenomenon prevents changes in glomerular
filtration rate, which cause large changes in the
filtered load of sodium, from destabilising sodium
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balance. The existence of glomerulotubular balance has
been confirmed in whole animal studies, in the isolated
perfused kidney preparation, and by micropuncture
experiments (Reineck et al, 1985). The renal tubules,
especially the proximal segment, play a major role in the
process.
1.3.1.2 Peritubular Capillary Starling Forces.
About 60% of the filtered load of sodium is
reabsorbed in the proximal tubule. Reabsorption of fluid
in this segment is for all practical purposes
iso-osmotic, sodium entering the tubular cell from the
urinary space across the apical membrane by passive
transfer down an electrochemical gradient. Its transfer
is linked to the transport of other ions and solutes in
both electrogenic and electroneutral processes. The
active transport of sodium across the basolateral
membrane of the proximal tubular cells is mediated by the
Na+-K+-ATPase complex. The final stage of reabsorption,
uptake of fluid from the interstitium into the
peritubular capillaries, is determined by the passive
Starling forces which govern all capillary transport
systems. Fluid flux may be simplistically represented
as:
Flux - Kffffc -TTi) - (Po - P.)
whereTT and Tf. are the oncotic pressures and P and P.
c l c l
the hydrostatic pressures in the capillary lumen and the
10
interstitium respectively, and Kf is the ultrafiltration
coefficient, a measure of capillary permeability. The
postglomerular capillary plasma has a high oncotic
pressure following filtration of albumin-free fluid into
the urinary space, while efferent arteriolar resistance
reduces postglomerular capillary hydrostatic pressure.
The rate of sodium uptake therefore depends on the
balance between these two opposing forces, which normally
favours reabsorption of fluid and sodium in the proximal
tubule (Knox et al, 1983), and to a lesser extent on the
plasma flow rate which determines the rate of delivery of
oncotically active particles. Peritubular oncotic
pressure is also important, and a direct relationship has
been shown between proximal sodium reabsorption and the
peritubular oncotic pressure ''Brenner et al, 1969) ,
although other studies did not confirm this (Holgreve and
Schrier, 1975). When glomerular filtration rate alters
without a change in renal plasma flow, peritubular
capillary oncotic pressure varies in parallel with the
filtration fraction, the fraction of plasma water
extracted from plasma during glomerular filtration. A
fall in glomerular filtration rate reduces the filtration
fraction and tends to reduce fractional tubular sodium
reabsorption, maintaining glomerulotubular balance.
The importance of Starling forces is not
incompatible with the simultaneous occurrence of active
sodium reabsorption in the proximal tubule, and both
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processes are accommodated by the "pump-leak" model of
reabsorption, in which alterations in the physical forces
influence the rate of uptake of reabsorbate from the
interstitial space. If the balance of physical forces
favours fluid rejection, interstitial pressure will
increase, and fluid will leak back into the tubular lumen
across the tight junctions (Reineck et al, 1985). The
interdependence of active and passive processes is
further demonstrated by the abolition of the influence of
peritubular oncotic pressure on proximal reabsorption of
sodium after inhibition of active sodium transport by
ouabain (Green et al, 1974).
The disruption of glomerulotubular balance by volume
expansion with saline is mediated by a reduction in
fractional proximal sodium reabsorption. Intravenous
saline loading reduces plasma protein concentration and
thus plasma oncotic pressure, while plasma expansion with
hyperoncotic albumin produces a smaller increase in
sodium excretion than an eguivalent degree of expansion
induced with saline (Levy and Levinsky, 1972), further
supporting the importance of changes in peritubular
forces. Although the volumes of saline and albumin used
to change plasma oncotic pressure in these studies are
unphysiological, this does not rule out a physiological
role for physical forces under normal conditions.
Glomerulotubular balance is also disrupted by
changes in renal haemodynamics through changes in the
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filtration fraction, which is influenced by glomerular
efferent arteriolar tone and can modulate both
peritubular capillary oncotic and hydrostatic pressures.
Factors increasing renal blood flow usually reduce the
filtration fraction and facilitate sodium excretion, and
reflex efferent vasodilatation with a reduction in
filtration fraction may partly account for the phenomenon
of pressure natriuresis which will be discussed later.
The peritubular physical forces can thus be modified
both by haemodynamic and tubular events.
1.3.1.3 Renal Nerves.
The kidney is innervated by postganglionic
adrenergic vasomotor fibres, which travel with the main
renal artery and terminate on all arterial components,
particularly the afferent arterioles in the region of the
juxtaglomerular apparatus, and on both proximal and
distal tubules (Barajas, 1978). The renal nerves may
modulate sodium excretion by more than one mechanism.
Changes in plasma volume modulate peripheral sympathetic
outflow: in the dog a 15 mmHg increase in left atrial
pressure reduced renal nerve activity by 40% and
increased sodium excretion by 80% (Prosnitz and DiBona,
1978), and this response was abolished by cervical
vagotomy. There is also an inverse relationship between
pulmonary artery pressure and renal nerve activity
(Thames, 1982). Direct renal nerve stimulation reduces
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GFR and renal plasma flow via vascular alpha adrenergic
receptors, and concomitant renin release may contribute
to this. Sodium excretion may also be reduced in the
absence of any haemodynamic changes by low level nerve
stimulation, and micropuncture studies confirm that this
is a tubular effect (Bello-Reuss et al, 1976), also
mediated by alpha receptors (Chan, 1980). Renal nerve
stimulation activates the renin-angiotensin and
prostaglandin systems, but blockade of these with
saralasin and indomethacin does not attenuate the effects
of renal nerve stimulation (Zambraski and Di Bona, 1976).
The phenomenon of denervation natriuresis is well
documented in anaesthetised animals, but studies on
conscious dogs have failed to confirm that denervation
affects sodium output (Smith, 1951). Most evidence
suggests that the renal nerves are of minor importance
under normal conditions (Gottschalk, 1985), but under
some circumstances a physiological role may become
apparent, as when renally denervated dogs fail to
conserve sodium when placed on a low sodium diet
(DiBona and Sawin, 1983), a phenomenon also exhibited by
patients with idiopathic autonomic neuropathy (Bartter et
al, 1959) .
14
1.3.1.4 Medullary Blood Flow, Interstitial Solute
Composition, and Distal Tubular Reabsorption.
Alterations in medullary blood flow can alter the
solute composition and hypertonicity of the medullary
interstitium. This may be important in the regulation of
sodium transport in the medullary and papillary portion
of the collecting ducts (Osgood et al, 1978), for example
during volume expansion (Stein et al, 1976). A number of
hormones have definite effects on renal sodium handling
predominantly through a distal tubular action (i.e
aldosterone, corticosteroids, the atrial natriuretic
peptides, vasopressin), but the interactions between
medullary haemodynamic effects and these hormonal factors
are less well delineated than is the case in the proximal
tubule. It is clear however that most parts of the
distal nephron exhibit load dependency of reabsorption to
maintain glomerulotubular balance, and the coupling of
the transport functions of the various nephron segments
by changes in medullary interstitial solute composition
(Knepper and Burg, 1983) means that the amount of
sodium finally excreted in the urine depends more on
distal tubule and collecting duct function than on events
occurring in the proximal tubule (DeWardener, 1978) .
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1.3.2 HORMONAL FACTORS.
Many hormones alter renal sodium handling in acute
experiments, but a more restricted number have a proven
physiological role in normal man. This overview will
concentrate on the renin-angiotensin-aldosterone system
(RAAS), whose actions are examined in the studies which
follow. Other systems will be mentioned mainly to
highlight their interactions with the RAAS.
1.3.2.1 Renin-Angiotensin-Aldosterone Axis.
It is almost one hundred years since an extract from
a fresh rabbit kidney was shown to have pressor activity
(Tigerstedt and Bergman, 1898) . The active agent in
this extract was called renin, but its major role as a
homeostatic regulator was recognised only much later
(Goldblatt, 1934) . The basic elements of the renin-
angiotensin-aldosterone system (RAAS) are shown in Figure
1.1. Renin is formed by the processing of its precursor
prorenin in the juxtaglomerular cells. These are
specialised myoepithelial cells at the distal end of the
afferent arteriole which are apposed to an area of
specialised cells in the early distal tubule of the same
nephron called the macula densa. This juxtaglomerular
apparatus (JGA) contains all the elements needed to exert
feedback control on glomerular function at the single
nephron level. One of the principle functions of the
RAAS is the maintenance of normal glomerular filtration,
16
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sodium balance and blood pressure during periods of salt
depletion or reduced renal perfusion pressure. The
prevailing state of sodium balance is therefore an
important determinant of the activity of the system, and
the inverse relationship between dietary sodium intake
and the endogenous concentrations of renin and
angiotensin II (ANGII) (Hollenberg et al, 1972) is
teleologically appropriate, since as dietary sodium
intake falls the RAAS is progressively more activated and
capable of a prompt response if sodium homeostasis is
threatened.
1.3.2.1.1 Renin.
The proteolytic enzyme renin acts on the
liver-derived alpha-2-globulin angiotensinogen to yield
the decapeptide angiotensin I (ANGI). This has little
physiological activity, but is metabolised by a
converting enzyme to the potent octapeptide ANGII. ANGII
is hydrolysed by angiotensinases to the heptapeptide
ANGIII, which has some physiological activity but is less
important because of its short biological half-life.
Four inputs are accepted as particularly important
in modulating the secretion of renin from the JGA (Davis
and Freeman, 1976):
1. A reduction in renal perfusion pressure stimulates
renin secretion through the intrarenal baroreceptor in
the juxtaglomerular apparatus. Prostaglandins are able
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to stimulate renin release through the same mechanism
(Dunn, 1979).
2. Sympathetic nerve stimulation and circulating
catecholamines increase renin release via the beta-
adrenergic receptors on juxtaglomerular cells.
3. Angiotensin II produces feedback inhibition of
renin release (Vander and Geelhoed, 1965), the 'short-
feedback loop'.
4. Changes in macula densa chloride transport affect
renin release, modulating feedback-mediated changes in
renal haemodynamics which stabilize glomerular
filtration rate, a process called tubuloglomerular
feedback (see Chapter 1.5).
1.3.2.1.2 Angiotensin II.
Angiotensin II (ANGII) is the most significant
effector peptide of the RAAS. It is a potent constrictor
of vascular smooth muscle, systemic vasoconstriction
increasing effective ECF volume, peripheral vascular
resistance and arterial blood pressure. A renal
vasoconstrictor effect of ANGII is apparent at both
afferent and efferent glomerular arterioles (Steinhausen
et al, 1990; Edwards, 1983), but there is controversy as
to which site of action is more important
physiologically. In micropuncture studies ANGII
increases afferent arteriolar resistance only when
infused at doses which also increase blood pressure in
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the rat (Myers et al, 1975), the dog (Hall and Granger,
1986b) and the rabbit (Edwards, 1983), suggesting that
afferent constriction is a secondary 'myogenic' response,
4
and in vitro dose response curves demonstrate a 10 fold
greater sensitivity of the efferent arteriole to
exogenous ANGII when compared to the afferent
(Steinhausen et al, 1990). However, peritubular ANGII
infusion causes a prompt reduction in stop flow pressure
when afferent arterioles retain their normal structural
relations, implying predominantly preglomerular
vasoconstriction under these conditions (Mitchell and
Navar, 1987).
Support for a 'mixed' afferent/efferent site of
action for ANGII in vivo also comes from a theoretical
analysis of the changes in segmental renal resistances
accompanying vasoconstrictor stimuli (Smith, 1951). When
renal plasma flow is reduced by a 'pure' efferent
vasoconstrictor, GFR rises because increases in efferent
arteriolar resistance elevate intraglomerular capillary
pressure and hence the filtration fraction. A 'pure'
afferent constrictor reduces GFR in parallel with renal
plasma flow without changing the filtration fraction.
Finally, equal changes in afferent and efferent
resistance maintain GFR as renal plasma flow drops, the
effect of falling renal perfusion on GFR being exactly
compensated by the rise in intraglomerular pressure.
This last analysis is most compatible with the known
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action of ANGII to produce a minimal fall in GFR and a
modest rise in filtration fraction when renal perfusion
is compromised, an action which is apparent even when
myogenic afferent vasoconstriction is prevented by
administering ANGII intrarenally (Johnson and Malvin,
1977). It is therefore very likely that ANGII affects
both afferent and efferent arteriolar tone under
physiological conditions.
Many vasoconstrictors, including ANGII, are capable
of inducing glomerular mesangial cell contraction
(Yoshimoto et al, 1990). The speculation that the
contractile properties of the mesangium may be linked to
modulation of the glomerular capillary ultrafiltration
coefficient Kf through changes in the filtering surface
area has recently been demonstrated in vivo (Fogo et al,
1990). ANGII-induced changes in Kf (Blantz et al, 1976)
therefore provide a further mechanism by which ANGII may
modulate GFR without directly affecting intrarenal
resistances. The capacity for ANGII to affect
structure-function relationships within the kidney is
also reflected in its effects on mesangial macromolecular
trafficking (Singhal et al, 1990), cell growth and
hypertrophy (Berk et al, 1989), and extracellular matrix
accumulation (Homma et al, 1990), topics which are beyond
the scope of this review.
ANGII affects renal sodium excretion by several
distinct but interconnected mechanisms. The importance
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of these direct effects outweighs the indirect effects of
ANGII-stimulated aldosterone release from the adrenal
cortex (Laragh and Sealey, 1973). Sodium excretion
during ANGII infusion shows a biphasic dose response
pattern, with antinatriuresis at low infusion rates but
increased sodium excretion at high doses (Barraclough,
1965). Interpretation of these studies is complicated by
large and variable changes in glomerular filtration rate
and renal plasma flow, but intrarenal infusion of
angiotensin II produces the same biphasic response, so
that systemic 'pressure-natriuresis' is not the only
explanation (Waugh, 1972). The physiological relevance
of the natriuretic action of ANGII at high doses is
questionable because the circulating levels produced far
exceed those attained by endogenous production (Johnson
and Malvin, 1977), but the increase in whole kidney
filtration fraction produced by physiological doses of
ANGII increases capillary oncotic pressure and reduces
peritubular capillary hydrostatic pressure, both changes
favouring an increase in sodium reabsorption at the
proximal tubule (Mujais, 1986).
ANGII can also directly promote proximal tubular
sodium reabsorption independent of haemodynamic effects
(Johnson and Malvin, 1977; Harris and Young, 1977;
Schuster et al, 1984). A bimodal effect is again
apparent, with inhibition of sodium reabsorption at high
concentrations and enhanced transport at lower levels
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which may relate to the way in which ANGII couples to its
receptors (Douglas et al, 1990). ANGII affects
epithelial function directly by occupying receptors on
the cell surface or indirectly by presynaptic receptors
which control catecholamine release from nerve terminals
on the cell. ANGII receptors exist on both luminal and
basolateral surfaces of proximal tubular cells (Brown and
Douglas, 1982; Brown and Douglas, 1983), which are also
richly innervated, giving the potential to use both
mechanisms.
The majority (85%) of sodium reabsorption in the
proximal tubule is linked to either bicarbonate or
chloride. Changes in sodium chloride transport occur
mainly through presynaptic receptors on renal nerves (Liu
and Cogan, 1989). ANGII predominantly affects
bicarbonate rather than chloride transport, via
epithelial cell receptors which enhance the activity of
the Na+-H+ antiporter, the major proximal tubular
acidification mechanism. This is achieved by reducing
the of the antiporter rather than by changes in vmax/
utilising inhibition of tubular adenylate cyclase as the
second messenger (Liu and Cogan, 1989). Additionally,
stimulation of glucose-linked sodium cotransport by ANGII
has recently been described (Garvin, 1990) ; this is
likely to be only a small component of total proximal
sodium reabsorption in the normal kidney, but may become
more significant when the filtered load of glucose is
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increased as in diabetes.
The bipolarity of ANGII signalling means that both
filtered and intravascular ANGII potentially have
physiological activity in the proximal tubule. The
ubiquitous presence of angiotensinogen mRNA in glomerular
and tubular cells, the capacity to endocytose
interstitial renin, and the ready availability of
converting enzyme makes local ANGII generation at various
intrarenal sites likely (Levens et al, 1981), especially
since intrarenal ANGII concentrations far exceed
circulating levels (Mendelsohn, 1979). Thus autocrine,
paracrine and endocrine mechanisms are all conceivable
for the control of proximal tubular function and the
regulation of intrarenal haemodynamics by ANGII (reviewed
by Carey, 1988).
ANGII regulation of proximal sodium chloride
transport does not exist in isolation, but affects
downstream tubular transport elements as well as
glomerular haemodynamics. The coordinated linkage of
filtered solute and proximal tubular reabsorption has
been described already, and the glomerular and tubular
actions of ANGII give it obvious potential as a mediator
of this response. As well as resetting glomerular
vascular resistances and Kf, ANGII modifies two other
factors which independently affect proximal tubular
sodium transport, neurogenic tone (via the presynaptic
receptors) and peritubular protein concentration (by
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changing the filtration fraction).
Abundant ANGII binding sites are found in the
medulla where ANGII may modulate medullary blood flow
(Cupples et al, 1988), but the physiological importance
of ANGII as a regulator of distal renal sodium and water
excretion remains uncertain and is probably limited in
comparison to its effect on proximal tubular events.
Loop of Henle sodium chloride reabsorption exhibits good
but not perfect load dependence, and increased ANGII
activity may also modulate sodium transport in the loop
by constricting the medullary circulation.
At the cellular level ANGII receptor numbers on
glomeruli are directly regulated by the circulating ANGII
level, with an increase in receptor density when plasma
ANGII is low, and a fall in density when plasma ANGII is
increased. Up- or down-regulation of receptor numbers
with increasing or decreasing dietary sodium intake is
not accompanied by any change in receptor affinity
(Bellucci and Wilkes, 1984). A 50% fall in ANGII
receptor density on human platelets occurs within 15
minutes of starting an infusion of ANGII, and is
maintained for up to 2 hours (Moore et al, 1984). This
is not an artefact due to receptor occupancy. Following
a change in dietary sodium intake an altered receptor
density is detectable after 2 days, concomitant with the
time scale of changes in plasma ANGII, which reaches a
new stable level after 6 days (Moore et al, 1984), and an
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increased ANGII receptor density accounts for the
enhanced sensitivity to exogenous ANGII seen in the renal
vasculature after sodium loading. The effect of the
plasma ANGII concentration on receptor density is
tissue-specific, the adrenal glomerulosa showing the
opposite pattern to that described above (Gordon et al,
1983). The effect of dietary sodium or plasma ANGII on
proximal tubular ANGII receptor density and affinity has
not yet been reported.
Many individual tissues have the capacity to
synthesize ANGI and ANGII, and the final response
probably represents a combination of the reaction to
circulating and locally generated ANGII, components which
may be separately regulated (Samani, 1991). The
concentrations of circulating renin and ANGII are not
therefore necessarily an accurate reflection of the
activity of the system in a particular tissue. All
components of the RAAS are also present in the brain, are
unable to cross the blood-brain barrier, and probably
operate independently of the systemic axis. However,
application of ANGII to the cerebral ventricles produces
a systemic pressor response in the rat (Al-Barazanji and
Balment, 1990), which may be partly due to facilitated
sympathetic outflow, providing another mechanism by which




Aldosterone secreted from the adrenal gland promotes
sodium retention in the distal tubule, acting on the
Na+-K+-ATPase system in the cortical collecting segment
(Gross, 1974). The circulating ANGII level is an
important regulator of aldosterone production, reflected
in the inverse relationship between dietary sodium intake
and the circulating level of both hormones (Best et al,
1971). Adrenal sensitivity to exogenous ANGII also
increases as dietary sodium intake falls (Gordon et al,
1983). The reduction of aldosterone levels in untreated
Addisons disease contributes to salt wasting, but these
patients maintain sodium balance on fixed physiological
replacement doses of glucocorticoid despite wide
variations in dietary sodium intake (Rosenbaum et al,
1959). Saline loading causes a natriuresis despite
exogenous mineralocorticoid excess (DeWardener et al,
1961; Singer et al, 1991), and chronic mineralocorticoid
administration causes only transient sodium retention,
followed by the phenomenon of "mineralocorticoid escape"
(Relman and Schwartz, 1952; August, 1958). These
findings all suggest that the maintenance of sodium
balance in healthy humans is not solely dependent on the




Dopamine is the precursor molecule for the synthesis
of the catecholamines noradrenaline and adrenaline.
Interest in its renal effects was stimulated by the
observation that intravenous infusion of pharmacological
doses of dopamine increases renal plasma flow, glomerular
filtration rate, and sodium and water excretion in both
dog and man (McDonald et al, 1964). The existence of a
highly specific renal vascular receptor (DA^ for
dopamine was subseguently confirmed, and dopamine
receptors are now classified as DA^ present at the
vascular receptor and in the renal proximal tubule, and
DA2, found in the post-ganglionic sympathetic neurone,
stimulation of which leads to emesis and the inhibition
of prolactin release (Goldberg, 1984).
The amount of dopamine in urine is ten to twenty
times greater than the urinary noradrenaline
concentration, while plasma dopamine concentrations are
much lower than noradrenaline, suggesting that dopamine
is synthesized within the kidney (reviewed by Lee, 1987) .
A physiological role for endogenous dopamine in renal
sodium handling is suggested by the increase in renal
dopamine synthesis which follows both acute and chronic
sodium loading (Ball et al, 1978), the parallel falls in
urinary DA output and sodium excretion following chronic
dopa decarboxylase inhibition (Ball et Lee, 1977), and
the blunting of saline-induced natriuresis after
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carbidopa administration in the dog (McClanachan et al,
1985) or dopaminergic blockade in man (Coruzzi et al,
1986). However, carbidopa does not influence the
natriuretic response to acute saline loading in normal
man (Jeffrey et al, 1989). The sensing mechanism for
dopamine formation is unknown but may depend on the
filtered load of sodium and chloride. Frusemide
increases urine dopamine output (Kuchel et al, 1978), but
inhibition of dopamine synthesis does not modify the
natriuretic response to frusemide (Jeffrey et al, 1987),
and the increased renal plasma flow following frusemide
administration is not dopamine dependent.
The interactions between dopamine and other
intrarenal hormone systems are relatively unexplored, but
there is some evidence that dopamine interacts with the
RAAS at several levels. The changes in responsiveness of
plasma aldosterone to exogenous ANGII infusion which
accompany changes in dietary sodium intake are modulated
by dopamine infusion (Drake and Carey, 1984; Connell et
al, 1987) and by dopaminergic blockade with
metoclopramide (Gordon et al, 1983). The dopaminergic
prodrug gamma-L-glutamyl-L-dopa (gludopa) increases urine
dopamine excretion several hundred-fold and reduces
plasma renin activity despite causing natriuresis and a
negative sodium balance (Worth et al, 1985), suggesting
that high intrarenal concentrations of dopamine may
directly inhibit renin release. Finally, acute
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angiotensin converting enzyme inhibition tends to
increase the rise in urine dopamine excretion produced by
frusemide, although the natriuretic response to frusemide
is not modified (MacDonald et al, 1990), suggesting that
changes in intrarenal ANGII levels within the
physiological range can modulate dopamine production.
Evidence of a physiological role for dopamine in the
kidney is complemented by abnormalities of dopamine
production in pathological states. Dopamine disappears
from the urine in patients with chronic renal failure
when the plasma creatinine exceeds 600 umol/1 (Itskovitz
and Gilberg, 1981), and patients with chronic renal
failure do not increase urinary dopamine excretion in the
normal way when given added dietary sodium (Casson et al,
1983). Secondly, when Caucasian patients with essential
hypertension are given added dietary sodium, urine
dopamine output paradoxically falls for two days before
rising towards the baseline values (Harvey et al, 1984),
in contrast to the prompt and sustained increase seen in
normotensive controls. The failure to mobilise dopamine
in response to sodium loading is likely to be a precursor
to and not a conseguence of hypertension because the
normal positive correlation between urine sodium
excretion and urine dopamine is absent in the
normotensive relatives of hypertensive patients (Saito et
al, 1986), and in normotensive black individuals
(Critchley et al, 1987) who respond in the same way as
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Caucasian hypertensives. This genetically determined
•dopamine defect' may contribute to the high incidence of
essential hypertension in negroid populations in
developed countries.
1.3.2.3 Prostaglandins.
Renal prostaglandins such as PGI2 (prostacyclin),
PGF2, pge2' PGD2 and thromboxane A2 are potential
modulators of renal haemodynamics and sodium excretion
(reviewed by Dunn, 1979). Prostaglandin synthesis is
regulated by angiotensin II, noradrenaline, vasopressin
and bradykinin. PGE2 and PGI2 are vasodilators which
antagonize the vasoconstrictor effects of ANGII (Aiken
and Vane, 1973), TxA2 (Anderson et al, 1976), and
catecholamines (Henrich et al, 1978a).
Prostaglandin production is compartmentalised within
the kidney, the principal synthetic sites being the
cortical arterioles (PGI2), and the glomerular mesangial
cells, medullary interstitial cells and collecting ducts
(PGE2). This anatomical segregation, and the problems of
assaying compounds with short biological half-lives, has
hampered attempts to assign physiological roles to the
various compounds, but they are believed to function more
by modulating other systems than as primary determinants
of renal function. In salt replete unstressed humans
endogenous prostaglandins do not affect renal plasma flow
or glomerular filtration rate, but when the RAAS is
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activated (by impaired renal perfusion or low dietary
sodium intake) inhibition of prostaglandin synthesis
produces clinically significant reductions in both renal
blood flow and GFR (Henrich et al, 1978b; Muther et al,
1981).
Prostaglandins exert a potentially pro-natriuretic
influence by several distinct mechanisms. Antagonism of
ANGII-mediated efferent arteriolar vasoconstriction
reduces the filtration fraction and so reduces proximal
tubular sodium reabsorption. Prostaglandins also reduce
medullary interstitial tonicity by increasing medullary
blood flow (Solez et al, 1974), reducing medullary urea
accumulation (Shimizu et al, 1969) and inhibiting sodium
reabsorption in the cortical collecting tubule (Stokes
and Kokko, 1977). PGE2 ma^ also decrease sodium
reabsorption in the medullary thick ascending limb
(Stokes, 1979). However, pharmacological doses have been
used in most studies, and exogenous administration cannot
reproduce the specific intrarenal localisation of
endogenous prostaglandins. Studies of the effect of
changing sodium balance on urinary prostaglandin
production have given confusing results, with salt
loading increasing, not affecting or even reducing
prostaglandin excretion in man and in animals. This may
reflect the difficulty of trying to use measurements of
total urinary prostaglandin excretion to detect small
changes in intrarenal prostaglandin production.
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1.3.2.4 Kallikrein-Kinin System.
Renal kallikrein is a serine protease which acts on
kininogen yielding the biologically active kinins
bradykinin, lys-bradykinin (kallidin), and met-lys-
bradykinin. These compounds are rapidly inactivated by
kininases present in both proximal and distal tubules
(reviewed by Scicli and Carretaro, 1986). All the
components of the kallikrein-kinin system exist within the
kidney, and the activity of the system is usually inferred
from measurements of the urinary excretion of kallikrein,
although the relationship of this parameter to intrarenal
kinin release is poorly defined. Because of the apparent
restriction of kinin synthesis to distal tubular elements
(Orstawik and Inagami, 1982) , the relevance of intrarenal
kallikrein to the regulation of renal haemodynamics and
tubular function has been questioned. However, the recent
demonstration of kallikrein-like granules and kallikrein
mRNA in the glomerular peripolar cell provides a mechanism
by which locally formed kallidin may gain access to the
glomerular vasculature and exert direct effects on renal
haemodynamics (Xiong et al, 1989).
The kallikrein-kinin system has a reciprocal
stimulatory relationship with the renal prostaglandins.
Kinins stimulate synthesis of phospholipase , releasing
arachidonic acid, while phospholipase Acan activate
membrane bound renal kallikrein, and prostaglandins also
increase urinary kallikrein excretion (Nasjletti and
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Malik, 1979). The rise in kallikrein excretion during low
dietary sodium intake (Margolius et al, 1974) supports the
hypothesis that prostaglandins and kinins act
synergistically to oppose the antinatriuretic and
vasoconstrictor effects of ANGII during salt depletion.
The conflicting evidence that acute intravenous salt
loading may increase kallikrein synthesis must be
interpreted in the light of the potential artefactual
effect of distal tubular 'washout* by the associated
diuresis (Grez et al, 1982). Intrarenal infusion of
kinins produces vasodilatation and natriuresis (Fadem,
1982) , and the administration of anti-kinin antibodies to
saline-expanded rats decreases sodium excretion (Grez,
1974) .
The kallikrein system interacts with the RAAS in
several ways. Urinary kallikrein activates prorenin in
vitro (Sealey et al, 1978) and bradykinin infusion
stimulates renin release in vivo (Flamenbaum et al,
1979) . Aldosterone is a powerful stimulus for renal
kallikrein synthesis (Margolius et al, 1976) . The kinin
degrading enzyme kininase II is identical to angiotensin
converting enzyme, so that increased kinin levels may
contribute to the effects of this class of drugs. This
question, and the physiological role of the kallikrein
system in sodium homeostasis, may be answered by studies
with the newly available specific kinin antagonists.
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1.3.2.5 Other Hormonal Factors.
There is experimental evidence for a distinct but
unidentified low molecular weight natriuretic hormone
involved in renal salt handling. Cross circulation
experiments in the dog (Buckalew and Nelson, 1974)
indicate the existence of a transferable hormonal factor,
which has also been found during volume expansion in
normal man (Epstein et al, 1978) and in patients with
chronic renal failure (Bourgoignie et al, 1974). The
factor may derive from the hypothalamus, is a normal
constituent of plasma, and inhibits sodium transport at
the nephron. Its action involves the inhibition of
Na+-K+-ATPase, and the same factor has been implicated in
the pathogenesis of essential hypertension, where
compensatory overactivity of the putative substance
increases sodium excretion by the kidney (DeWardener and
MacGregor, 1983).
Other substances affecting intrarenal haemodynamics
and tubular sodium transport in experimental studies
include the atrial natriuretic peptides, serotonin,
neuropeptide Y, adenosine, histamine, glucagon,
parathyroid hormone, calcitonin and insulin. With the
exception of ANP, the evidence that any of these has an
important influence on renal sodium handling in healthy
humans is highly speculative. Some are potentially
more important in disease states, as will be discussed
later in the case of insulin.
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1.4 RENAL-BODY FLUID FEEDBACK CONTROL OF ARTERIAL
BLOOD PRESSURE.
Changes in arterial pressure and renal perfusion
pressure influence the renal excretion of sodium and
water, to provide a negative feedback control on ECF
volume, a phenomenon known as 'pressure-natriuresis'
(Thompson and Dickinson, 1976). This feedback loop
(Figure 1.2) operates through the neurohumoral controls
described above to regulate blood pressure both acutely
and in the long term. According to this viewpoint
long-term blood pressure control is dictated primarily by
renal excretory function; persistently abnormal renal
haemodynamics or tubular reabsorption initiate a
resetting of the pressure-natriuresis mechanism so that
sodium balance is restored, but only at the expense of
hypertension. Changes in cardiac output or total
peripheral resistance are not considerd to be as a
primary 'cause' of hypertension, but merely a means of
adjusting blood pressure to the level required for the
prevailing renal excretory capacity.
An opposing view is that alteration of the pressure-
natriuresis mechanism is a secondary consequence of an
increase in arterial pressure (Omvik et al, 1980).
However, the observation that transplantation of a kidney
from a normotensive strain of rat into a genetically
hypertensive recipient reduced the recipient's blood




this is not the case. Experiments in the conscious dog
with chronic antinatriuretic influences such as
mineralocorticoid excess (Hall et al, 1984a) or ANGII
infusion (Hall et al, 1984b) also support the central
importance of pressure-natriuresis; when a rise in renal
perfusion pressure was prevented mechanically, relentless
sodium retention occurred and blood pressure rose without
plateauing until cardiovascular collapse ensued. When
renal perfusion pressure was then allowed to move in
parallel with systemic blood pressure there was a prompt
escape from sodium retention and a fall in arterial
pressure. Thus at least in these experimental situations
chronic hypertension is an essential compensatory
response to a primary inability of the kidney to excrete
appropriate amounts of sodium and water at normal
arterial pressure.
The acquisition of mechanisms to conserve sodium
probably conferred an evolutionary advantage when man
inhabited only salt-poor areas. Migration to temperate
habitats and the introduction of meat into the diet
produced a steady increase in dietary sodium intake, and
intrarenal mechanisms have evolved in parallel to allow
the excretion of large salt loads in order to maintain
sodium balance. Economic and social forces in the
developed world today encourage the consumption of a diet
with a relatively high sodium content, and a positive
association has been consistently found between the
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prevalence of essential hypertension in a population and
its dietary sodium intake (Intersalt, 1988). The
hypothesis has been advanced that all populations contain
individuals who through genetic variability are less
able to excrete dietary sodium loads efficiently, and
that in an indigent population which is acculturated to a
low salt diet there are likely to be more individuals who
are genetically •sodium-retainers'. If this sub-group of
the population is suddenly exposed to an increased
dietary salt intake, sodium balance can be maintained
only by increasing plasma volume and blood pressure in
order to produce a pressure-natriuresis. The high
incidence of volume-dependent hypertension in American
Negroes in comparison to American Caucasians may be an
example of this phenomenon (Brier et al, 1991) .
Renal abnormalities that cause hypertension commonly
increase the ratio of tubular sodium reabsorption to GFR.
This can be due to primary reductions in GFR (ie chronic
renal failure), increased preglomerular resistance
(Goldblatt hypertension), decreased Kf (glomerulo¬
nephritis) , or a primary increase in tubular reabsorption
(antinatriuretic hormones). As well as secondary
compensations which may obscure the initial abnormality,
circulatory changes due to increased arterial pressure
subsequently develop. Attempts to define any postulated
renal defect must therefore involve the study of subjects
during the earliest stages of the disorder.
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1.5 INTEGRATION OF THE RENAL RESPONSE: RENAL
AUTOREGULATION AND TUBULOGLOMERULAR FEEDBACK.
Three separate mechanisms operate to maintain the
stability of glomerular filtration in normal man. The
classical 'myogenic1 response buffers glomerular
filtration rate against sudden changes in systemic
arterial pressure by causing reflex changes in afferent
arteriolar tone. The renin-angiotensin system is
activated primarily when renal perfusion pressure falls,
maintaining GFR via an increase in efferent arteriolar
resistance. The existence of a third system, the
tubuloglomerular feedback mechanism (TGF) (Figure 1.3),
was first suspected after the demonstration that
injection of a solution with a high sodium chloride
concentration into the early distal tubule caused the
proximal tubule to collapse, implying a large fall in
glomerular filtration rate (Thurau and Schnermann, 1965).
Micropuncture studies have confirmed that individual
nephrons have a feedback mechanism which operates on the
afferent arteriole to stabilize GFR at normal systemic
arterial pressure (Navar et al, 1980; Schnermann and
Briggs, 1985; Wright and Briggs, 1979).
Although mostly studied in the rat, the existence of
TGF has been confirmed in the dog (Bell et al, 1978) and
in the isolated human kidney (Schnermann et al, 1977b).
The response exhibits nephron heterogeneity, with juxta-
medullary nephrons having a greater maximal response
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Figure 1.3: Simplified outline of proposed operation
of the tubuloglomerular feedback system.
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and a greater sensitivity to changes in tubular flow
rate than superficial nephrons (M=±=ller-Suur et al, 1983) .
About 50% of the maximal response occurs within a
physiological range of tubular flow rates in the rat
(10-20 nl/min), and the maximal sensitivity to changes in
tubular flow rate is also found within this span
(Schnermann and Briggs, 1985).
1.5.1 Afferent Mechanism.
A change in the composition of fluid reaching the
macula densa is essential to elicit a TGF response, since
changes in flow rate alone induced by mannitol have no
effect (Thurau and Schnermann, 1965). Sodium chloride
concentration in the early distal tubule is flow-
dependent, the change in tubular fluid composition
between the end of the thick ascending loop of Henle and
the macula densa being greatest at low flow rates. The
change in single nephron GFR is inversely related to the
macula densa NaCl concentration between 15-60 mM, and the
overall sensitivity of the system has been estimated to
be about 0.5 mlGFR.min 1.mM.[Na+] 1 (Schnermann et al,
1976).
The TGF response is independent of tubular fluid
osmolarity at constant NaCl concentrations, and
proximally acting diuretics such as carbonic anhydrase
inhibitors do not affect responsiveness (Wright and
Schnermann, 1974). However, inhibition of sodium
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chloride transport in the thick ascending loop of Henle
with either diuretics or metabolic inhibitors does block
the TGF response (Wright and Schnermann,1974), as does
replacement of chloride in the perfusion fluid with a
variety of other anions (Schnermann et al, 1976). This
suggests that changes in macula densa transport activity
rather than changes in luminal NaCl concentrations
initiate the subseguent vascular response, a hypothesis
which has recently received direct experimental support
(Ito and Carretero, 1991).
1.5.2 Effector Mechanism.
The glomerular vasoconstriction produced by the TGF
response is consistently localised to the afferent
arteriole (Schnermann et al, 1980). Most functional
studies report a fall in filtration fraction and
intraglomerular pressure which is also consistent with an
afferent response (Wright and Briggs, 1979). Conflicting
evidence showing a constant intraglomerular pressure
during high tubular flow rates (Ichikawa, 1982) ,
suggesting 'balanced' afferent-efferent vasoconstriction,
may reflect differences in the range of tubular flow
rates studied.
TGF responsiveness is very sensitive to changes in
volume status. Acute infusion of isotonic saline
(Persson et al, 1979b) or isotonic plasma (Ploth et al,
1978) suppresses feedback activity, and responsiveness is
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preserved during volume depletion or hypotension (Kaufman
et al, 1982; Bell et al, 1979). Changes in TGF after
chronic stimulation follow the same pattern, with a high
dietary sodium intake suppressing feedback responses (Dev
et al, 1974) and sodium and water depletion (Persson et
al, 1982) and ureteric occlusion (Morsing and Persson,
1991) accentuating the activity of the system. Resetting
of TGF involves unknown mechanisms. An increase in net
interstitial pressure is common to the situations in
which the response is suppressed (Persson et al, 1979a),
and this might be translated into changes in
juxtaglomerular cell volume. Luminal factors have also
been proposed (Blantz et al, 1982; Haberle and Davis,
1984) .
1.5.3 Mediating Mechanisms.
No single mediator of the TGF pathway has been
firmly established. Circulating ANGII is not likely to
be relevant: hypertonic saline infusion (increasing
distal tubular flow rate of sodium) depresses plasma
renin activity despite causing renal vasoconstriction
(Nashat et al, 1976), and hypotension increases renin
release (Davis and Freeman, 1976) despite renal
vasodilatation which is at least partly feedback-mediated
(Schnermann and Briggs, 1981).
A 'paracrine' role for ANGII formed locally in the
JGA is a more plausible suggestion, because perfusion of
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the loop of Henle with saline increases JGA renin
activation (Thurau et al, 1972) only when TGF is active,
and not when feedback responses are blocked (Wright and
Schnermann, 1974). TGF responses are also reduced in
kidneys depleted of renin by sodium loading (Schnermann
et al, 1975) or by creation of a contralateral renal
artery stenosis (Ploth et al, 1977). However, the
restoration of TGF activity after acute volume depletion
in sodium-expanded rats without any change in renal renin
content (Moore and Mason, 1983) emphasises that the above
results show only parallel shifts in the two systems and
do not prove a direct causal role for intrarenal ANGII.
Furthermore, both ACE inhibitors (Ploth et al, 1979) and
the ANGII receptor-blocking agent saralasin (Ploth et al,
1982) reversibly reduce TGF responsiveness, but can not
abolish the response completely even at high doses,
further suggesting that ANGII is a modulator rather than
a mediator of the response. Blockade of renal
prostaglandins with indomethacin reduces TGF activity
only in salt replete states, and does not modulate
responsiveness in salt-depleted animals when TGF is most
activated. Renal nerves have no direct influence
(Schnermann et al, 1977a), but may act indirectly through
stimulation of the renin-angiotensin system (Stowe et al,
1979) .
The evidence favouring adenosine as a local mediator
is more convincing: TGF is blocked by administration of
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theophyllines (Osswald et al, 1980) either from the
vascular or the luminal side, and by adenosine deaminase
(Osswald et al, 1982). Dipyridamole, which increases
extracellular adenosine concentrations, augments TGF
(Osswald et al, 1980). The working hypothesis that
adenosine is formed as an intracellular messenger in
response to macula densa NaCl transport is also
compatible with a modulatory role for ANGII because
adenosine infusion does not cause renal vasoconstriction
in renin-depleted kidneys (Osswald et al, 1975).
1.5.4 Tubuloglomerular feedback and renal
autoregulation.
Renal blood flow is constant over a wide range of
systemic arterial pressures in normal man. Tubulo¬
glomerular feedback activation may contribute to this
regulation because glomerular filtration rate falls in
parallel with blood pressure when TGF is interrupted in
the dog (Navar et al, 1980). In the rat whole kidney GFR
and distal SNGFR are better preserved against changing
arterial pressure than proximal GFR (Ploth et al, 1977),
and this autoregulatory capacity is also dependent on an
intact TGF loop since autoregulation is absent after
frusemide treatment or in the hydronephrotic kidney when
TGF is inactivated (Morsing and Persson, 1991).
The observed fall in GFR during a reduction in blood
pressure after TGF blockade is smaller than would be
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expected on the basis of theoretical considerations
(Moore et al, 1980), implying that an alternative pathway
continues to contribute autoregulatory capacity. This
may relate to intrinsic myogenic reactivity (Gilmore et
al, 1980) which is responsible for up to half of the
change in renal vascular resistance in the higher
pressure range. The time course of autoregulatory
resistance changes has two phases (Young and Marsh,
1981) . The first phase is complete in three seconds,
before a change in tubular flow could have been
transmitted to the macula densa, and is therefore
believed to be myogenic in origin. The second phase is
slower, with a time course compatible with a
feedback-dependent mechanism. Both phases account for
about 50% of the total resistance change.
In the subnormal pressure range, the fraction of
autoregulation attributable to TGF falls progressively
with decreasing blood pressure (Schnermann et al, 1984),
and hormonal factors become relatively more important.
An ANGII-mediated increase in efferent arteriolar
vasoconstriction and prostaglandin-mediated afferent
arteriolar vasodilatation both serve to augment
glomerular filtration pressure and maintain GFR in the
face of reductions in renal perfusion pressure
(Schnermann et al, 1984).
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CHAPTER TWO.
THE KIDNEY IN DIABETES MELLITUS.
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2.1 THE NATURAL HISTORY OF DIABETIC NEPHROPATHY.
The occurrence of proteinuria in diabetic patients
is not a recent observation (Cotunnius 1770; Rollo 1798),
but the ominous prognosis for patients with this diabetic
complication was not apparent until insulin therapy
allowed the prolonged survival of patients with Type 1
(insulin-dependent) diabetes. Pathological definition of
nodular and diffuse hyaline masses in glomeruli
(Kimmelstiel and Wilson, 1936; Fahr, 1942) was followed
by recognition that death from kidney failure in Type 1
diabetic patients is more likely in subjects of long
duration, especially those with a young age of onset of
diabetes (Mann et al, 1949), and diabetic nephropathy was
soon established as one of the specific microangiopathic
complications of diabetes (Lundbaek, 1954).
The peak prevalence of diabetic nephropathy has been
reported as about 40% of Type 1 diabetic patients after
40 years of diabetes (Knowles et al, 1974; Deckert et al,
1978; Borch-Johnsen et al, 1985). During the 1970's the
mean time from the appearance of clinical renal disease
to renal death was only seven years (Deckert et al,
1981a), but many diabetic patients never develop
nephropathy, and the proportion of patients affected is
falling steadily (Krolewski et al, 1985; McNally et al,
1990) for reasons which remain obscure. The clustering
of cases within families (Deckert et al, 1981b; Seaquist
et al, 1989), and the increased incidence in certain
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racial groups (Cowie et al, 1989) suggests that genetic
influences are involved. This is likely to bias attempts
to examine the influence of environmental factors on the
development of nephropathy.
The association in individual diabetic patients
between nephropathy and the other microangiopathic
complications of diabetes emphasises the importance of
the diabetic state per se as a predisposing factor in the
development of diabetic complications. The incidence and
prevalence of nephropathy are both increased in patients
with poor cumulative chronic glycaemic control (Pirart,
1978); the incidence in this study also correlated with
the quality of control in the year before the
examination, whatever the overall degree of control in
preceding years. The important relationships between
arterial blood pressure and the development of
nephropathy will be discussed later.
Proteinuria in Type 1 diabetic patients is usually
due to diabetic nephropathy, but about 10% of cases have
alternative or associated glomerular diseases (Lynn et
al, 1988). The annual incidence of proteinuria peaks
between 15 and 20 years diabetes duration, and it is rare
to find new cases after more than 30 years of diabetes
(Mogensen et al, 1989; Drury et al, 1989). Established
diabetic nephropathy progresses at a variable but usually
inexorable rate to end stage renal failure if the patient
survives long enough. The incidence of end stage renal
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failure due to diabetes in Britain exceeds 10 per million
per year (Joint Working Party, 1988), and about 15% of
patients receiving renal replacement therapy have
diabetes, usually Type 1 disease. Diabetic patients with
renal disease suffer a greatly increased morbidity and
mortality from macrovascular disease, especially younger
patients whose relative mortality is up to 100 times that
of age and duration-matched non-proteinuric diabetic
patients (Borch-Johnsen et al, 1985); more of these
patients die from myocardial infarction and stroke than
from uraemia.
Current understanding of the natural history of
diabetic nephropathy is based on cross-sectional studies.
Three distinct phases have been defined in the evolution
of diabetic kidney disease. The first stage comprises
functional and pathological changes including increased
glomerular filtration rate, nephromegaly and intermittent
microalbuminuria (Keen et al, 1981). These changes often
regress if meticulous diabetic control is achieved. In
the second stage small amounts of protein (predominantly
albumin) become detectable in the urine, initially
intermittently and later persistently. Microalbuminuria
is an indicator that early diabetic nephropathy is
present (Berglund et al, 1987; Chavers et al, 1989), and
is strongly predictive of the development of overt
proteinuria, by which time there is a significant
relationship between structural kidney damage and
impairment of function (Viberti et al, 1982). During
this period further thickening of the glomerular basement
membrane and mesangial matrix occurs, and mesangial cell
expansion progresses (Steffes et al, 1989). Arteriolar
hyalinosis leads to glomerular occlusion, and glomerular
filtration rate begins to fall in parallel with the loss
of filtration surface, although still within the normal
range. Hypertension develops and accelerates progression
to the third stage of overt clinical nephropathy with
frank proteinuria and nephrotic syndrome, worsening
hypertension, and a declining glomerular filtration rate.
Morphometric studies have emphasised the central
role of mesangial expansion in early glomerular
hypertrophy (Steffes et al, 1989). Mesangial expansion
causes glomerular damage only when it is proportionately
greater than the increase in glomerular size, by
adversely affecting glomerular capillary density and
filtration surface area (Mauer et al, 1984; Ellis et al,
1986). However, the relationship between structural
damage and impairment of renal function in diabetes is
poorly defined. Morphological glomerular damage is
present in >90% of Type 1 diabetic patients after 20
years of diabetes (Thomsen, 1965), but most of these
patients have normal kidney function. Interstitial
fibrosis is also a prominent feature of established
diabetic nephropathy (Thomsen et al, 1989). This tubular
damage may be more important as a determinant of the
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effect of structural damage on glomerular filtration rate
than has previously been considered (Pinter and Atkins,
1991), as it is in patients with non-diabetic glomerular
disease (Risdon et al, 1968) .
Structural changes leading to nephron loss are
clearly important in the later stages of diabetes, but
patients at risk of clinical nephropathy cannot be
identified by the detection of early structural changes
alone. Alterations in GFR after changes in metabolic
control occur over too short a time scale to be directly
related to changes in filtration surface area (Kroustrup
et al, 1977), stressing the predominance of functional
factors in the early stages of diabetes. Much attention
has therefore been directed towards delineating renal
functional changes in the diabetic kidney which precede
the development of clinical renal disease.
2.2 RENAL HAEMODYNAMICS IN EARLY TYPE 1 DIABETES.
Many studies have confirmed the initial observation
(Cambier, 1934) that glomerular filtration rate (GFR) is
increased in some patients with early Type 1 diabetes
(Stalder and Schmid, 1959; Ditzel and Schwartz, 1967;
Mogensen et al, 1971a; Christiansen et al, 1981a; Wiseman
et al, 1984) . The proportion of patients with a GFR
which is statistically abnormally high, termed glomerular
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hyperfiltration, depends on the subgroup studied and the
population from which they are drawn. It cannot be
determined whether a GFR within the 'normal range' in a
diabetic patient is always higher than that individual's
'pre-diabetic' GFR; the unimodal rather than bimodal
distribution of GFR in the uncomplicated diabetic
population suggests that this may be so.
2.2.1 Determinants of increased GFR in diabetes.
Most of the experimental data in this area comes
from animal models of diabetes, and the prospective
studies needed to test the relevance of renal functional
changes in early human diabetes to the development of
clinical nephropathy are notable by their scarcity.
Because of the problems inherent with prolonged follow-up
and repeated investigations, and recognition that the
aetiology of diabetic nephropathy is multifactorial,
definitive data is not likely to be forthcoming on a
large scale.
Of the four determinants of GFR (Brenner et al,
1977), renal plasma flow (RPF) and glomerular
transcapillary hydraulic pressure (AP„„) have been mostbL
studied in diabetes. Increased single nephron RPF in
insulin-treated hyperglycaemic diabetic rats results from
reductions in intrarenal resistances; afferent arteriolar
resistance is reduced more than efferent resistance, and
mean glomerular hydraulic pressure is elevated (Hostetter
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et al, 1981a; Jensen et al, 1981). The ultrafiltration
coefficient Kf is normal in the rat (Hostetter et al,
1981a). Glomerular hyperfiltration in the rat is
therefore apparently due to a combination of increased
glomerular flow and increased intraglomerular capillary
pressure.
Effective renal plasma flow (ERPF) and GFR correlate
well in human Type 1 diabetes (Mogensen et al, 1973;
Christiansen et al, 1981a; Puig et al, 1981; Hannedouche
et al, 1990a), and renal plasma flow in Type 1 diabetes
has been reported as elevated (Mogensen et al, 1971a;
Christiansen et al, 1981a), suggesting that at least some
of the increase in GFR is plasma flow dependent.
However, other studies have found normal (Ditzel et al,
1972; Hannedouche et al, 1990a; Jenkins et al, 1990;
Fioretto et al, 1991) or even reduced (Stalder and
Schmid, 1959) ERPF in Type 1 diabetic patients with and
without increased GFR. In the more recent studies these
results were certainly not due to underestimation of ERPF
by the formation of a PAH-glucose adduct in glycosuric
urine (Dalton et al, 1988), so that other factors must
also be involved.
GFR correlates with RPF in both diabetic and control
subjects (Hannedouche et al, 1990a), but in most studies
GFR adjusted for ERPF remains increased in diabetes, and
this increase in the filtration fraction (GFR/ERPF) has
been interpreted as an indication that elevated
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intraglomerular pressure may independently contribute to
the rise in GFR in human Type 1 diabetes (Mogensen et al,
1976a) . Intraglomerular pressure cein not be measured
directly in humans, and interpretation of the filtration
fraction as an eguivalent measurement is only valid if
both oncotic pressure and the ultrafiltration coefficient
Kf are unchanged. Oncotic pressure is normal in early
human Type 1 diabetes, as judged by plasma protein
concentration (Hommel et al, 1990), and arteriolar
oncotic pressure is not different in diabetic and control
rats (Hostetter et al, 1981a). However, the increased
glomerular filtration surface area in human Type 1
diabetes (Kroustrup et al, 1977) correlates with GFR in
patients with and without nephropathy (Hirose et al,
1980; Osterby et al, 1988), and could augment GFR simply
by increasing Kf independently of haemodynamic factors
(Premen et al, 1988). Filtration fraction data in human
studies must always be interpreted very cautiously.
2.2.2 Mechanisms of GFR elevation.
An increase in GFR occurs only during moderate
hyperglycaemia: a blood glucose greater than 16 mmol/1 in
human diabetes leads to a normal or reduced glomerular
filtration rate (Mogensen et al, 1971b; Wiseman et al,
1984) , and severely hyperglycaemic animals have normal
GFR and normal intraglomerular pressure (Hostetter et al,
1981a; Michels et al 1981). Acute increases in blood
56
glucose following either oral ingestion or intravenous
infusion of glucose (mean increase 11 mmol/1) have either
shown minimal effects on GFR and ERPF (Mogensen et al,
1971c; Jenkins et al, 1989), or have produced small
increases both in normal subjects and in diabetic
patients with hyperfiltration (Christiansen et al, 1981b;
Wiseman et al, 1987). GFR in the diabetic rat is
normalised by insulin treatment in some (Jensen et al,
1987; Tucker et al, 1991) but not all studies (Bank et
al, 1988). Acute reduction of blood glucose from
hyperglycaemic to normal levels by bolus insulin
injection reduces GFR and ERPF in diabetic patients
(Mogensen et al, 1978). However, the elevated GFR in
human diabetic patients at the time of diagnosis is only
partially normalised by one week of insulin treatment,
before there has been any change in renal size
(Christiansen et al, 1982), and only if euglycaemia is
achieved and not if hyperglycaemia is maintained
(Christiansen et al, 1981c). This suggests that the
quality of longer term glycaemic control is an important
modulator of intrarenal haemodynamics in addition to the
effects of acute changes in blood glucose on glomerular
filtration rate.
Vascular beds throughout the body tend to show a
decreased resistance to blood flow in early Type 1
diabetes (Parving et al, 1983c), implying that a
generalized diabetes-related impairment of autoregulation
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exists which interacts with local factors. Abnormalities
of vasoregulatory hormones have obvious potential as
mediators of the renal haemodynamic effects of chronic
hyperglycaemia. PGE2 production by mesangial cells from
diabetic rats is increased (Schambelan et al, 1985), and
is normalized by insulin administration (Kreisberg and
Patel, 1983). Enhanced production of vasodilatory
prostaglandins has been confirmed in human Type 1
diabetes (Esmatjes et al, 1985; Fioretto et al, 1991).
Prostaglandins have most significance as regulators of
renal vascular tone when vasoconstrictor hormones are
activated, but the glomerular contractile response to
ANGII, noradrenaline and vasopressin remains normal in
experimental diabetes (Barnett et al, 1987). The absence
of any change in GFR after cyclooxygenase inhibition in
early human Type 1 diabetes (Christiansen et al, 1985)
also argues against a primary role for vasodilatory
prostaglandins in initiating hyperfiltration.
Urinary kallikrein is reduced in untreated rats with
streptozotocin-induced diabetes (Jaffa et al, 1987), but
is increased above control values when insulin treatment
is given, urinary excretion then correlating with GFR and
ERPF (Harvey et al, 1990). However, the effects of acute
infusion of the kallikrein inhibitor aprotinin are
conflicting (Bank et al, 1988; Harvey et al, 1990), and
the role of kinins remains unclear.
A possible role for endogenous atrial natriuretic
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peptide (ANP) rests on the parallel increases in plasma
ANP and GFR during moderate hyperglycaemia both in the
diabetic rat (Ortola et al, 1987) and in human diabetes
(Laragh and Atlas, 1988). Infusion of a specific
anti-ANP antiserum reduces GFR in hyperfiltering diabetic
rats (Ortola et al, 1987), while ANP infusion in normal
rats raises glomerular capillary pressure (Dunn et al,
1986). Plasma ANP correlates with the quality of
glycaemic control in human diabetes (Bell et al, 1989),
but systemic infusion of low dose ANP in normal man
slightly decreases GFR and ERPF despite causing
natriuresis and suppression of plasma renin activity and
ANGII levels (Cottier et al, 1988), effects which differ
from those of poorly controlled diabetes.
Plasma ANGII concentrations and plasma renin
activity tend to be reduced in early diabetes, which
combined with the reduction in ANGII receptor density in
diabetic glomeruli (Ballermann et al, 1984) might suggest
a permissive role for a suppressed renin-angiotensin
system in causing hyperfiltration. However, the decrease
in ANGII receptor density does not prevent the renal
vascular response to exogenous ANGII (Bank et al, 1988),
and non-renal vascular beds actually show an increased
responsiveness to exogenous ANGII (Christlieb, 1976).
Moreover, baseline renal plasma flow and the response of
renal plasma flow to acute angiotensin converting enzyme
inhibition both correlate with the prevailing level of
59
glycaemic control (Jenkins et al, 1990). This has been
interpreted as implying that intraglomerular pressure is
elevated by ANGII-mediated efferent arteriolar
constriction in parallel with worsening hyperglycaemia.
In diabetic rats acute hyperglycaemia and glycosuria
separately and additively blunt the tubuloglomerular
feedback (TGF) mechanism causing relative hyperfiltration
(Blantz et al, 1982). However, in chronically
hyperglycaemic rats either normal (Seney and Salmond,
1988) or increased activity of the TGF response has
been described (Pollock et al, 1991; Tucker et al, 1991).
The feedback response curve is reset so that the TGF
system only partially restores the elevated GFR towards
normal, a higher than normal distal tubular flow then
coexisting with a higher than normal GFR. Persistence
of TGF activity in chronic diabetes is also shown by the
blunting of the hyperfiltration response after partial
control of blood glucose with insulin, and by the finding
that the increased renal blood flow and decreased renal
resistance coincident with the elevation in GFR do not
occur if TGF is blocked (Woods et al, 1987). The
relevance of these findings to human diabetes is unknown.
2.2.3 Glomerular Hyperfiltration as a Potential
Initiator of Renal Injury.
The suggestion that glomerular hyperfiltration may
contribute to the development of diabetic nephropathy
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arose from the observation that morphological changes of
diabetes in a patient with unilateral renal artery
stenosis were confined to the nonstenosed kidney (Berkman
and Rifkin, 1973). Nephron destruction in non-diabetic
renal disease often progresses despite removal of the
initial injury (Schimamura et al, 1975; Hostetter et al,
1981b). Single nephron GFR in surviving nephrons rises
as an adaptive response due to increases in single
nephron capillary flow and transglomerular hydraulic
pressure. This response may be maladaptive (Anderson and
Brenner, 1989) since increases in capillary flow and
intra- glomerular pressure accelerate the development of
proteinuria and progressive glomerular injury in healthy
surviving nephrons (Brenner et al, 1985). These nephrons
in turn will sclerose and cause whole kidney GFR to
decline further. The occurrence of 'glomerular
hypertension' has now been documented in a wide range of
experimental nephropathies (Anderson and Brenner, 1989) .
The possible importance of glomerular hypertension
as an initiator of diabetic nephropathy has been
vigorously championed by Brenner, and is supported by
experimental work in the rat showing that manoeuvres
which aggravate the haemodynamic effects of early
diabetes also accelerate glomerular injury (O'Donnell et
al, 1986; Zatz et al, 1985). The reduction of filtration
surface area following glomerular tuft occlusion will
reduce whole kidney K^, which in turn will increase
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transglomerular pressure further at constant renal plasma
flow unless efferent arteriolar resistance is reduced.
It is therefore very important that intraglomerular
hypertension and its sequelae are prevented in the
diabetic rat by reducing dietary protein intake (Zatz et
al, 1985) or by giving the angiotensin converting enzyme
inhibitor enalapril which reduces efferent arteriolar
tone and intraglomerular pressure (Zatz et al, 1986).
The hyperfiltration hypothesis elegantly describes
events in the diabetic rat, but there are problems in
extrapolating the theory to human diabetes. Firstly, the
streptozotocin-diabetic rat develops focal glomerular
sclerosis, a lesion histologically different from human
Type 1 diabetes, and similar but milder histological
changes are a normal aging phenomenon in the non-diabetic
rat (Bras, 1969). This led to the suggestion that
progressive renal disease in the rat following induction
of glomerular hyperfiltration is an exaggerated form of a
species-specific phenomenon (Bovee et al, 1979; Watnick
et al, 1988). Recent data refutes this hypothesis
however (Bourgoignie et al, 1987; Novick et al, 1991),
and the discrepancy between the rat and larger species is
probably related more to the severity of the insult
applied, the time scale of follow-up, and possibly to the
initial nephron number (Fine, 1991) than to a fundamental
difference between species.
The second problem lies in proving a causal relation
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between glomerular hypertension and glomerular injury.
One study has suggested that increasing intraglomerular
pressure initiates renal injury only in diabetic rats
with hypertension, and not in rats with diabetes or
hypertension alone (Bank et al, 1987). Furthermore,
glomerular hyperfunction induced by ureteric diversion
(without nephrectomy) does not by itself promote the
glomerular hypertrophy which is a necessary precondition
for the development of glomerular sclerosis (Yoshida et
al, 1989).
Short-term studies in diabetic patients have shown
that dietary protein restriction can reduce albuminuria
(Cohen et al, 1987) and slow the progression of diabetic
nephropathy (Evanoff et al, 1987) . However, longer term
studies, some prospective, have not agreed whether an
early increase in GFR is (Mogensen, 1986; Rudberg, 1991)
or is not (Lervang et al, 1988; Messent et al, 1991) a
risk factor for nephropathy independently of glycaemic
control and blood pressure. Other factors which are of
possible relevance to the expression of nephropathy
include basement membrane glycosylation (Spiro et al,
197 6) , the effects of systemic hypertension (Mogensen et
al, 1976b; Viberti et al, 1985), abnormal capillary
permeability to macromolecules (Parving, 1975) , and
genetic susceptibility (Seaquist et al, 1989) . The
failure to conclusively confirm that an elevated GFR
independently predicts the development of diabetic
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nephropathy is therefore perhaps not surprising, and may
have been caused by a type II statistical error due to
heterogeneity within the relatively small groups of
patients studied.
The variety of abnormalities that have been
described in the diabetic kidney make it almost
inevitable that for any individual patient the
development of nephropathy is multifactorial. The rest
of this review will concentrate on just one important
area, describing the changes in the relationships between
renal and whole-body sodium homeostasis and systemic
blood pressure which precede and accompany the
development of nephropathy.
2.3 HYPERTENSION AND NEPHROPATHY IN DIABETES MELLITUS.
Systemic hypertension often complicates both Type 1
and Type 2 diabetes and is an important risk factor for
the development of microangiopathy. Elevation of blood
pressure shortens the time interval between the onset of
diabetes and the occurrence of nephropathy (Hasslacher et
al, 1985), and accelerates the rate of decline of
glomerular filtration rate once nephropathy is
established (Mogensen, 1982; Parving et al, 1983a).
Slightly elevated systolic blood pressure has been found
in some diabetic patients in some (Moss, 1962;
Cruickshanks et al, 1985; Hasslacher et al, 1985) but not
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other (Kaas Ibsen et al, 1983) cross-sectional studies,
and only a very small increase in diastolic pressure has
been reported (Tarn and Drury, 1986). Two large and
important studies have recently argued persuasively
firstly that blood pressure is not increased in
uncomplicated diabetes (Norgaard et al, 1990), and
secondly that elevation of urinary albumin excretion
precedes the rise in blood pressure during the
development of incipient nephropathy (Mathiesen et al,
1990). The evidence therefore suggests that at most only
small increases in blood pressure occur in diabetic
patients without complications. An increase in arterial
pressure into the hypertensive range is a response to the
development of incipient or overt nephropathy, occurring
before kidney function is impaired. The speed with which
hypertension develops is evident from the finding that
more than 50% of young Type 1 diabetic patients with
incipient or established nephropathy with a normal serum
creatinine already have a diastolic blood pressure
>95mmHg (Parving et al, 1983a).
Transmission of systemic hypertension to the
glomerular microcirculation increases glomerular
capillary tuft pressure in various models of hypertensive
kidney disease (Andersen et al, 1986), including SHR rats
with streptozotocin-induced diabetes (Bank et al, 1987)
and normotensive rats with insulin-treated diabetes
(Hostetter et al, 1981a; Jensen et al, 1986). Such
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increases in pressure may be more injurious to the
enlarged glomerular capillaries found in the diabetic
kidney since the wall tension created for a given
transmural pressure gradient is proportional to vessel
size (Fries et al, 1988). This may account for the
clinical observation that an accelerated rate of decline
of glomerular filtration rate can be detected in
hypertensive diabetic patients at levels of blood
pressure which would not cause nephron failure in
non-diabetics with essential hypertension (Parving et al,
1983b).
The causes of hypertension at different stages of
diabetes are uncertain, but effective antihypertensive
treatment reduces microalbuminuria and the rate of
decline of GFR in hypertensive patients with overt
nephropathy (Mogensen, 1982; Parving et al, 1983b;
Parving et al, 1987, Parving et al, 1988; Bjorck et al,
1986; Parving et al, 1989a), and improves the renal
prognosis (Parving and Hommel, 1989b). A beneficial
effect of antihypertensive treatment is also apparent in
both hypertensive and normotensive patients with
incipient nephropathy (Marre et al, 1988; Mathiesen et
al, 1991). It is controversial whether any particular
antihypertensive therapy confers a specific advantage;
various drug regimes are being compared to determine
whether lowering of blood pressure within the 'normal'
range can modify or prevent the development of
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nephropathy in normoalbuminuric diabetic patients.
The relationship between blood pressure and
nephropathy in diabetes is complex. Increased blood
pressure does not cause diabetic nephropathy, but a
rising blood pressure is apparent soon after the
development of incipient nephropathy, and undoubtedly
accelerates the progression of nephropathy. Two
hypotheses have been postulated to explain the available
data. First, diabetes may cause metabolic and hormonal
changes which lead by separate pathways to both kidney
damage and hypertension. Alternatively, a genetic
predisposition to essential hypertension may exist and
act as an additional risk factor in the presence of
diabetes, promoting kidney damage. The debate over the
possible value of a parental history of essential
hypertension or an increase in red cell sodium-lithium
countertransport activity as a predictor of the risk of
nephropathy is beyond the scope of this discussion
(Viberti et al, 1987; Jensen et al, 1990; Walker et al,
1990). However, in considering possible causes for the
unusually early appearance of rising blood pressure in
young subjects with normal kidney function, abnormalities
of renal sodium handling and cardiovascular reactivity
are present in Type 1 diabetes and may be of relevance.
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2.4 SODIUM HOMEOSTASIS IN DIABETES.
Patients with diabetic nephropathy develop sodium and
water retention early in the course of their chronic
renal failure, and some patients require dialysis solely
to relieve salt and fluid overload before symptoms of
uraemia have developed. 'Volume-dependent' hypertension
results at least partly from expansion of the
extracellular fluid volume due to defects in the renal
excretion of sodium and water (Hamlyn and Blaustein,
1986). Extracellular fluid volume and cardiac output are
maintained within relatively normal limits at the expense
of an increase in blood pressure and hence renal
perfusion pressure in the chronic phase of the disease
(see Chapter 1.4). Patients with uncomplicated diabetes
already have an increased exchangeable body sodium pool
(Weidmann et al, 1979), and definition of the relations
between abnormal sodium homeostasis, other factors
regulating blood pressure control, and the development of
hypertension and diabetic nephropathy therefore has
practical as well as academic importance.
Many studies of sodium handling in diabetes have
been performed upon heterogenous patient groups, or have
used inappropriate criteria when defining the presence of
hypertension (a blood pressure cutoff of ^160/90 mmHg
which is 'normotensive' in a non-diabetic 60 year old by
WHO criteria should not be regarded as normal in a Type 1
diabetic population mostly aged from 20 to 50 years).
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Some important studies were completed before the
assessment of medium term glycaemic control by means of
glycated haemoglobin assays became available, and these
could not determine whether relationships exist between
exchangeable sodium and chronic glycaemic control. Many
studies have also not differentiated patients with Type 1
(insulin-dependent) from Type 2 (non-insulin-dependent)
diabetic patients, in whom the causes and the
consequences of raised blood pressure may not be the
same. These sources of potential bias will be
highlighted as necessary.
2.4.1 Exchangeable Sodium.
Cross-sectional studies have shown that patients
with diabetes have an increased exchangeable body sodium
pool (TENa) (de Chatel et al, 1977; Weidmann et al, 1979;
Beretta-Piccoli et al, 1982a; O'Hare et al, 1985;
Feldt-Rasmussen et al, 1987). The greatest increases
occur in patients with incipient or frank nephropathy
(O'Hare et al, 1985; Feldt-Rasmussen et al, 1987), but
the excess of extracellular sodium, which in most studies
is about 10% greater than control groups, is apparent in
normotensive and hypertensive patients, across all age
groups and in both genders, and in both Type 1 and Type 2
diabetic subgroups. Despite overall sodium retention,
plasma volume is normal in normotensive and even low in
some hypertensive diabetic subjects (de Chatel et al,
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1977; Beretta-Piccoli et al, 1982a). This contrasts with
the situation in uncomplicated essential hypertension in
which TENa and plasma volume are normal (Lebel et al,
1974; Schalekamp et al, 1974).
O'Hare et al (1985) found a positive correlation
between TENa (increased to a mean of 118% of control
values) and mean arterial pressure in 16 patients with
overt diabetic nephropathy, and Weidmann et al (1985)
reported a similar finding among 124 unselected diabetic
patients, the closest correlation being between systolic
blood pressure and TENa in patients with high blood
pressure (>90 mmHg diastolic). In 17 hypertensive Type 2
diabetic patients studied before and after six weeks
treatment with a diuretic (chlorthalidone), TENa fell
from an initial value of 109% of the control value to the
same level as the control group, while blood pressure
fell from 165/93 to 145/82 mmHg over the same period
(Weidmann et al, 1979) . This suggests a link between
increased total body sodium and the rise in arterial
pressure in these patients, although a fall in blood
pressure due solely to a weak venodilator effect of
chlorthalidone can not be excluded. Conversely, patients
with Type 2 diabetes changing from a low to a high sodium
diet retained more sodium than nondiabetic controls (Tuck
et al, 1990), although only hypertensive patients (either
diabetic or control) showed any rise in blood pressure
during sodium loading.
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Experimental evidence of a defect in renal sodium
handling in Type 1 diabetes has come from analysis of the
renal responses to head-out water immersion and
intravenous saline infusion. The natriuretic response to
both stimuli in a group of uncomplicated diabetic
patients was blunted by about 50% when compared with a
carefully matched control group (Roland et al, 1986;
O'Hare et al, 1986). The absence of changes in
glomerular filtration rate in these experiments (albeit
assessed using creatinine clearance) suggested that
abnormal tubular function caused the altered renal sodium
handling rather than a haemodynamic abnormality. The
site of this defective sodium handling could not be
determined, but several groups have recently used the
lithium clearance method as a means of studying tubular
sodium handling in more detail in diabetic patients.
These studies have consistently shown an increase in
fractional proximal sodium reabsorption in both Type 1
and Type 2 diabetic patients (Mbanya et al, 1989;
Nosadini et al, 1989; Hannedouche et al, 1990a; Trevisan
et al, 1990), sodium balance being maintained by a
reduction in fractional distal tubular sodium
reabsorption.
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2.4.2 Mechanisms of Sodium Retention.
2.4.2.1 Sodium-glucose cotransport.
Mildly raised blood levels of glucose and ketone
bodies, as found in treated diabetes, increase the
filtered load of these substances entering the proximal
tubule and undergoing active reabsorption in the proximal
tubular cell. This reabsorption is accompanied by sodium
reabsorption in an approximately 1:1 ratio by distinct
cotransport mechanisms (Ullrich, 1976; Crane, 1977) .
Glucose reabsorption also changes the transtubular
osmotic pressure gradient to favour sodium and water
reabsorption by increasing solvent drag. In the rabbit
isolated proximal tubule, perfusion with 5.5 mM D-glucose
augments sodium reabsorption by up to 25% (Burg et al,
1976). This mechanism is insulin-independent (Harris et
al, 1986) and is demonstrable within four days of the
onset of STZ-induced diabetes in the rat (Kumar et al,
1988). Mild hyperglycaemia with blood glucose
concentrations below the T for glucose therefore
m
promotes excess proximal sodium reabsorption; more severe
metabolic decompensation during periods of very poor
control leads to a glycosuric osmotic diuresis, net
sodium losses, hypovolaemia and decreased blood pressure
(Atchley et al, 1933; McCance and Lawrence, 1935).
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2.4.2.2 Insulin.
The pathophysiological effects of insulin on renal
sodium handling may also be relevant in diabetes. Miller
and Bogdonoff (1954) showed that normal subjects
undergoing solute or water diuresis had a reduced sodium
excretion when given insulin. This effect is independent
of the sodium-retaining effect of hypoglycaemia (Patrick
et al, 1989). DeFronzo used clamp techniques in the dog
to show that sodium retention is due to insulin alone and
not to hyperglycaemia (DeFronzo et al, 1976), and
suggested that excess sodium reabsorption occurs in the
distal nephron. The plasma concentrations of insulin
used were far higher than would normally occur in Type 1
diabetes, but suppression of endogenous insulin release
in normal subjects by somatostatin infusion increases
sodium excretion (DeFronzo et al, 1978), although an
effect due to other hormonal changes can not be excluded.
Insulin may enhance sodium reabsorption through
stimulation of the renal tubular Na+-K+-ATPase
(Jorgensen, 1980; Moore, 1983) and the Na+-H+ antiporter
(Moore, 1983; Mahnensmith and Aronson, 1985), or by
amplifying the action of aldosterone on Na+ and K+
transport (Fidelman and Watlington, 1984). The effect
has been observed only acutely in humans (Saudek et al,
1974; DeFronzo et al, 1975; Skott et al, 1989a; Gans et
al, 1991a). Chronic insulin infusion in the non-diabetic
dog leads to sodium retention followed by an "escape"
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phenomenon similar to that occurring after
mineralocorticoid administration (Hall et al, 1990) .
Mansell et al. (1990) studied the renal response to
acute hyperinsulinaemia in normal subjects by infusing
insulin (or vehicle) at stepped doses reproducing
•physiological* plasma free insulin concentrations during
a natriuresis produced by head-out water immersion. They
interpreted the absence of a change in urinary sodium
excretion during hyperinsulinaemia as indicating that
insulin has no physiological role in the control of renal
sodium handling.
Trevisan et al (1990) studied the effect of
hyperinsulinaemia on atrial natriuretic peptide release
and the natriuretic response to isotonic volume expansion
in normal and Type 1 diabetic subjects. In the diabetic
group the natriuretic response to intravenous saline
loading was impaired as expected, mainly due to greater
rates of proximal sodium reabsorption (assessed by
lithium clearance). Infusion of insulin into the normal
subjects for 24 hours, at doses reproducing the levels
seen at baseline in the diabetic group, increased
proximal tubular sodium reabsorption and reduced urinary
sodium excretion, with no evidence of a separate distal
tubular effect. Insulin infusion increased plasma ANP
levels at baseline, but impaired the normal increase in
ANP secretion seen during saline loading. The authors
concluded that insulin primarily increased proximal
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tubular sodium reabsorption.
The contrasting results of these two studies may
reflect different experimental designs, in particular the
differing durations of insulin infusion. The effects of
insulin on renal sodium handling may be mediated
indirectly by changes in other intrarenal hormone systems
rather than by a direct insulin-receptor interaction
within the kidney, and it is interesting that euglycaemic
insulin infusion stimulates noradrenaline release (Rowe
et al, 1981), and raises plasma renin activity and plasma
ANGII levels (Trovati et al, 1989), providing further
mechanisms which may promote proximal tubular sodium
retention.
2.4.2.3 Physical and hormonal factors.
Intravascular oncotic pressure may be reduced in
some hypoalbuminaemic nephrotic diabetic subjects due to
accompanying reduced albumin synthesis (Ejarque et al,
1959) , and increased microvascular permeability to macro-
molecules (Parving, 1975) will facilitate elevation of
transcapillary microvascular pressure in the presence of
hypertension, favouring a shift of fluid and sodium to
the extracellular space, which may be further aggravated
by increased tissue avidity for sodium following changes
in collagen composition (Francis et al, 1974) . This
tendency to intravascular hypovolaemia may result in a
finite degree of sodium retention as an 'appropriate'
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renal response, leading to a new steady state with a
restored blood volume at the cost of increased ECF sodium
and interstitial volume (de Chatel et al, 1977) .
Plasma atrial natriuretic peptide levels are
increased in Type 1 diabetic subjects with incipient or
clinical nephropathy (Sawicki et al, 1988), and this
increase correlates positively with the quality of
glycaemic control in uncomplicated patients (Bell et al,
1989). The response of plasma ANP to acute saline
loading is enhanced in some (de Chatel et al, 1986) but
not all (de Chatel et al, 1986; Haak et al, 1986)
normotensive diabetics. These results in themselves may
simply reflect the presence of ECF expansion due to
sodium retention, but impairment of the natriuretic
response to exogenous atrial natriuretic peptide has also
been described in diabetic subjects with (Liebermann et
al, 1991) and without nephropathy (Nosadini et al, 1991),
suggesting that end-organ responsiveness is genuinely
abnormal.
Finally, a genetic defect in renal sodium handling
in diabetes has been suggested, based on the parallel
between the increased Na+-Li+ red cell countertransport
seen in some Type 1 diabetic patients (Krolewski et al,
1988; Mangili et al, 1988) and the postulated enhanced
activity of the proximal tubular brush border Na+-H+
exchanger (Weder, 1986). This hypothesis awaits
experimental verification.
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2.5 CARDIOVASCULAR REACTIVITY IN DIABETES
AND DIABETES-ASSOCIATED HYPERTENSION.
Variations in cardiovascular responsiveness to vaso¬
active stimuli are important in blood pressure
regulation, and in normal man blood pressure responses to
noradrenaline (NE) and ANGII are inversely related to
their basal blood levels (Chinn et al, 1972; Philipp et
al, 1978). In stable uncomplicated diabetes, plasma
total catecholamines (Christensen, 1972), plasma and
urinary noradrenaline and adrenaline (de Chatel et al,
1977; Beretta-Piccoli et al, 1979; Christensen, 1979;
Feldt-Rasmussen et al, 1987), plasma active renin, ANGII,
and plasma aldosterone (de Chatel et al, 1977;
Christlieb, 1976; Beretta-Piccoli et al, 1979;
Beretta-Piccoli et al, 1981a; Fernandez-Cruz et al, 1981;
Ferriss et al, 1982; Feldt-Rasmussen et al, 1987; Tuck et
al, 1990) are all normal or sometimes low with respect to
age and/or urinary sodium excretion. Noradrenaline
spillover and clearance rates are also normal (Beretta-
Piccoli et al, 1982b).
Hypertension in diabetic patients is therefore not
initiated primarily by activation of the sympathetic
nervous system or the RAAS, but even normal plasma levels
of these effector hormones could be regarded as
inappropriately high in the presence of concomitant
sodium retention (Weidmann et al, 1985). Furthermore, in
stable diabetic patients pressor responsiveness to
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exogenous NE is often exaggerated relative to plasma
levels (Barany, 1955; Christlieb et al, 1976; Weidmann et
al, 1979; Christensen, 1979; Beretta-Piccoli et al,
1981b), the dose needed to elevate mean arterial pressure
by 20mmHg being less than half that required in normal
subjects. This hyperresponsiveness is independent of
age, duration of diabetes, diabetic complications, or the
presence of hypertension (Weidmann et al, 1979;
Beretta-Piccoli et al, 1981b).
Pressor responsiveness to exogenous ANGII also
exceeds a physiological adaptation to circulating renin
and ANGII levels in some diabetic patients, the dose of
ANGII needed to raise MAP by 20mmHg being reduced in
nonazotaemic diabetic patients despite no parallel
decrease in plasma renin activity (Weidmann et al, 1985;
Tuck et al, 1990). This abnormality is a function of
the diabetic state per se, being apparent in normotensive
diabetic subjects without microvascular complications
(Drury et al, 1984), and is reflected in an inappropriate
increase in ANGII binding sites on diabetic platelets
(Mann et al, 1989), although this has not been a
consistent finding (Connell et al, 1986). It is also
interesting to note that improved glycaemic control in
Type 2 diabetes decreases plasma ANGII levels and lowers
blood pressure (Sullivan et al, 1980).
The hyperreactivity to exogenous NE and ANGII seen
in normotensive diabetic patients differs from the
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pattern in the normotensive offspring of essential
hypertensive families, who are hyperreactive only to NE
(Bianchetti et al, 1984). Sodium retention has been
suggested to play an important role as a contributor to
abnormal vascular hyperreactivity in diabetes. Removal
of excess body sodium by diuretic treatment restored NE
responsiveness to normal without changing pre-infusion
plasma NE levels, implying an improvement in the
initially disturbed relationship between NE reactivity
and the prevailing sympathetic nerve activity (Weidmann
et al, 1979) . The same diuretic therapy also reduced
pressor responsiveness to ANGII but failed to normalize
the relationship between ANGII reactivity and plasma
renin activity, the vasodepressor effect of reduced body
sodium on pressor reactivity to ANGII being opposed by
the increased circulating renin following diuretic
treatment. The hypothesis that relative 'inappropriate'
systemic vasoconstriction exists at any given level of
total body sodium in diabetes is also supported by the
failure of dietary sodium restriction to normalize
pressor reactivity to ANGII in hypertensive Type 2
diabetic patients (Tuck et al, 1990).
Vascular reactivity to both NE and ANGII is in part
calcium-dependent (Trost and Weidmann, 1987). Calcium
channel blockade (with nitrendipine) in Type 2 diabetic
subjects with mild hypertension markedly reduced blood
pressure and improved vascular hyperreactivity to both NE
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and ANGII without changing body sodium content,
consistent with a decrease in vascular tone due to
2 +
reduced cytosolic Ca . Morphological alterations in
resistance vessels develop early in the course of
diabetes (Blumenthal et al, 1965), and even mild
vasculopathy may enhance reactivity to pressor agents.
Hypertension of any aetiology may also be complicated by
secondary hypertrophy of the vascular wall as a
complementary mechanism perpetuating the initial abnormal
milieu (Folkow, 1971). Autonomic reflex arc interruption
by diabetic autonomic neuropathy also promotes
exaggerated pressor responsiveness (Reid et al, 1990),
and this may be relevant in some patients with
established nephropathy and associated hypertension and
autonomic neuropathy who develop the constellation of low
plasma renin and aldosterone levels with severe
hyperkalaemia, the syndrome of hyporeninaemic






3.1 AIMS OF THE WORK.
Interacting physical and hormonal systems regulate
renal sodium handling and total body sodium content,
glomerular haemodynamics and systemic blood pressure.
Alterations in both renal sodium handling and glomerular
haemodynamics have been described from the early stages
of Type 1 diabetes, changes which may be relevant to the
later development of hypertension and diabetic
nephropathy. The determinants of these early changes
have been examined in detail in experimental animal
models of Type 1 diabetes, but much less information is
available from in vivo human studies to establish the
relevance of animal data to diabetes in man.
The renin-angiotensin-aldosterone system (RAAS) is
one of the most powerful hormonal systems controlling
intrarenal haemodynamics and tubular reabsorption of
sodium. Abnormalities of the systemic actions of the
effector hormone angiotensin II occur in early diabetes;
the aim of the studies in this thesis was to determine
whether the intrarenal actions of ANGII are also changed
in early diabetes by comparing dynamic renal responses to
acute changes in RAAS activity in normal man and patients
with uncomplicated Type 1 diabetes. The validity of
lithium clearance as a marker of tubular sodium handling
was evaluated systematically with the intention of




The subjects studies were either healthy volunteers
or patients with Type 1 diabetes attending the Department
of Diabetes of the Royal Infirmary for long-term
supervision of their condition. All the protocols were
approved as ethically acceptable by the Lothian Health
Board Ethics of Medical Research Sub-Committee for
Medicine and Clinical Oncology. Subjects gave fully
informed consent after a careful explanation of the
nature and purpose of the investigation concerned had
been given.
3.3 EXPERIMENTAL PROTOCOLS.
3.3.1 Experimental changes in RAAS activity:
angiotensin II infusion or ACE inhibition?
It is important when studying ANGII-mediated events
in vivo to select the most physiologically appropriate
intervention. RAAS components are localized within the
kidney in different nephron subpopulations and within
different anatomical parts of the nephron (Hollenberg,
1984; Levens et al, 1981), and intrarenal concentrations
of renin and ANGII far exceed plasma levels (Mendelsohn,
1979). Systemic infusion of ANGII does not reproduce the
normal pattern of intrarenal ANGII generation, and its
effects may differ from those following endogenous
intrarenal ANGII generation, which for example may
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produce local concentrations of ANGII sufficient to
constrict the efferent arteriole or directly stimulate
proximal tubular reabsorption of sodium, but without
affecting nephron sites with a higher threshold or
spilling over into the systemic circulation. The effects
of systemic infusion of ANGII on cardiac output,
sympathetic activity and systemic blood pressure (Scroop
and Lowe, 1969) may also produce independent and
confounding effects on renal haemodynamics and
natriuretic responses.
Recent studies have therefore often adopted the
alternative strategy of removing endogenous ANGII using
inhibitors of angiotensin converting enzyme (ACE), an
approach which assumes that converting enzyme inhibition
produces a balanced reduction in plasma and tissue ANGII
concentrations. Converting enzyme is not specific for
ANGI and is identical to the enzyme kininase II which
inactivates bradykinin, so that by attenuating intrarenal
kinin degradation ACE inhibition introduces the
possibility of separate effects due to potentiation of
the intrarenal actions of kinins. Infusion of ANGII
after ACE inhibition may confirm that the effects of ACE
inhibition are due to removal of ANGII rather than to
accumulation of kinins, but reintroduces all the problems
of ANGII infusion and may complicate rather than clarify
the issue.
Because of the potential non-specificity of ACE
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inhibition, systemic ANGII infusion has been used as the
intervention in the majority of the present studies.
Vascular reactivity to ANGII, especially the renal
haemodynamic response, is extremely sensitive to changes
in sodium intake through inverse changes in ANGII levels
and tissue ANGII receptor numbers (Hollenberg et al,
1972). The protocols therefore aimed to achieve low
baseline levels of endogenous ANGII through controlled
increases in dietary sodium intake before the study.
This allowed infusion of low doses of ANGII which
produced increments in plasma ANGII levels within the
physiological range while minimising the systemic actions
of ANGII. The sodium-loading phase lasted 5-7 days in
order to allow a new level of stable whole body sodium
balance to be established before the acute study.
3.3.2 Experimental design.
The renal and systemic effects of infusion of
angiotensin II (ANGII) have been examined under various
circumstances in different groups of subjects. The basic
clearance protocol is outlined in Figure 3.1; any
deviations from this protocol are specified as necessary
in individual experimental chapters.
Female subjects were not studied because of the
practicalities of urine collection and the potential for
variations in sodium balance during the menstrual cycle.
Normal volunteers were healthy normotensive (<140/90
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mmHg, diastolic phase V) males aged 18-45 years on no
medication. The diabetic patients had Type 1
(insulin-dependent) diabetes defined on the basis of age
at diagnosis and mode of presentation, which included the
presence of ketonuria at diagnosis indicating an absolute
need for insulin therapy. They were taking no medication
other than insulin, and were treated with at least two
injections of unmodified (soluble, regular) and isophane
(NPH) insulins daily ('conventional regime'). Some were
using a 'basal-bolus* insulin regime (unmodified insulin
before each meal, supplemented by an evening dose of
intermediate-acting insulin). In order to study only
the 'functional' changes associated with diabetes,
patients were screened to exclude those with any evidence
of diabetic tissue damage: this included a detailed
review of clinical records, a full physical examination
including direct ophthalmoscopy through dilated pupils,
and measurement of urinary albumin excretion in at least
two overnight urine collections. Objective tests of
cardiovascular autonomic function were not performed, but
no subject had any symptoms or signs of diabetic
autonomic neuropathy. All subjects were in good health
when studied with no recent episodes of hypoglycaemia or
other metabolic upset.
Subjects avoided xanthine-containing drinks, alcohol
and tobacco for at least 12 hours before each study.
Urine was collected for 24 hours before each study to
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document dietary sodium intake. Studies were performed
after an overnight fast in the Clinical Research
Laboratory starting at about 0800h, when a Teflon cannula
(Venflon) was inserted into a large forearm vein in each
arm. The subjects were supine except when passing urine.
They drank 500 ml of tap water between 0700h and 073Oh,
and a further 600 ml of iced water over a twenty minute
period after arriving at the hospital. The bladder was
emptied at about 0830h, and after this and all subsequent
urine collections the subjects drank an appropriate
volume of water, adjusted according to the volume of
urine passed and the volumes of fluid infused and blood
sampled, so as to maintain a stable positive water
balance. This hydration regime produced a near-maximal
diuresis at baseline: maximal diuresis was avoided
because of the possible effects of very high urine flow
rates on the renal handling of para-aminohippurate
(Smith, 1951) .
A sterile solution of Val5~ANGII amide (Hypertensin,
Ciba, Hoddesdon, UK) 5ju.g/ml was prepared in the Royal
Infirmary Pharmacy, and 3 0/*g aliquots stored in glass
ampoules at -70°C. This stock solution was thawed slowly
on the study day and diluted to a concentration of
0.2ju.g/ml in 0.15M sodium chloride before infusion.
Effective renal plasma flow and glomerular filtration
rate were estimated by measuring the renal clearances of
sodium para-aminohippurate (PAH) and Polyfructosan-S
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(Inutest) respectively. Priming doses of PAH (0.45g) and
Inutest (3.5g) were infused over 15 mins, followed by a
maintenance infusion of PAH (8.3g/l) and Inutest (10g/l)
in 0.15M sodium chloride at 120 ml/h. After a 75 minute
equilibration phase blood samples were withdrawn at the
beginning and end of accurately timed 30 minute clearance
periods. Two baseline periods preceded two urine
collections during infusion of ANGII at each of two
doses, with a final collection after the ANGII infusion
was stopped. Blood pressure and heart rate were
monitored every 10 minutes throughout the study using an
automated sphygmomanometer (Sentron, CR Bard Inc.,
Lombard, IL, USA). A 25 mmHg rise in mean arterial
pressure from baseline during ANGII infusion was
predetermined as the maximum safe increase, above which
the ANGII infusion would be stopped immediately. This
safety limit was never exceeded.
Sample collection.
Blood was collected before each voiding for
measurement of PAH, Inutest, electrolytes, creatinine and
haematocrit. Samples for PRA, plasma aldosterone (ALDO)
and plasma ANGII were drawn at baseline and before each
change in ANGII infusion dosage. Samples were collected
into chilled heparinized tubes stored on ice, except
those for ANGII estimations which were collected (total
volume 10ml) into chilled plastic tubes containing 0.5ml
phenanthroline 0.025M/EDTA 0.125M. After centrifugation
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at 4°C, aliquots of plasma for hormonal assays were
stored at -70°C. Assays of renal haemodynamic markers
and electrolytes were performed within 48 hours of the
study.
3.4 ANALYTICAL METHODS.
3.4.1 Renal Haemodynamics: the concept of 'clearance'.
Many of the technical advances which have given
novel insights into renal structure and function in vitro
are practically and ethically inapplicable to human
experimentation. Hypotheses generated in animal models
can often still only be tested in man using the
long-established techniques of whole kidney clearance
methodology (Smith, 1951) .
The renal 'clearance' of a substance is defined as
'the volume of plasma from which all of a substance can
be removed by the kidney in unit time'. This is an
artificial concept physiologically since the kidney
actually removes a much smaller proportion of the
substance concerned from all of the plasma passing
through it, but it gives a useful measure of excretory
capacity. Renal haemodynamic parameters are measured by
estimating the clearance from the blood of infused marker
substances which are chemically inert in the circulation.
After a loading dose and a period of equilibration to
ensure that net extrarenal tissue uptake of the infused
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marker is zero, the rate of infusion is assumed to be
equal to the rate of urinary excretion; the clearance is
calculated using the formula U/P * V/T, where U and P
X X X X
are urinary and plasma concentrations of the marker and
V/T is the urine flow rate.
A suitable marker for glomerular filtration rate
must be excreted only by the kidney, and after free
filtration at the glomerular barrier must not undergo
secretion or reabsorption in the tubules. Inulin is a
multimeric polymer of fructose with a molecular weight of
approximately 3500 which possesses these properties, and
is the standard against which new methods are compared.
The principal requirement in measuring renal plasma flow
is for a marker which is completely extracted from the
blood in one passage through vhe kidney; the weak acid
para-aminohippurate (PAH) fulfils this criterion. The
proportion of PAH in renal arterial blood excreted during
a single passage through the kidney (the Extraction
Ratio) varies between species, and in normal humans is
between 90 and 95%. Incomplete extraction of PAH is
mainly due to the shunting of blood through the inert
perirenal fat and the capsule, and recirculation of this
small proportion of PAH makes the measured clearance a
slight underestimate of true renal plasma flow. This
systematic source of error is acknowledged by using the
term effective or estimated renal plasma flow (ERPF) when
presenting results. Fortunately the error has minimal
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physiological importance because most shunting occurs
through structures which do not contribute to glomerular
filtration.
Two important assumptions are made when using PAH
clearance as an estimate of renal plasma flow. The first
is that the Extraction Ratio is the same for all
participants in the study, and the second that PAH
extraction is not affected by an experimental
intervention. Changes in the renal extraction ratio for
PAH during ANGII infusion may invalidate the use of PAH
clearance as a measure of renal plasma flow (Gassee et
al, 1976), but in the dog this effect is only important
-1 . -1
at high doses of ANGII (40 ngkg min intrarenally),
when the extraction ratio changes from 0.76 to 0.86. It
is therefore unlikely that the low doses of ANGII infused
in the present studies (up to 2.5 ng.kg 1min 1
intravenously) significantly affected the renal
extraction of PAH. Similarly, the extraction ratio for
PAH in patients with uncomplicated Type 1 diabetes does
not differ from normal controls (Nyberg et al, 1982).
3.4.1.1 Glomerular Filtration Rate.
Glomerular filtration rate was estimated by
measuring the clearance of Polyfructosan-S (Inutest,
Laevosan, Linz, Austria). The assay used a chemical
method (Dawborn, 1965) in which Inutest is hydrolysed to
fructose and then linked to indolylacetic acid to form a
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coloured adduct. Urine samples were diluted 10 to
50-fold before analysis, plasma samples were analyzed
without dilution.
Reagents.
i) A stock solution of Inutest (1000 mg/dl in
distilled water) was diluted to produce standard
solutions with concentrations from 5-50 mg/dl.
ii) Concentrated hydrochloric acid (conc. HC1, s.g.
1.18) .
iii) 0.5M hydrochloric acid. 174ml of conc. HCl
was made up to 4000ml in distilled water.
iv) 3-indolylacetic acid (3-IAA). 0.25g of 3-IAA
was added to 50ml 80% ethanol.
Procedure.
A semi-automated technigue was used (Technicon
Autoanalyzer, Technicon Instruments Corp., Tarrytown,
NY). Aspirated sample (0.4 ml/min) was mixed with 0.5M
HCl (1.8 ml/min) and air (0.8 ml/min, to encourage
mixing), and heated (10 mins, 60°C) to hydrolyse Inutest
to fructose. Protein was removed by dialysis, and
protein-free dialysate (0.3 ml/min) mixed with conc. HCl
(2.3 ml/min), 3-IAA (0.1 ml/min), and air (0.6 ml/min).
The colour was produced by heating this mixture for 8
minutes at 60°C. The intensity of colour (proportional
to inulin concentration) was estimated spectrophoto-
metrically (by absorbance at 520nm), and recorded
graphically. Standards were run before and after every
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assay run to confirm the validity of the standard curve
throughout the procedure, and unknown samples read from
the standard curve by interpolation.
3.4.1.2 Effective Renal Plasma Flow.
Effective renal plasma flow was estimated as the
renal clearance of para-aminohippurate (PAH). This was
assayed by a modification of a chemical method (Harvey
and Brothers, 1962) which diazotises the amino- group in
PAH to produce a coloured adduct. Urine samples were
diluted before analysis 50 or 100 fold to produce
concentrations lying within the standard curve. Plasma
samples were analyzed without dilution.
Reagents.
i) A solution of 0.25ml of 20% PAH (Merck, Sharp and
Dohme) in 100ml of distilled water (50 mg/dl), was
prepared every two months, and stored in darkness at 4°C.
Standard PAH solutions were prepared by dilution to
produce concentrations ranging from 0.5 to 5.0 mg/dl.
ii) Sodium nitrite. 0.25g NaNO^ in 100ml
concentrated hydrochloric acid, diluted to 1000ml in
distilled water.
iii) Ammonium sulphamate. 3.25g in 1000ml distilled
water.
iv) N-(1-napthyl)ethylenediamine hydrochloride




The same semi-automated apparatus was used as
described for inulin. Sample was aspirated (0.6 ml/min),
diluted with 0.15M sodium chloride (0.8 ml/min), and
aerated (0.8 ml/min). This mixture passed through a
•cuprophane' dialyzer, transferring PAH but excluding
larger molecules containing amino- groups such as
proteins. After diazotisation with sodium nitrite (0.6
ml/min), excess nitrite was destroyed by the ammonium
sulphamate (0.32 ml/min), and the colour produced by
coupling with NEDDC (0.32 ml/min). A complete cycle
lasted 30 minutes. After removing the air the intensity
of the colour was measured in a spectrophotometer
(absorbance, 550nm) and recorded graphically. Standards
were run at the beginning, middle and end of each series
to correct for baseline drift. A standard curve was
constructed, and the PAH concentration in samples read
from this by interpolation.
3.4.2 HORMONAL ESTIMATIONS.
3.4.2.1 Plasma Renin Activity.
Blood was collected into chilled tubes containing
sodium EDTA as anticoagulant, centrifuged immediately at
4°C, and separated plasma stored at -70°C until assay.
Plasma renin activity (PRA) was measured using a
commercial kit by radioimmunoassay (RIA) of angiotensin I
95
(ANGI) generated under standard conditions (SB-REN-2,
CIS, Gif-sur-Yvette, France) (Haber et al, 1969). The
assay involved two stages:
i) generation of ANGI in plasma samples under
standard conditions (renin being the rate limiting step
for the production of ANGI),
ii) single antibody solid phase (coated-tube) RIA in
two aliguots of the sample, one incubated at 37°C and the
other non-incubated (sample blank). RIA involved
competition between unlabelled ANGI (sample/standard) and
radiolabelled ANGI for binding sites in the solid phase.
The concentration of labelled ANGI on the solid phase
after incubation was inversely proportional to the sample
concentration.
Procedure.
1. Angiotensin I generation.
500pl of sample, lOpl of phenylmethylsulfonyl
fluoride ethanol (a converting enzyme inhibitor), and
50pl of buffer (pH 6) were added in turn to a non-coated
generation tube in an ice-bath. After mixing, 200pl was
transferred to a second generation tube which was
incubated for 4-5 hours in a thermostatically controlled
water bath. This long generation time was necessary
because PRA levels in the samples were generally low
after the period of dietary sodium loading before the
study. After incubation the tubes were immediately
placed in an ice-bath.
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2. Radioimmunoassay.
All assays were performed in duplicate. 50ul of
sample, sample blank or standard (0-50 ng/ml) and 500ul
12 5
of [ I] ANGI were added to an antibody-coated tube, and
incubated for 12-18 hours at room temperature. The
liquid contents of the tube were carefully aspirated, and
the residual radioactivity counted with a gamma counter.
Calculation.
For each standard ANGII concentration the ratio B/BQ
was calculated as: standard mean counts x 100%
•zero standard1 mean counts
A standard curve was constructed by plotting B/B0 against
ANGI concentration (ng/ml). The concentrations of ANGI
in an incubated sample (37°C) and its corresponding
non-incubated sample blank (4°C) were read directly from
the calibration curve, and PRA calculated as;
PRA = rnqr37oC) ~ ng(4°Cn x 1.12 ngANGI.ml-1h_1
generation time (hours)
The antibody used was highly specific for ANGI, with
cross-reactivity against ANGII of <0.2%. The lower
detection limit of the assay was 0.2 ng/ml (equivalent to
a PRA of about 0.04 ngANGI.ml 1h 1). The intra- and
interassay coefficients of variation were 7% and 8%
respectively.
3.4.2.2 Plasma Angiotensin II.
Extraction of plasma samples was followed by a
single antibody radioimmunoassay using a modification of
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the method developed and validated in the MRC Blood
Pressure Unit, Western Infirmary, Glasgow (Morton and
Webb, 1984). The antibody (R6B4) has a cross-reactivity
with ANGI of 0.5%; because of the low plasma renin
activity and ANGI levels after sodium loading, which fell
further during ANGII infusion due to the short feedback
loop, a correction for ANGI was not applied to the plasma
ANGII results.
Reagents.
i). Converting enzyme inhibitor for sample
collection. 4.65g EDTA dissolved in 100ml distilled
water was mixed with 0.45g c-phenanthroline dissolved in
lml absolute alcohol, and stored at 4°C.
ii). Assay buffer. 1.51g tris (hydroxymethyl)
methylamine [2-amino-2(hydroxymethyl)propan-1,3-diol
(tris)] dissolved in 250ml distilled water, mixed with
150ml 0.05M hydrochloric acid, with 0.1% sodium azide,
and stored at 4°C.
iii). Charcoal suspension. A suspension of 0.6%
activated charcoal (Sigma C-5260), 0.06% dextran, and
0.04% gelatin in 0.1M phosphate buffer pH 7.4 was stored
at 4°C.
iv). Radiolabel. The radiolabel was synthesized
using a chloramine-T iodination procedure, purified by





9.5ml of blood was collected into a chilled plain
tube containing 0.5ml of phenanthroline/EDTA, transported
on ice, centrifuged immediately (20 min, 4°C, 3000g), and
plasma stored at -70°C until extraction.
2. Extraction of plasma samples.
Samples were thawed at 4°C. Columns (Sep-Pak C18,
Millipore, Milford, Mass., USA) were pre-washed with 5ml
methanol and 5ml distilled water. 5ml of plasma (volume
accurately noted) was then applied to the column, and
washed with 5ml distilled water. ANGII was eluted by
passing through 2.2ml 80% methanol, the eluate collected
into polypropylene tubes (LP4), and evaporated to dryness
under an air stream in a sample concentrator at 40°C (3-4
hours). The dried extract was then resuspended in 0.5ml
of assay buffer (pH 7.4) containing 0.1% bovine serum
albumin.
3. Radioimmunoassay.
The antibody was made up in assay buffer and used at
a final dilution of 1:300,000, which bound 60-70% of the
radiolabel in the zero standard tube. Assays were
performed in duplicate. Radiolabel, standards and
quality controls were all made up in assay buffer. 50pl
of standard/QC/sample, 100pl antibody, and lOOpl
radiolabel (final concentration about 5000cpm) were added
in turn to LP3 tubes, and incubated overnight at 4°C.
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Free and bound radiolabel were separated by adding 0.6ml
of charcoal suspension at 4°C, centrifuging (30 min, 4°C,
1720g), and aspirating the supernatant (bound fraction).
The charcoal pellet was then counted for two minutes (LKB
gamma-counter). A standard curve was constructed using
standards between 0 and 10.24 ng/ml; quality controls and
unknown samples were read from this by interpolation.
Calculation.
The ANGII assay value (ng/ml) was multiplied by 0.5
(resuspended in 0.5ml), then by 10/9.5 (dilution during
sample collection), and divided by the volume of plasma
applied to the Sep-Pak column to give ANGII per ml of
plasma. All samples from each study were analysed in one
batch, with an intraassay coefficient of variation of
11%. The interassay c.v. was 10%; one batch of samples
(see Table 7.2) gave results which were consistently much
higher than expected. The reasoning that this is likely
to represent an assay problem rather than a real
difference is discussed in a footnote to the Table.
3.4.2.3 Aldosterone.
Blood was collected into plain tubes, centrifuged
promptly, and separated serum stored at -70°C until
assay. Aldosterone was measured by a single antibody
solid phase radioimmunoassay (RIA) (Coat-A-Count,
Diagnostic Products Corporation, Los Angeles, CA, USA)
without an extraction step (Tan et al, 1978).
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Procedure.
All samples were analyzed in duplicate. 200ul
aliquots of sample or standard (0-1200 pg/ml) were added
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to antibody-coated tubes, followed by 1 ml of [ I]-
aldosterone. After gentle mixing the tubes were
incubated for 3 hours at 37°C, and the liquid contents
then thoroughly aspirated. Residual radioactivity was
counted for one minute in a gamma counter.
Calculation.
For the standards the binding (mean counts) was
expressed as a percentage of maximum binding (the zero
standard): a plot of 'Percent Bound' against
'Concentration' on logit-log paper yielded a straight
line. Aldosterone concentrations in unknown samples were
read from this line by interpolation.
The antibody used had negligible cross-reactivity
against other steroid hormones or plasma constituents.
The lower detection limit of the assay was 16 pg/ml, and
the intra- and interassay coefficients of variation were
5% and 8% respectively.
3.4.2.4 Urine Free Dopamine.
About 80% of dopamine in urine is conjugated, mainly
as the sulphoconjugate, but free dopamine is believed to
be the physiological moiety. Urine samples were
therefore extracted to bind free dopamine, which was then
eluted. Free dopamine was measured by HPLC with
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electrochemical detection, using epinine (N-methyl
dopamine) as internal standard.
Urine samples.
Urine (20ml) was collected into Universal containers
containing 0.4 ml 5M HC1, giving a final pH <3 to prevent
oxidation of free dopamine. Samples were stored at -40°C
before assay.
Reagents.
i) Standards were prepared by diluting a stock
solution of dopamine HC1 (Sigma) (50mg in 50 ml M HC1)
first 1:99 with distilled water and then 1:49 with 0.01M
HC1, producing a final dopamine concentration of 200
ng/ml. The internal standard epinine (Sigma) was
prepared by diluting a stock solution (50 mg in 50 ml of
M HC1) first 1:9 with distilled water and then 1:199 with
0.01 M HCL to produce a final concentration of 500ng/ml.
ii) The HPLC solvent contained citric acid
monohydrate (5.75 g); sodium acetate trihydrate (6.80g);
sodium hydroxide (2.40g); 1-octane sulphonic acid, sodium
salt (0.10g); acetic acid (1.05 ml); and di-sodium EDTA
(0.10g) made up to one litre with deionised water, pH
5.2. Solvent was filtered through a 0.22 pm membrane
(Millipore) and methanol 10% (v/v) added prior to use.
Dissolved oxygen was removed by bubbling helium through
the mixture.
iii) Aluminium hydroxide (Brockman grade 1, BDH) was
pre-activated by heating at 200°C for 2 hours and stored
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at 100°C. Activated alumina was washed with 0.5M EDTA
before use.
Procedure.
Extraction of dopamine from urine.
The extraction process used the method of Anton and
Sayre (1964). Undiluted urine was used. 5 ml of test
sample and 0.5 ml of internal standard were added to 0.5
g of washed activated alumina, and buffered to pH 8.3
with 0.5M Tris. After mixing and centrifugation (lOOOg,
2 min, 4°C), the supernatant was syphoned off, and the
deposit washed three times with distilled water.
Dopamine was eluted by addition of 2 ml of 0.2M acetic
acid. Tubes were shaken for 10 minutes at 37°C and
centrifuged at 4°C. The supernatant was removed and
stored at -40°C. All samples were processed and analysed
in duplicate.
Dopamine standards were prepared in the range 5-50
ng/ml, and 0.5 ml of the internal standard, 0.5 pg/ml,
was added to 5ml of each standard concentration. All
standards were extracted by the same procedure as test
samples, and were frozen at -40°C. Fresh standards were
prepared every month. The recovery of dopamine from the
extraction process was 69.7(SD 0.5%) compared against
unextracted standards.
Analytical system.
Each assay consisted of test samples, duplicate
standards, run at the beginning and end of each batch,
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and two quality control samples. 5 jal were injected
automatically into a solvent stream delivered at 1 ml/min
to a Waters 4 pm, Novapak C18 HPLC column under radial
compression. The column effluent stream was delivered to
an electrochemical detector (Waters 460), at a potential
of 0.4 volts, in oxidative mode, with background current
approximately 0.5 mA. Output signals were passed to a
computerised integrator which measured the area under the
curve of peaks of interest.
Calculation.
The integrated area of each standard peak was
divided by the area of its internal standard. The
duplicated standard ratios were averaged and a standard
curve plotted against the known concentrations, the plot
providing a straight line relationship. Test sample
ratios were read from the curve and urine dopamine
expressed in nmol/1. The sensitivity of the assay was 5
ng/ml. Intra- and interassay co-efficients of variation
were 4% and 6% respectively.
3.4.3 Miscellaneous.
Sodium and potassium concentrations in plasma and
urine were measured by emission flame photometry (Corning
435, Ciba Corning Diagnostics) with lithium as internal
standard. Osmolality was measured by freezing point
depression (3M0 Osmometer, Advanced Instruments Inc.,
Mass., USA). Creatinine, total protein and albumin were
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measured by standard chemical methods using a Gemstar
autoanalyser. Urinary albumin concentration was
estimated by an immunoturbidimetric assay (Albusure QNT,
Cambridge Life Sciences, Cambridge) (Spencer and Price,
1985), urinary and plasma glucose by the glucose oxidase
method, and glycated haemoglobin by an electrophoretic
method (Read et al, 1980). Plasma free insulin was
assayed by double antibody radioimmunoassay (Soeldner and
Stone, 1965); samples from diabetic subjects were
extracted with polyethyleneglycol (PEG) 6000 immediately
after sampling to remove the fraction of insulin bound to
anti-insulin antibodies in diabetes (Nakagawa et al,
1973). The intraassay c.v was 8%. Serum converting
enzyme activity was estimated by measuring the in vitro
rate of hydrolysis of a synthetic analogue of ANGI,
N-(3-{2-furyl}acrolyl)-L-phenylalanylglycylglycine, using
a spectrophotometric assay (Maguire and Price, 1985) .
3.4.4 Lithium estimation.
Two methods were assessed for the estimation of
lithium concentrations in serum and urine. Urinary
lithium assay by flame emission photometry has
conventionally been regarded as unreliable because of
variable background interference by sodium and potassium
(internal standards for measuring serum lithium by
emission photometry contain sodium 140mM and potassium
5mM as background 'blanks'). Lithium estimation was
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therefore initially attempted by flameless atomic
absorption spectrophotometry (Perkin Elmer 272,
Beaconsfield, Bucks.)/ using lOpl samples without
dilution or deproteination. Surprisingly, in this system
the absorbance for any given lithium concentration was
markedly affected by the background sodium concentration.
The pattern of interference suggested that sodium was
suppressing detection of the signal produced by the much
lower concentration of lithium (Figure 3.2).
The validity of emission photometry was therefore
re-examined (IL943, Instrument Laboratories, Warrington)
using caesium chloride 1.50mM as internal standard.
'Blank' values for a range of sodium and potassium
concentrations alone and in combination were measured by
aspiration directly into the flame after predilution into
CsCl 1.5mM (Figure 3.3). The interference produced by
both cations was independent of lithium concentration,
and the total background 'blank' was accurately predicted
by an additive model (Figure 3.4), with no evidence of
separate indirect interference beteen sodium and
potassium. The data for each lithium concentration was
therefore pooled to provide separate regression equations
for background sodium and potassium (Figure 3.5).
Samples collected after pretreatment with lithium
750mg were diluted approximately 100-fold by an automated
sampler before entering the flame. At this dilution the
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Figure 3.2: Effect of background sodium on Absorbance(Li)
for a) 10mM, b) 50pM. c) 200mM and d) 500/jM
lithium. A is shown in arbitrary units.
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Figure 3.3: Effect on apparent lithium concentration of varying
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Figure 3.5: Regression of 'error' in lithium estimation due to back¬
ground a) sodium and b) potassium concentration. Data for
four concentrations of lithium (Fig 3.3) has been pooled.
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0.1—0.2mM, serum 1.4 mM) and potassium concentrations
(urine 0.05-0.1mM, serum 0.05mM) were very small and were
constant throughout the study within each subject (see
Figure 3.5). These very minor errors were therefore
ignored when calculating lithium clearance.
Samples collected after lithium 250mg were diluted
manually 1:10 into 1.65mM caesium chloride (0.2778 g/1),
producing a final caesium concentration of 1.50mM as
above: this sample was then aspirated into the flame
without further dilution. By avoiding the large dilution
produced by the automated sampling procedure the overall
sensitivity of the assay was increased about 9-fold.
Serum lithium concentrations of O.lOmM could thus be
measured to three decimal places with an intraassay
coefficient of variation of 2%. However, because the
sample was diluted only 11-fold there was a greater
disparity in background interference between serum and
urine samples (Na+; urine l-2mM, serum 13mM: K+; urine
0.5-1.0mM, serum 0.5mM). These results were therefore
corrected using the equations in Figure 3.5 before
calculating lithium clearance. The need to apply a
correction for sodium and potassium concentrations
probably makes these results less reliable than those
obtained after lithium 750mg.
Samples from each study were always assayed together
to prevent interassay variation from having any effect on
the lithium clearance results (U*V/P).
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3.5 CALCULATIONS AND STATISTICAL ANALYSES.
Renal clearance was calculated using the formula
Ux*V/Px, and Px being the urinary and plasma
concentrations of the substance x, and V the urine flow
rate. P^ was the mean of the plasma level at the
beginning and end of the clearance period concerned.
Fractional clearance was defined as (Clearance/GFR)*100%.
Mean arterial pressure (MAP) was estimated as
diastolic pressure plus one third of the pulse pressure.
Effective renal vascular resistance (ERVR) was estimated
by the formula:
-5
(MAP—10) x (1-Hct) x 72269 dynes.sec.cm
ERPF
which assumes a constant renal venous pressure of
lOmmHg.
Statistical analyses were performed on an IBM/PC
microcomputer using Statistical Package for Social
Sciences software (SPSS/PC+ version 2.0). The results
are presented as mean(sem) unless otherwise stated. In
all the studies (with the exception of Chapter 9),
results from the two baseline periods were not
significantly different for any variable, and the mean of
these periods was therefore used in the analyses. The
influences of group, ANGII infusion, and drug treatment
were assessed by two-way analysis of variance with
repeated measures correction (SPSS/PC+ MANOVA; Snedecor
•f
and Watson, 1987). This procedure allows for the
non-independence of successive data points in experiments
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involving repeated measurements on a subject on one
occasion, or on more than one occasion after different
treatments. Data sets were always tested for inequality
of variances, and when this was detected the number of
degrees of freedom was adjusted using the
Greenhouse-Geiser Epsilon to give a more conservative
significance level. T-tests (two-tailed) were paired or
unpaired as appropriate, and were corrected when
necessary for multiple comparisons (Bonferroni's method).
In many of the Figures which illustrate differences
between whole response curves for either groups or
treatments, time interactions are not listed and only
summary F ratios and P values for group interactions are
quoted, without using subsequent t-tests. This
simplifies the presentation of data and avoids the
attribution of particular (often artificial) significance
to specific timepoints. Correlation between variables
was tested by univariate (least squares) or multivariate
linear regression analysis. Non-parametrically
distributed data was log-transformed before analysis, or
was analysed by the Kruskal-Wallis test (a generalized
analysis of variance for non-normally distributed data)
followed by Wilcoxon 'Z' or Mann-Whitney "LP tests. A




THE ACTIONS OF EXOGENOUS
ANGIOTENSIN II IN NORMAL MAN.
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4 .1 INTRODUCTION.
The physiological actions of angiotensin II (ANGII)
and its interactions with other renal hormone systems
were reviewed in Chapter 1. This preliminary study was
designed firstly to determine whether the expected
physiological actions of ANGII on the kidney could be
demonstrated in normal man when ANGII is administered
systemically in very low doses. Secondly, because the
intrarenal actions of ANGII are the opposite of the
effects attributed to endogenous dopamine (DA), which may
interact with the RAAS at several levels, the effect of
inhibition of endogenous DA synthesis on the renal
response to ANGII infusion was also examined to determine
whether there is any intrarenal interaction between the
RAAS and DA.
4.1.1 Protocol.
Six healthy subjects (mean age 32 years, range 27-39
years) were studied on two occasions at least one month
apart. Their normal diet was supplemented with sodium
chloride 200 mmol/day ('Slow Sodium', Ciba, Horsham) for
five days before each study to suppress endogenous ANGII
and to augment intrarenal DA levels. Renal responses to
-1 . -1
infusion of ANGII at 0.5 and 1.0 ng.kg bodyweight .mm
were determined using the clearance protocol outlined in
Chapter 3. On the 'active' day the subjects took
carbidopa (Merck, Sharp, and Dohme, Hoddesdon, Herts,
115
U.K.) by mouth, lOOmg at 0700h and 50mg at lOOOh, to
suppress intrarenal DA production. Neither ANGII
infusion nor carbidopa caused any side effects.
4.2 RESULTS.
Mean arterial pressure rose minimally during ANGII
infusion on both days (control: 91(2) to 94(3) mmHg,
P=NS; carbidopa: 89(2) to 95(1) mmHg, P<0.02). Heart
rate did not change during ANGII infusion (data not
shown). Plasma ANGII levels were low at baseline (Table
4.1), and the increment in ANGII levels during infusion
was not affected by carbidopa. Plasma renin activity and
plasma aldosterone were suppressed at baseline and did
not change significantly during ANGII infusion on either
day. Plasma sodium and potassium concentrations and
urinary potassium excretion did not change during ANGII
(data not shown).
Carbidopa did not change baseline GFR, or the small
but significant fall in GFR that occurred during ANGII
infusion on both days (Fig 4.1a). There was a consistent
elevation in ERPF after carbidopa pretreatment during
the baseline period and during ANGII (Fig 4.1b), but the
reduction in ERPF during ANGII was the same on both days.
Filtration fraction rose to the same extent during ANGII
on both days (control: 18.4(0.6) to 21.9(1.9) %, P<0.02;
carbidopa 15.8(1.3) to 18.6(1.4) %, P<0.01).
Urinary dopamine excretion (Fig 4.2) was suppressed
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Table 4.1: Plasma renin activity (PRA), plasma
angiotensin II (ANGII), and plasma aldosterone (ALDO) in
six normal subjects during ANGII infusion with and
without carbidopa pretreatment.
B1 B2 ANGII(ng.kg "^.itiin ^")
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Figure 4.1: a) glomerular filtration rate and b) effective renal plasma flow in 6
normal subjects during ANGII infusion with (■) and without (o) carbidopa.

























21060 90 120 150
Time (minutes)
Figure 4.2: Urine dopamine (DA) excretion in 6 normal subjects during
ANGII infusion without carbidopa pretreatment.
Mean(sem). MANOVA; F|lhlM]=3.55f P=0.007. *, P<0.05 vs baseline.
DA excretion was below the detection limit after carbidopa.
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suppressed to undetectable levels (<0.16 nmol/min) in each
subject throughout the study after administration of
carbidopa. On the control day urine DA fell in all
subjects during ANGII infusion (1.23(0.10) to 1.08(0.08)
nmol/min, P<0.05), with a rebound in excretion above the
baseline level during the recovery period afer the ANGII
infusion had been stopped (P<0.05).
Urine flow rate (Figure 4.3) fell to a similar
extent during ANGII on both days (control 7.1(0.3) to
4.7(0.7) ml/min, P<0.05; carbidopa 9.2(1.1) to 5.5(0.9)
ml/min, P<0.01). Urinary sodium excretion was similar
during the 24 hours before both study days (control
370(37) mmol, carbidopa 335(27) mmol). Baseline
absolute sodium excretion (Fig 4.4a) was not influenced
by carbidopa (control 468(68) jumol/min, carbidopa 423 (56)
jumol/min) , and the antinatriuretic response to ANGII was
not modified by carbidopa pretreatment, either in terms of
absolute (Figure 4.4a) or fractional excretion of sodium
(Figure 4.4b). Cumulative sodium excretion was the same
on both days (total excretion: control 66(8) mmol,
carbidopa 64(9) mmol). The sodium load infused during the
study was approximately 70 mmol on both days, hence sodium
balance was stable throughout both studies.
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Figure 4.4: a) absolute (UNaV) and b) fractional sodium excretion (FENa) in 6
subjects during ANGII infusion with (■) and without (o) carbidopa.
Mean(sem). * P<0.05, ** P<0.02, *** P<0.01 vs baseline.
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4.3 DISCUSSION.
This study confirms that physiological increments in
plasma ANGII concentrations which induce minimal effects
on the peripheral circulation cause renal vaso¬
constriction, antinatriuresis and antidiuresis in normal
man. The rapidity of onset of the changes in sodium and
water excretion, the absence of changes in urinary
potassium excretion, and the attenuated response of
aldosterone to exogenous ANGII all suggest that the
response to ANGII was independent of the sodium-retaining
effect of aldosterone (Ames et al, 1965). The fall in
glomerular filtration rate and filtered load of sodium
during ANGII reduced total tubular reabsorption of
sodium, but the fraction of the filtered load which was
reabsorbed was increased. This effect of ANGII may be
predominatly localised to the proximal tubule (Hall et
al, 1986a; Seidelin et al, 1989), but it is not possible
from this data to determine whether the mechanism
promoting increased sodium reabsorption is a direct
tubular action of ANGII, a change in peritubular
capillary haemodynamics, an altered distribution of
intrarenal blood flow, or a combination of these factors.
However, the doses of ANGII used in this study have no
effect on intrarenal blood flow distribution in the dog
(Johnson and Malvin, 1977).
Urinary dopamine (DA) excretion is a sensitive
marker of intrarenal DA synthesis (Brown and Allison,
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1981), and the fall in urinary DA during ANGII infusion
and the rebound above baseline during the recovery phase
indicate real changes in the renal levels of the hormone.
Similarly, the suppression of urinary DA to undetectable
levels after carbidopa administration indicates that renal
DA synthesis was effectively prevented. Such acute
inhibition of DA synthesis did not affect basal sodium
excretion in this study, as previously reported (Jeffrey
et al, 1989). One explanation of the discrepancy between
these results and previous studies is that dopamine may
modulate the activity of other natriuretic or
antinatriuretic systems, rather than directly influencing
tubular sodium handling itself. This is the postulate
which was examined in the present study by inhibiting the
formation of endogenous dopamine, and under these
conditions there was no direct interaction between
intrarenal DA and the renal actions of ANGII. The direct
negative feedback effect of exogenous ANGII on renin
release precludes any conclusions regarding the influence
of renin release on DA synthesis.
The fall in urine DA during ANGII infusion did not
affect the renal response to ANGII, but is nonetheless
interesting. Changes in urine DA were qualitatively
similar to the changes in water excretion, but were
probably not causally related since urine DA is
unaffected by a pure water diuresis (Casson and Lee,
unpublished data). Variations in urine DA also
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paralleled the changes in absolute and fractional sodium
excretion during the study. Since acute inhibition of
intrarenal DA synthesis did not affect urinary sodium
excretion at baseline or during ANGII infusion, the
correlation between urine DA and sodium excretion
suggests if anything that renal tubular sodium handling
may exert a modulatory effect on DA synthesis rather than
vice versa.
If the reduced proximal tubular sodium delivery due
to the fall in GFR during ANGII infusion led to reduced
absolute proximal sodium reabsorption, despite the
increase in fractional proximal sodium reabsorption which
ANGII produces (Seidelin et al, 1989), then the present
data would be consistent with the notion that proximal
tubular reabsorptive capacity in some way regulates the
synthesis of DA in the proximal tubular cells. Such a
hypothesis does not discount a physiological role for
dopamine in regulating sodium handling in some
circumstances, but could explain why several studies in
addition to this one have failed to show any influence of
dopaminergic inhibition or blockade on a variety of
interventions causing both natriuresis and
antinatriuresis.
The renal haemodynamic response to ANGII was
unchanged after pretreatment with carbidopa, but ERPF was
consistently elevated on the carbidopa day. This finding
was unexpected as inhibition of a putative vasodilator
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might be expected to accentuate the renal vasoconstrictor
effect of ANGII and to reduce ERPF. Pooling of the data
for plasma PAH (n=54) and urinary PAH excretion (n=48)
shows that the urinary excretion of PAH was unchanged by
carbidopa (control 375(20) mg, carbidopa 349(13) mg;
P=NS), but that the plasma PAH level was reduced (control
2.69(0.09) mg/dl, carbidopa 1.95 (0.05) mg/dl; P<0.0001,
unpaired t-test). The increase in calculated PAH
clearance after carbidopa is therefore attributable to
the use of a reduced denominator in the clearance formula
U*V/P. PAH and carbidopa both contain an amino group,
but the peak heights of the PAH standard curve were
unaffected by the presence of carbidopa over a wide range
of PAH and carbidopa concentrations, and pure carbidopa
was not detectable by the PAH assay system, so that an in
vitro artefact was not involved. In any event such an
interaction would have tended to increase rather than
decrease the plasma PAH concentration. The speculation
that the presence of carbidopa may alter the renal
extraction ratio of PAH is also untenable since ER is
about 0.95 in man (Nyberg et al, 1982) and the potential
for an increase in ER (<5%) can not account for the 25%
difference in the plasma PAH levels between the study
days. The explanation for the difference in ERPF is
therefore not clear, but does not affect the main
conclusion of the study, as carbidopa did not affect the
fall in renal plasma flow which occurred during ANGII.
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In conclusion, this experiment confirmed that the
known actions of angiotensin II described in previous
human and animal studies can be reproduced in normal man
by infusion of a very low dose of ANGII which produces
plasma ANGII concentrations within the physiological
range. The results additionally show that dopamine plays
little part in regulating the renal response to
physiological concentrations of ANGII. Dopamine inhibits
noradrenaline release from sympathetic ganglia and nerves
via DA2 receptors (Goldberg, 1984), and it would be
relevant to establish whether dopamine inhibition or DA2
receptor blockade modifies the renal response to other
antinatriuretic stimuli such as noradrenaline infusion.
The mechanism for the reduction in urinary DA excretion
which occurs during ANGII infusion is not clear.
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CHAPTER FIVE.
THE EFFECT OF LITHIUM ON RESPONSES TO
EXOGENOUS ANGIOTENSIN II IN NORMAL MAN.
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5.1 LITHIUM IN RENAL PHYSIOLOGY.
Micropuncture techniques used in animal studies are
inapplicable to human renal physiology, and the
contributions of proximal and distal tubular sites to
overall sodium and water reabsorption can not be measured
directly. Various markers of proximal tubular sodium
delivery in man, such as uric acid and phosphate
clearances, have been found to be unsuitable. Analysis
of tubular function during maximal water diuresis is also
unreliable because of the existence of "backflow" of
water across the collecting duct even in the absence of
vasopressin (Bartoli et al, 1983). Use of the renal
clearance of the monovalent cation lithium as an estimate
of proximal tubular sodium rejection has therefore
aroused great interest.
In normal subjects given a single oral dose of
lithium, diuretic drugs with a predominantly proximal
tubular action increased the clearances of sodium and
lithium equally, while diuretics with an action on the
distal nephron (amiloride, spironolactone, triamterene)
affected lithium clearance minimally or not at all
(Thomsen and Schou, 1968; Thomsen et al, 1969; Thomsen
and Leyssac, 1986). Fractional lithium excretion was
similar to existing estimates of fluid delivery into the
loop of Henle based on data from experiments performed
using the maximal water diuresis method, and was
independent of GFR, leading Thomsen to suggest that
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lithium clearance provides a quantitative measure of
fluid and sodium delivery from the proximal tubule
(Thomsen, 1984).
The validity of this postulate depends on three
assumptions. Firstly, lithium should be reabsorbed in
the proximal tubule in the same proportion as sodium and
water. Secondly, lithium should be neither reabsorbed
nor secreted distal to the late proximal tubule.
Thirdly, lithium should have no pharmacological effects
on renal function in the doses used. If these criteria
are fulfilled the urinary clearance of lithium is equal
to the proximal tubular delivery of sodium (and to
proximal water delivery since proximal reabsorption of
sodium is iso-osmotic). The equations describing tubular
sodium handling then require the measurement only of
urinary sodium and lithium clearances, and glomerular
filtration rate:
Absolute proximal sodium reabsorption = (GFR-C^) x PNa
Fractional proximal sodium reabsorption = 1-(C^/GFR)
Absolute distal sodium reabsorption = (CT.-C„ ) x P„^ v Li Na' Na
Fractional distal sodium reabsorption = 1-(CNa/cLi)
where GFR is glomerular filtration rate, and CNa and CL.
are the urinary clearances of sodium and lithium.
Similar expressions allow calculation of segmental water
handling.
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Early micropuncture studies (Hayslett and
Kashgarian, 1979; Thomsen et al, 1981; Shirley et al,
1983) supported the validity of lithium clearance as a
proximal marker, and numerous clinical studies have
tested the method in man by comparing lithium clearance
with measurements of sodium excretion made during maximal
water diuresis, or by studying the effects of diuretics
on renal lithium handling (Thomsen 1990, refs 16-28) .
Some of this data questions the validity of lithium
clearance, especially in sodium-depleted states. Thomsen
himself showed (Thomsen, 1977) that lithium clearance
decreased relatively more than maximal urine flow rate in
rats with diabetes insipidus during low sodium intake,
and that the urinary lithium level became less than the
plasma lithium concentration, indicating that lithium was
being reabsorbed against its concentration gradient, an
improbable event in the proximal tubule as lithium can
diffuse freely via the paracellular pathway in the
electrically 'leaky' proximal tubular epithelium
(Holstein-Rathlou, 1990). Amiloride-sensitive 'post-
proximal' lithium reabsorption occurs during severe
sodium restriction in rats (Kirchner, 1987) and dogs
(Boer et al, 1987), suggesting that the phenomenon occurs
in the late distal tubule or the collecting duct where
amiloride-sensitive channels are most prominent (Brown,
1989). Transport of lithium does not depend upon
Na+-K+-ATPase (Dunham and Senyk, 1977), and lithium
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therefore theoretically could not be reabsorbed through
•tight' epithelia such as the distal renal tubule. It
has thus been suggested (Holstein-Rathlou, 1990) that
sodium restriction induces amiloride-sensitive lithium
transport due to the insertion of sodium channels into
the apical surface of distal tubular cells (Bridges,
1989), such channels being activated by the high levels
of aldosterone found in sodium-depleted animals, and
possibly also by vasopressin (Boer, 1988a). Human
studies have not conclusively demonstrated amiloride or
spironolactone-sensitive lithium reabsorption during low
dietary sodium intake (Roos et al, 1985; Boer, 1988b;
Atherton et al, 1987; Bruun et al, 1987), but it is
nonetheless tacitly accepted that sodium repletion is a
prudent precondition for valid interpretation of human
lithium clearance data.
There is also debate as to whether the increased
lithium clearance induced by intravenous frusemide
(Atherton et al, 1987), an effect which is also more
easily demonstrated after sodium depletion, shows that
lithium can be carried by the Na-K-2C1 cotransporter in
the thick ascending limb, or simply reflects the weak
carbonic anhydrase activity of frusemide which could
directly increase delivery of sodium from the proximal
tubule. Ethacrynic acid, which lacks carbonic anhydrase
activity, also increases lithium clearance but to a
smaller extent than frusemide, suggesting that some
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lithium reabsorption (estimated at about 10% of the
filtered load) occurs in the loop of Henle (Boer et al,
1990). The validity of lithium clearance is also dubious
during osmotic diuresis (Skott et al, 1987) and after
prostaglandin synthetase inhibition (Rabelink et al,
1989), and during vasopressin-induced antidiuresis
(Kirchner, 1989). Despite these shortcomings lithium
clearance remains the only method available for analyzing
segmental renal sodium reabsorption in humans, albeit
approximately, and delineation of its reliability in
different experimental situations and diagnostic groups
is an important prerequisite for the application of the
method to the study of disease states.
The controversy as to how 'post-proximal' handling
of lithium affects the validity of lithium clearance has
overshadowed evidence that lithium interacts pharmaco¬
logically with intrarenal hormone systems even at the low
plasma levels produced by single doses. Lithium causes a
natriuresis when given acutely (Murphy et al, 1969;
Shirley et al, 1991), but attenuates the natriuretic
responses to the dopamine prodrug gamma glutamyl-L-dopa
(Jeffrey et al, 1988), to saline infusion (Jeffrey et al,
1989), and to atrial natriuretic peptide (Freestone et
al, 1990). Lithium also increases plasma renin activity
(Jeffrey et al, 1988; Jeffrey et al, 1989), and inhibits
the distal tubular action of mineralocorticoids (Stewart
et al, 1987; Stewart et al, 1988).
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The dose of lithium used for analyzing tubular
sodium handling in normal man is usually 300-500mg
(Girbes et al, 1990; Seidelin et al, 1989), but doses of
600-750mg have usually been given in studies of sodium
handling in diabetes (Hannedouche et al, 1990; Trevisan
et al, 1990) . It is not known whether these higher doses
of lithium interact with the RAAS at the level of the
proximal tubule. Because the effects of angiotensin II
(ANGII) on renal sodium handling are mediated mainly at
proximal tubular level, this study examined renal and
systemic responses to ANGII infusion in normal man after
pretreatment with two different doses of lithium in a
placebo controlled study.
5.1.1 Protocol.
Ten subjects, mean age 30.7 (SD 3.3) years (range
2
27-45 years) and body mass index 22.7(1.2) kg/m , were
studied on two occasions at least one week apart. Six of
these subjects also completed the protocol on a third
occasion. Their normal diet was supplemented with sodium
chloride lOOmmol/day ('Slow Sodium') for five days before
each study. The subjects collected urine from 2100h
until 0700h on the day before the study, and at 2100h
took lithium carbonate 750mg (Camcolit, Norgine, Oxford)
(Li750, n=10), lithium 250mg (Li250, n=6), or placebo
control (C, n=10), in single blind random order. Renal
and systemic responses to infusion of ANGII at doses of
-1 . -1
1.25 and 2.5 ng.kg bodyweight mm were studied.
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5 . 2 RESULTS.
5.2.1 Hormonal responses to angiotensin II (Table 5.1).
There were no untoward effects due to either ANGII
or lithium during any of the studies. Plasma ANGII
concentrations were comparable at baseline on all three
study days when levels were low after the period of
sodium loading, and during ANGII infusion. Lithium did
not affect baseline PRA or the fall in PRA during ANGII
infusion. Plasma aldosterone (ALDO) was higher at
baseline after Li750 than after C (P=0.03) or Li250
(P=0.02), but the increment in ALDO during ANGII (all
days PcO.Ol) was similar on each day (&ALDO: C 223(59),
Li250 223 (43), Li750 214 (52) pmol/1).
5.2.2 Systemic responses to angiotensin II (Table 5.2).
Baseline heart rate was similar before each study,
and did not fall during ANGII infusion (data not shown).
Mean arterial pressure (MAP) was significantly higher at
baseline after Li750 had been given (P=0.014); this
difference was due to a rise in systolic blood pressure
(P<0.02) rather than the very small change in diastolic
pressure. Because of this increase in baseline MAP, the
rise in MAP during ANGII was significantly reduced after
Li750 (P<0.02), with an attenuated increase in both
systolic and diastolic blood pressures. The pressor
response to ANGII after Li250 was not significantly
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Table 5.1: Plasma hormone responses to ANGII infusion in
ten normal subjects in presence or absence of lithium.






















ANGII C 6.1(1.2) 10.4(2.1) 21.3(3.9)
(pg/ml) Li2 50 8.8 (1.6) 13.8 (3.7) 25.2 (6.7)
Li750 5.7(1.1) 11.6(3.4) 16.0(3.1)
Mean(sem) or median(lst-3rd quartiles).
PRA, plasma renin activity: ALDO, aldosterone: ANGII,
angiotensin II. C, control; Li250, lithium 250mg; Li750,
lithium 750mg. a, P<0.05; P<0.01 vs baseline: C,
P<0.05 vs Li750.
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Table 5.2: Blood pressure responses during angiotensin II
infusion in ten normal subjects in presence or absence of
lithium.
Baseline Change from baseline (mmHg)
R
1.25 2.5






















Mean(sem). R, recovery period. SBP: systolic blood
pressure; DBP: diastolic blood pressure; MAP: mean
arterial pressure; C: control; Li250: lithium 250mg;
Li750: lithium 750mg. a, P<0.01; b, P<0.02; c, P<0.05 vs
d e
baseline: , P<0.05; , P<0.02 vs control.
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different from control. Haematocrit did not differ
between the three study days, and did not change during
ANGII (C 42(1)% to 41(1)%, Li250 40.5(1)% to 40(1)%,
Li750 41(1)% to 40.5(0.5)%).
5.2.3 Renal haemodynamics.
Baseline GFR and ERPF were not changed by the
administration of lithium (Figure 5.1a,b). ANGII
infusion produced a dose-dependent fall in ERPF and a
proportionately smaller fall in GFR, leading to a rise in
filtration fraction (Figure 5.1c). Li250mg did not
modify the renal haemodynamic response to ANGII (data is
omitted from the Figures for clarity). The absolute
changes in ERPF and GFR during ANGII infusion were
smaller after Li750 but were not significantly different
from C: however, the rise in filtration fraction during
ANGII 2.5 ng.kg 1min 1 was reduced after Li750 (Figure
5.1c, 5.2a) (MANOVA test of interaction between treatment
and change in FF with time, P=0.01). Baseline effective
renal vascular resistance (ERVR) was not affected by
either dose of lithium, but the increase in ERVR during
ANGII was smaller after Li750 than C (Li750 5530(270) to
9230(450), C 5140(255) to 10235(550) dynes.sec.cm"5;
MANOVA test of interaction between treatment and change


























cJ E500 £400- 300J











Figure5.1:a)lomerularfiltrationt ,b)effec iveenalp asmowdcfrac nnor lsubjectsd i gANGIIin on. Mean(sem).Allp ram tersch ng dsignificantlydur ngNGII,PvaludLi250th vbeeo tedfsakefc rity.
a)AFFbAERVR ANGII(ng.kg~1min~1)
Figure5.2:Increasifiltrationrac(FF)ndnalvascularres stance(ERVR) intenormalsubjectsdu ingANGIIinf s onafterplac bocon r l□, lithium250 g■,andlit i7El.★P<0.05vsplacebo.Mean( em).
5.2.4 Electrolyte excretion.
The volume and sodium content of the overnight urine
collection increased after lithium (Na+: Li750 131(21)
mmol, Li250 96(14) mmol, C 79(10) mmol, Li750 vs C
P=0.007; volume: Li750 0.81(0.13)1, Li250 0.60(0.08)1, C
0.50(0.06)1, Li750 vs C P=0.021). Significant changes in
overnight urine potassium excretion and osmolality were
not detected after lithium (K+; Li750 27.8(4.1) mmol,
Li250 18.9(2.2) mmol, C 20.9(2.3) mmol: osmolality; Li750
610(78), Li250 751(120), C 780(85) mOsm/kg) . Baseline
urine flow rate and the antidiuresis which occurred
during ANGII infusion were not affected by the presence
of lithium (Li750, 12.2(0.9) to 4.4(0.7) ml/min, P<0.001;
Li2 50, 12.7 (0.6) to 4.4(0.8) ml/min, P<0.005; C,
13.1(1.0) to 5.3(0.6) ml/min, P<0.001). The fall in
urine flow rate during ANGII was accompanied by a rise in
urine osmolality on each day (Li750 110(11) to 225(30)
mOsm/kg, Li250 104(10) to 219(41) mOsm/kg, C 115(10) to
168(17) mOsm/kg, all P<0.02).
Baseline sodium excretion and the antinatriuretic
response to ANGII were indistinguishable after Li250 and
C. Despite the overnight natriuresis after Li750, the
urinary excretion rate of sodium (UNaV) was not increased
at baseline after Li750 (Fig 5.3a). Cumulative sodium
excretion during ANGII infusion was higher after Li750
than C (67.6(3.5) vs 55.7(2.8) mmol; P<0.05). Although
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Figure 5.3: a) absolute and b) fractional sodium excretion in ten normal
subjects during ANGII infusion after placebo and lithium
750mg. Mean(sem). Li 250mg data is omitted for clarity.
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(P=0.065), the absolute fall in UNaV during ANGII was not
significantly reduced after Li750 (165(21) vs 206(30)
umol/min). Baseline fractional sodium clearance (FENa)
was not increased after either dose of lithium, but the
minimum level to which FENa fell during ANGII was
slightly but significantly higher after Li750 (2.73(0.24)
to 1.34(0.08)%) than after C (2.69(0.26) to 1.01(0.11)%;
MANOVA test of interaction between treatment and change
in FENa with time, P=0.02), implying attenuation of the
whole kidney tubular antinatriuretic response to ANGII
after lithium pretreatment.
5.2.5 Lithium clearance data (Table 5.3).
Serum lithium concentrations twelve hours after the
750mg and 250mg doses were 0.29(0.02) mmol/1 and
0.10(.01) mmol/1 respectively. FET. fell during ANGIIIjI
(PcO.Ol), suggesting an increase in fractional proximal
reabsorption of sodium. In addition the ratio CNa/CLi
also fell during ANGII (P<0.05), implying an increase in
fractional distal tubular sodium reabsorption. Both the
baseline data and the ANGII-induced changes in lithium
clearance were similar after both doses of lithium.
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Table 5.3: Sodium and lithium clearances during
angiotensin II infusion in normal subjects after
pretreatment with lithium 250mg (n=6) and lithium 750mg
(n=10).
Baseline ANGII(ng.kg 1min 1) R
1.25 2.5
CM Li2 50 2.4(0.2) 1.3(0.2)° 1.0(0.1)d 1.8(0.3)
(Mi/
min) Li750 2.8(0.2) 1.6(0.2)° 1.2(0.1)d 2.0(0.2)
CT. Li250 29.4(2.1) 16.5(0.9)° 14.9(0.9)d 20.3(1.2)
(&!/
rnin) Li750 31.5(2.1) 20.7(2.0)° 17.8(1.7)d 25.8(2.5)
FET . Li2 50 28.3 (2.0) 17.8 (1.2)b 16.9(0.9)° 21.1(1.1)LI
(%) Li750 31.1(2.0) 21.3(2.3)° 19.7(1.9)d 25.2(2.9)
C / Li250 8.3(0.4) 8.1(1.2) 6.6(0.8)a 8.7(1.0)
(£f Li750 9.2(0.9) 8.9(1.3) 7.1(0.8)b 8.3(1.3)
Mean(sem). R, recovery period. CNa' sodium clearance;
CT., lithium clearance; FET., fractional lithiumLi' ' Li'
clearance.
a, P<0.05; b, P<0.02;°, P<0.01; d, P<0.005 vs baseline.
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5.3 DISCUSSION.
A precondition for applying lithium clearance to the
analysis of tubular sodium handling is that an inert dose
of lithium should be used, and this study aimed to
establish whether lithium pretreatment modifies renal
responses to angiotensin II. The two doses of lithium
studied encompass the range used in published studies,
most having used between 300mg and 600mg. A 250mg dose
of lithium had no measurable effect on responses to
ANGII, but after a 750mg dose overnight sodium excretion
was increased, systemic and renal haemodynamic responses
to ANGII were slightly altered, and there was a
suggestion that the tubular antinatriuretic response to
ANGII was attenuated.
Equality of daytime sodium excretion before each
study was not documented, but the difference in overnight
sodium excretion after lithium 750mg was consistent (mean
52 mmol) and similar to the results of a recent
controlled study using a 600mg dose of lithium (48 mmol,
Shirley et al, 1991), making a systematic difference in
dietary sodium intake very unlikely. Two possibilities
for the natriuresis which occurs after a single dose of
lithium are either antagonism of the distal tubular
action of aldosterone (Stewart et al, 1987), or
inhibition of proximal tubular sodium reabsorption. The
proportionate increases in sodium and water excretion and
the absence of a fall in potassium excretion after
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lithium are more compatible with a proximal than a distal
action, as previously suggested (Shirley et al, 1991;
Hecht et al, 1978).
Sodium intake was increased before each study to
minimise the potential impact of a natriuretic effect of
lithium on vascular reactivity to ANGII mediated through
changes in total body sodium (Hollenberg et al, 1972).
Since a significant natriuresis did occur, further
control studies would be required to establish whether
the observed differences in renal responses to ANGII
after pretreatment with lithium 750mg were a direct
effect of lithium or due to the relative sodium depletion
which followed lithium pretreatment. This uncertainty
does not however negate the validity of the present
investigation, which was designed only to determine
whether renal responses to ANGII are different after
lithium pretreatment.
Despite the overnight natriuresis, baseline sodium
excretion in the clearance study was not increased after
lithium 750mg, in contrast to some (Jeffrey et al ,1988;
Jeffrey et al, 1989; Freestone et al, 1990) but not all
previous studies (Hannedouche et al, 1990b). UNaV was
higher in eight out of the ten subjects after Li750, but
the greater variance in UNaV after sodium loading makes
small differences harder to demonstrate. Nonetheless,
the normal renal response to acute sodium loss is sodium
retention, and the absence of a reduced baseline UNaV
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after lithium in itself suggests that lithium was still
exerting a natriuretic effect. The absence of the
previously reported rise in PRA after Li750 probably
reflects the relatively larger analytical errors when
measuring low levels of PRA in sodium-loaded subjects;
the increased plasma aldosterone after Li750 argues that
RAAS activation did occur.
The small fall in GFR and the modest increase in
filtration fraction during ANGII seen after placebo
indicates a balanced increase in pre- and postglomerular
arteriolar resistances (Smith, 1951), consistent with the
consensus from in vitro studies that ANGII increases both
afferent and efferent glomerular arteriolar tone at doses
within the physiological range (Steinhausen et al, 1990).
The smaller increase in renal vascular resistance during
ANGII infusion after lithium 750mg was only partly
attributable to the reduced rise in MAP during ANGII
which followed the lithium-induced change in baseline
blood pressure, and suggests that the renal
vasoconstrictor response to ANGII was genuinely blunted
after lithium. Attenuation of the ANGII-induced rise in
filtration fraction after lithium may be interpreted as
indicating that the balance of pre- and post-glomerular
resistances moved towards afferent dominance (Smith,
1951), but the data can not determine whether the
reactivity of one or both of the major resistance
segments was primarily affected.
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Reports of increased blood pressure after both short
term and prolonged lithium administration do exist (Gross
et al, 1990; Johnstone et al, 1990; Meltzer and Sealey,
1990), but it was surprising to find that a single 750mg
dose of lithium could cause a consistent, albeit small,
increase in mean arterial pressure. The absolute level
of MAP during ANGII infusion was the same after Li750 and
placebo (Table 5.2), and it could be suggested that the
smaller ANGII-induced rise in MAP after lithium is an
artefact related to the unequal baseline values.
However, this result is of interest irrespective of
whether one expects ANGII infusion to increase blood
pressure by or to a certain level, as the pressor
response reported if lithium had been administered
without a control experiment would have been
substantially smaller than the true value. The uniformly
low baseline plasma angiotensin II levels suggest that
endogenous RAAS activation did not cause the rise in
baseline blood pressure, and the mechanism of the
increase is unexplained. Lithium affects other
vasoactive hormone systems such as the kallikrein-kinin
cascade and renal eicosanoids (Gross et al, 1990), and
the effect of longer term lithium administration on
hormonal responses, and the influence of sodium balance
on these actions, has not been studied.
Pretreatment with lithium 750mg had a statistically
significant effect on the fall in fractional sodium
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excretion during ANGII infusion, but the difference
between the responses after lithium and placebo was
numerically much smaller than the effect of lithium on
the natriuretic response to gludopa and atrial
natriuretic peptide previously reported (Jeffrey et al,
1988; Freestone et al, 1990). This may stem partly from
the use of pharmacological doses of dopamine (as gludopa)
and ANP in those studies compared with the
'physiological' doses of ANGII infused in the present
investigation, but may also reflect the fact that several
distinct mechanisms exist by which ANGII can influence
renal sodium handling. The changes in lithium clearance
and the derived indices of tubular sodium handling during
ANGII infusion under these particular experimental
conditions were comparable after 750mg and 250mg doses of
lithium, emphasising that the effect of lithium 750mg on
the renal tubular response to ANGII was slight in
comparison to the major changes in sodium reabsorption
occurring during ANGII infusion. It is nonetheless
undesirable to measure lithium clearance after a dose of
lithium (750mg) which affects baseline sodium balance,
and which may modify haemodynamic and antinatriuretic
responses to ANGII. The lack of effect of a 250mg dose
of lithium on the kidney is in accord with other studies
(Shirley et al, 1991; Girbes et al, 1990; Strazzullo et
al, 1988) and confirms the sense of using the lowest
possible dose of lithium rather than the "conventional'
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dose of 500-600mg.
In conclusion, pretreatment with lithium in a dose
of 750mg produces increases in sodium excretion and
plasma aldosterone which suggest that baseline sodium
balance is altered, and produces significant but
numerically small changes in the measured responses to
angiotensin II infusion. No interference with the
response to ANGII infusion is apparent after a 250mg dose
of lithium, making this a more suitable marker dose for
the analysis of tubular sodium handling. The actions of
lithium on the kidney may be different in normal man and
in disease states; the assessment of these possible
differential effects is essential before using lithium in
studies of pathophysiological mechanisms.
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CHAPTER SIX.
RESPONSES TO EXOGENOUS ANGIOTENSIN
TYPE 1 (INSULIN-DEPENDENT) DIABETES.
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6.1 INTRODUCTION.
In experimental models of diabetes mellitus, an
increase in intraglomerular pressure may initiate the
development of glomerular sclerosis and proteinuria
(Hostetter et al, 1982; Zatz et al, 1985). Treatment
with angiotensin converting enzyme inhibitors (ACEI)
prevents glomerulopathy in these animal models (Zatz et
al, 1986), and may be protective in some human diabetic
patients (Parving et al, 1989a), but it remains unclear
whether these actions of ACEI indicate a role for an
abnormal intrarenal vasoconstrictor response to
endogenous angiotensin II (ANGII) in the pathogenesis of
nephropathy.
Cross-sectional measures of plasma concentrations of
RAAS components in diabetic subjects have provided
variable results (Christlieb et al, 1976; DeChatel et al,
1977; Burden and Thurston, 1979; Ferriss et al, 1985).
Plasma ANGII concentrations are suppressed in diabetic
patients without complications (Feldt-Rasmussen et al,
1987) , although plasma renin activity and converting
enzyme levels are normal. A fall in plasma ANGII levels
is the normal physiological response to sodium retention
(Hollenberg et al, 1972), and the increased systemic
pressor response to exogenous ANGII infusion in
uncomplicated human Type 1 diabetes (Weidmann et al,
1979; Drury et al, 1984) could simply reflect the
increase in total body sodium content in these patients
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(Weidmann et al, 1985; Feldt-Rasmussen et al, 1987), but
the absence of a concurrent fall in plasma renin activity
is unusual.
The reduced density of ANGII receptors on
glomerular mesangial cells in diabetic rats (Ballermann
et al, 1984; Wilkes, 1987) and on platelets from patients
with uncomplicated Type 1 diabetes (Connell et al, 1986)
is consistent with the blunted renal haemodynamic
response to exogenous ANGII recently reported in human
diabetes (Fioretto et al, 1991). In normal man however
sodium loading increases angiotensin II receptor density,
without affecting receptor affinity (Moore et al, 1984).
Because of the dichotomy that appears to exist between
renal and systemic vascular reactivity to ANGII in human
diabetes, the renal response to infused ANGII was
examined in Type 1 diabetic patients and in non-diabetic
controls after a period of controlled high dietary sodium
intake.
6.1.1 Protocol.
Nine Type 1 diabetic patients (mean duration 18
(range 6-29) months) and nine matched non-diabetic
controls were studied (Table 6.1). Seven of the diabetic
patients were treated with a conventional insulin regime,
and two were using a 'basal/bolus' regime ('Novopen',
Novo-Nordisk). The normal diet was supplemented with
sodium chloride 200 mmol/day ('Slow Sodium') for 5 days,
and a 24h urine collection was completed on the fifth day
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Body mass index 24(2.3) 25(3.3)
(kg.m )
Duration of - 18(6)
diabetes(months)
HbA1 (%) - 7.5(1.4)
Insulin dose - 0.53(0.21)
(U.kg day )
*
Urinary albumin , 10.2 16.6
excretion (mg.24h ) (3.9-16.7) (11.9-29.4)
Mean(SD), or median(range). , P<0.05 vs control
group. Normal range for HbA^, 5.0-8.0 %.
of the sodium loading phase. Diabetic subjects were
admitted to hospital at 1800h on the day before the
study. Their normal evening insulin dose was omitted,
and intravenous infusions of D-glucose 50 g/1 (80 ml/h)
and unmodified human insulin (Actrapid, Novo, Bagsvaerd,
Denmark, 0.5 U/ml) were started with the evening meal.
The rate of insulin infusion was adjusted manually to
maintain a blood glucose concentration of around 6.5
mmol/1 overnight and throughout the acute study. Both
groups fasted from 2200h, and followed the clearance
protocol from 0700h onwards. Renal responses to infusion
of ANGII at 0.5 and 1.0 ng.kg 1min 1 were studied.
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6.2 RESULTS.
6.2.1 Systemic and hormonal responses (Tables 6.2, 6.3).
There was no change in heart rate in either group during
ANGII infusion, but small increases in systolic (diabetic
P=0.023, control P=0.035), diastolic (diabetic P=0.014,
control P=0.001) and mean arterial blood pressure
(diabetic P=0.004, control P=0.002) occurred in both
groups during ANGII infusion (Table 6.2), which did not
differ between the two groups (diastolic blood pressure;
MANOVA test of interaction between group and change in
blood pressure with time, P=0.10). Blood glucose was
adequately controlled in the diabetic subjects, plasma
glucose being on average only 2 mmol/1 higher than
corresponding values in the control group (Table 6.2).
No subject had glycosuria at any time. The overnight
insulin infusion rate in the diabetic group was
1.25(0.10) U/h, which was not greater than the infusion
rate before or during ANGII infusion (1.03(0.13) U/h and
0.97(0.12) U/h respectively). Plasma free insulin
concentrations were low in both groups at baseline, and
were essentially unchanged during ANGII (Table 6.2).
Plasma renin activity and plasma aldosterone
concentrations were low at baseline, and did not change
during ANGII infusion. However, plasma renin activity
was significantly higher in the diabetic group throughout
the clearance study (P<0.02, Table 6.3). Plasma ANGII
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Table 6.2: Blood pressure, heart rate, plasma glucose
and plasma free insulin concentrations during angiotensin
II infusion in nine diabetic and nine control subjects.
Baseline ANGII (ng.kg 1min 1)
0.5 1.0
SBP D 128.5(3.4) 129.8(3.1) 131.2(4.2)a
(irunHg) C 126.9 (2.0) 126.8 (3.0) 129.8 (3.5)a
DBP D 76.4(3.2) 78.1(3.2) 80.3(3.5)a
(mmHg) C 74.2(2.2) 73.8(2.5) 77.1(2.1)a
MAP D 93.8(3.0) 95.3(3.0) 97.2(3.5)a
(mmHg) C 91.8(2.0) 91.5(2.6) 94.7(2.4)a
Heart D 65(5.0) 64(4.5) 62(4.0)
rate
(bpm) C 59(1.5) 56(1.4) 56(2.0)
Plasma D 6.9(0.4)b 6.8(0.5)b 6.2(0.6)b
glucose
(mmol/1) C 5.1(0.3) 4.7(0.3) 4.2(0.3)
Plasma D 8.0 8.4 4.8a
free (4.8-18) (4.8-20) (4.8-14)
insulin
(mu/1) C 6.8 4.8 4.8
(4.8-23) (4.8-18) (4.8-6.2)
Mean(sem) or median(range). D, diabetic; C, control.
ci b
, P<0.05 vs baseline; , P<0.02 vs corresponding
control.
156
Table 6.3: Plasma renin activity (PRA), plasma
aldosterone (ALDO), and plasma angiotensin II (ANGII)


































ANGII D 2.6(0.5) 2.8(0.5)
(pmol/1) C 2.7(0.5) 2.6(0.6)
6.9(l.l)b 13.0(3.0)b
8.0(1.0)b 10.3(0.8 )c
Mean(sem) or median(range). a, P<0.02 vs control;
b, P<0.01; c, P<0.001 vs baseline.
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concentrations were suppressed at baseline in both
groups, and comparable increments in plasma ANGII levels
were produced during ANGII infusion (Table 6.3). Plasma
potassium concentration was similar in both groups at
baseline (diabetic 3.7(0.10), control 3.8(0.07) mmol/1),
and did not change during ANGII, and urinary potassium
excretion was similarly unaffected (data not shown).
Urine flow rate fell during ANGII infusion in both
diabetic and control subjects (diabetic 10.9(1.4) to
7.6(0.8) mlmin \ P<0.05; control 9.6(1.3) to 5.6(1.2)
mlmin 1, P<0.05). Venous haematocrit was unchanged
during ANGII infusion.
6.2.2 Renal haemodynamics.
GFR was similar in both groups at baseline and fell
significantly (P<0.05) and to a similar extent in both
groups during ANGII infusion (Figure 6.1a). Effective
renal plasma flow fell in a dose-dependent manner during
ANGII, again to a similar extent in the two groups
(diabetic 694 (46) to 521(21) ml.min "'"l^lm 2, P<0.005;
control 665(41) to 498(30) ml.min 11.73m 2, P<0.02),
returning to the baseline values during the recovery
period (Figure 6.1b). Filtration fraction (GFR/ERPF)
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6.2.3 Sodium excretion.
Total urinary sodium excretion and urine volume were
similar in both groups in the 24 h period before the
study (diabetic 335(21) mmol, 2.76(0.28)1; control
348(26) mmol, 2.52(0.33)1). The urinary excretion rate
of sodium (UNaV) was lower in the diabetic subjects
during the first control period (P<0.05, Figure 6.2a), a
difference which persisted during the substantial
antinatriuresis induced by ANGII infusion. Fractional
sodium excretion (FENa) (Figure 6.2b) showed the same
pattern. The decrements in absolute and fractional
urinary sodium excretion during ANGII were not
significantly different between the groups (absolute
excretion; diabetic 103(24), control 195(42) pmol/min,
F, . . =3.14, P=0.10: fractional excretion;(group x time) '
diabetic 0.58(0.10)%, control 1.09(.26)%, F(gr0up x
time)=3"56' p=0-08)* When the antinatriuretic response
to ANGII was expressed as a percentage of the baseline
result to compensate for the differing baseline sodium
excretion rates, there was no difference in the tubular
response to ANGII infusion between the two groups (% fall
from baseline of UNaV; diabetic 30(7)%, control 38(6)%; %
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Figure 6.2: a) absolute and b) fractional sodium excretion during ANGII
infusion in nine diabetic patients and nine control subjects.
Mean(sem). *, P<0.05 vs control group.






Infusion of angiotensin II to levels within the
physiological range produced similar changes in renal
haemodynamics in both diabetic and control subjects as
were reported in Chapter 4. The finding that renal
vascular reactivity to ANGII in these diabetic patients
with good chronic metabolic control did not differ from a
matched control group extends the results of previous
studies which measured the concentrations of RAAS
components without examining dynamic renal responses.
The renal tubular reabsorption of sodium was abnormal at
baseline, but the antinatriuretic response to ANGII in
the diabetic group did not differ from normal controls.
However, since only whole kidney tubular responses were
assessed it is not possible to comment on whether
ANGII-mediated reabsorption of sodium in the proximal
tubule was altered as a primary contributor to the
increased fractional reabsorption of sodium seen in these
patients at baseline.
Chronic glomerular hyperfiltration in Type 1
diabetic patients may increase the risk of diabetic
nephropathy, and is at least partially ameliorated by
improved glycaemic control (Christiansen et al, 1982).
ANGII receptor density and affinity vary with the
duration of hyperglycaemia and with the intensity of
treatment of experimental diabetes (Ballermann et al,
1984; Wilkes, 1987), and RAAS activity is affected by
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glycaemic control in human diabetes (Sullivan et al,
1980; Jenkins et al, 1990). Only one of the diabetic
patients in this study had a glycated haemoglobin level
>9%, and this uniformly good glycaemic control precludes
any comment on whether any correlation exists between
renal vascular reactivity to ANGII and the quality of
glycaemic control. These patients are at low risk of
diabetic nephropathy, and additional studies of the renal
response to ANGII in patients with poorly controlled
diabetes who have an increased long-term risk of kidney
disease are needed to clarify whether ANGII has a primary
role in the development of microvascular disease.
Urinary sodium excretion during the 24 hours before
the study was similar in both groups, but was reduced in
the diabetic group during the acute study. The volume of
saline infused during the equilibration phase was too
small (350 ml, 52 mmol of sodium) to suggest that the
blunting of the acute natriuretic response to saline
infusion seen in Type 1 diabetes was relevant (Roland et
al, 1986), while the similar urine flow rates in both
groups exclude any "washout" effects, and the day/night
sodium excretion pattern is normal in uncomplicated Type
1 diabetes (Bell et al, 1987).
The period of high sodium intake before the study
allowed infusion of low doses of ANGII which elicited
only a minimal systemic pressor response and did not
appreciably affect aldosterone secretion, and also
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ensured that both groups had similar baseline plasma
concentrations of ANGII so that the renal haemodynamic
response to ANGII could be compared (Hollenberg et al,
1972) . A criticism of this approach is that the
responsiveness of the tubuloglomerular feedback loop is
reduced by sodium loading and augmented by a rise in
intrarenal ANGII (Wright and Briggs, 1979), so that
sodium loading may change the feedback relationship
between the tubular handling of sodium and intrarenal
haemodynamics.
Acute insulin administration increases renal tubular
reabsorption of sodium in normal man (DeFronzo et al,
1975; Skott et al, 1989a), and a correlation has been
found between plasma free insulin concentrations and
indirect indices of tubular sodium reabsorption in Type 2
diabetic patients (Mbanya et al, 1989). Chronic (24h)
low dose insulin infusion in normal subjects causes a
small reduction in urinary sodium excretion, from 242 to
221 umol/min (Trevisan et al, 1990). In the present
study the overnight infusion rate of insulin received by
the diabetic subjects was similar to the infusion rate
during the clearance study, and to the patient's normal
insulin dosage, and produced plasma free insulin levels
which were certainly not higher (and were probably much
lower) than those previously described (Trevisan et al,
1990) . The antinatriuretic potential of exogenous
insulin is retained in human Type 2 diabetes (Skott et
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al, 1991; Gans et al, 1991b) but the effect of sodium
balance on the renal actions of insulin, and the extent
to which overnight hyperinsulinaemia ray have contributed
to the large difference in sodium excretion at baseline
between these Type 1 diabetic patients and control
subjects remains to be established.
Plasma ANGII levels were suppressed to the same
extent at baseline in both groups, but plasma renin
activity was higher in the diabetic group throughout the
study. This is in keeping with some recent reports
(Liebermann et al, 1991; O'Donnell et al, 1990), although
PRA has previously been reported as normal in
uncomplicated diabetic patients in sodium balance
(Christlieb et al, 1976; DeChatel et al, 1977; Burden and
Thurston, 1979; Feldt-Rasmussen et al, 1987). Plasma
prorenin is also normal in most patients with diabetes of
short duration (Feldt-Rasmussen et al, 1987), and
artefactual cryoactivation of prorenin to active renin
can not account for the difference between the groups
since all the renin assays were performed on one
occasion.
Incomplete suppression of renin release can not be
attributed to retention of a smaller proportion of the
supplementary dietary sodium load in the diabetic
subjects because fractional sodium excretion was reduced
at baseline and because osmotic diuresis with increased
distal tubular sodium losses secondary to glycosuria did
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not occur in any of the patients. One speculative
explanation of the differences in plasma renin activity
after sodium loading is that diabetic subjects may regain
sodium balance more slowly after a change in dietary
intake than normal subjects. The reduced fractional
sodium excretion in the diabetic patients after sodium
supplementation may in fact indicate that there was a
greater increase in total body sodium in the diabetic
group after sodium loading, although current methods for
measuring total exchangeable body sodium in humans are
not sufficiently sensitive to detect small differences.
However, if this were so the normal renal response to
exogenous ANG II would represent an attenuated response
when compared to a normal subject in balance on the same
dietary sodium intake.
In summary, the renal vascular response to exogenous
angiotensin II was normal in these well controlled short
duration Type 1 diabetic patients during euglycaemia.
However, vascular reactivity to angiotensin II must
always be considered in relation to the prevailing state
of sodium balance, and altered renal tubular reabsorption
of sodium was apparent even at this early stage of
diabetes. This abnormal renal sodium handling was
examined in more detail in Chapters 7 and 8.
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CHAPTER SEVEN.
EFFECT OF LITHIUM ON RESPONSES
ANGIOTENSIN II IN TYPE 1 DIABETES.
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7.1 INTRODUCTION.
A parallel has been drawn between elevation of
single nephron glomerular filtration rate and plasma flow
in moderately hyperglycaemic rats (Hostetter et al,
1981a) and renal haemodynamics in a proportion of
patients with Type 1 diabetes. Because increased renal
plasma flow during hyperglycaemia is not a uniform
finding in Type 1 diabetic patients with increased
glomerular filtration rate (Ditzel and Junker, 1972;
Stalder and Schmid, 1959; Jenkins et al, 1990), increased
intraglomerular capillary pressure may be another
precursor to the later development of nephropathy. Renal
tubular sodium handling may modulate these haemodynamic
factors in several different ways. The whole kidney
sodium handling data in Chapter 6 gives no insight into
the mechanism(s) of sodium retention in early diabetes,
and more detail is needed concerning the reabsorption of
sodium at specific tubular sites, and the humoral
determinants acting at these sites .
Abnormal renal sodium handling and sodium retention
may affect renal haemodynamics indirectly through effects
on vascular reactivity and systemic blood pressure
(Weidmann et al, 1985), or directly via intrarenal
factors such as a change in sensitivity of the
tubuloglomerular feedback mechanism (Ushiogi and Haberle,
1991). A correlation has been reported between increased
absolute and fractional proximal tubular sodium
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reabsorption, measured by lithium clearance, and
glomerular filtration rate in Type 1 diabetes
(Brochner-Mortensen et al, 1984; Skott et al, 1989b;
Nosadini et al, 1989; Hannedouche et al, 1990a; Trevisan
et al, 1990). This correlation suggests that
glomerulotubular balance is appropriately adjusted to the
increased glomerular filtration rate in diabetes in order
to maintain a normal distal tubular sodium delivery,
regardless of whether or not this occurs at a normal
total body sodium content. There is a statistical
problem in assigning physiological importance to this
finding however, because the correlation of FET .
(C ./GFR) with GFR will always be significant. The
problems in using lithium clearance as a marker of
tubular sodium handling discussed in Chapter 5 apply
equally to its use in diabetes, notably doubt over the
site(s) of tubular reabsorption of lithium, the effects
of osmotic diuresis due to glycosuria (Skott et al,
1987), and the pharmacological interactions between
lithium and intrarenal hormone systems demonstrated in
normal man. The potential for interaction between
lithium and the RAAS in Type 1 diabetes has not been
explored, and in this study the effect of lithium on
baseline renal function and the renal response to ANGII
infusion was examined in a group of stable Type 1
diabetic patients, using the same 750mg dose of lithium
as in the studies in Chapter 5.
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7.1.1 Protocol.
Fifteen normotensive Type 1 diabetic patients
(clinical details in Table 7.1) were studied on two
occasions at least two weeks apart. Ten patients were
treated with a twice daily insulin regime, while the
other five were using a 'basal/bolus' regime. Their
normal diet was supplemented with sodium chloride
lOOmmol/day ('Slow Sodium*) for seven days before each
study to allow comparison of the data with the
experiments in Chapter 5. The subjects collected all
urine for 2 4 hours before each study into 'Day* and
'Night* bottles, which were used respectively before and
after 2100h when lithium carbonate 750mg (Li750) or
placebo control (PI) was taken in a single blind
randomized order. After fasting from 2200h, they omitted
the morning insulin dose, and attended the clinical
laboratory at 0830h. An infusion of unmodified human
insulin (Actrapid 0.2 Uml \ Novo, Bagsvaerd, Denmark)
was started, and the infusion rate adjusted to establish
and maintain a whole blood glucose concentration
(Reflolux-S, Boehringer Mannheim, Germany) of 4-7
mmoll 1. The absence of glycosuria (urine glucose
<5mmol/l) was confirmed in all urine samples during the
acute study (Diastix, Ames, England). Renal responses to
infusion of ANGII at 1.25 and 2.5 ng.kg "^min 1 were
studied. The patients were then fed and given an
appropriate dose of insulin before leaving the hospital.
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7.2.1 Systemic responses to angiotensin II infusion
(Table 7.2, Table 7.3).
Whole blood glucose on arrival at the laboratory was
14.8(1.1) and 14.6(1.3) mmol/1 after placebo and lithium
pretreatment respectively. The blood glucose
concentration and the insulin infusion rate were similar
at all times throughout both studies, falling slightly as
the study progressed. During ANGII infusion at 2.5
-1 . -1
ng.kg min one patient felt slightly nauseated and
another noticed a sensation of mental alertness. Both
these side effects occurred after placebo pretreatment.
Plasma ANGII concentrations were similar at baseline
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on both days, and comparable elevations in plasma ANGII
concentration occurred during ANGII infusion on each day.
Baseline PRA was also low on each study day, and fell
significantly during ANGII infusion, neither baseline PRA
nor the fall in PRA during ANGII being affected by
lithium. The fall in PRA during ANGII infusion was
similar to the fall which occurred in the control
subjects in Chapter 5 (Table 5.1); this supports a
previous report suggesting that the intrarenal short
feedback loop is intact in diabetes (Trujillo et al,
1989). Plasma ALDO levels rose during ANGII on each
study day (all P<0.005); baseline ALDO and the increment
in plasma ALDO during ANGII infusion were unaffected by
lithium pretreatment.
Heart rate was similar on all three days, and did
not change during ANGII (data not shown). Baseline mean
arterial pressure, and the pressor response to ANGII were
unchanged after lithium pretreatment (Figure 7.1).
7.2.2 Renal haemodynamics.
Baseline GFR did not change after lithium (Figure
7.2a), but baseline ERPF was significantly increased
after Li750 (Figure 7.2b). This renal vasodilatation
produced a fall in the filtration fraction (Figure 7.2c).
Pretreatment with lithium did not alter the changes in
ERPF (F, .. .=1.55, P=NS), GFR (F,v (group x time) ' ' ' v (group x
time)=1*91' p=0,09)' or filtration fraction during ANGII
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Table 7.2: Whole blood glucose (GLUC) and insulin
infusion rate (INS) before and during angiotensin II
infusion in fifteen diabetic subjects.
ANGII infusion.
Time(mins) : A 0 60 120 180
PI 14.8 7.2 5.5 4 . 9 4 . 7
(1.1) (0.5) (0.3) (0.3) (0.2)
GLUC Li250 11.9 6 . 2 6.2 5.8 5.2
(mmol/ (n=7) (1.6) (0.8) (0.7) (0.6) (0.4)
1)
Li750 14.6 7 . 7 5.7 5 . 4 5.0
(1.3) (0.5) (0.4) (0.4) (0.4)
PI 3.8 1.2 0.7 0.4 0.4
(0.6) (0.3) (0.2) (0.15) (0 . 15
INS Li2 50 5.1 0.7 0.7 0.6 0 . 2
(U/h) (n=7) (1.2) (0.4) (0.4) (0.3) (0.1)
Li750 5.3 1.5 1.1 0.7 0 . 3
(0.8) (0.4) (0.3) (0.2) (0.1
Mean(sem). A, arrival at laboratory; 0-60 mins,
baseline; 60-180 mins, ANGII infusion.
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Table 7.3: Plasma renin activity (PRA), plasma
aldosterone (ALDO), and plasma angiotensin II (ANGII)
during angiotensin II infusion in fifteen diabetic
subjects.
B/line ANGII(ng.kg 1min 1)
1.25 2.5
C 330(220-460) - 190(120-260)3
PRA (pmol AI. Li250 540(320-890) - 270(140-365)











C 9.8(1.2) 24.3(2.6) 47.4(3.1)
ANGII Li2 50 11.8 (0.8) 22.6 (2.0) 40.2 (2.6)
(pg/ml) Li750 11.8(1.4) 25.8(2.6) 44.2(4.9)
a b
Mean(sem). ' P<0.05; , P<0.005 vs baseline.
Technical note: plasma ANGII concentrations at baseline
and during ANGII infusion are substantially higher than
the levels reported in the control subjects in Chapter 5
(Table 5.1). The intraassay c.v. for this series of
(triplicated) assays was acceptable at 9%, but the
quality control samples indicated that the ANGII standard
used had probably deteriorated with time. This shifts
the standard curve to the right of its true position,
hence the spuriously high results from experimental
samples. Therefore, the ANGII data is useful in showing
that a comparable stimulus was applied during each study
in this diabetic group, but no valid comparisons can be
made with the normal subjects in Chapter 5.
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Figure 7.1: Change in a) systolic, b) diastolic, and c) mean arterial
pressure during ANGII infusion in 15 diabetic patients after
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infusion. The absence of effect of any lithium on renal
haemodynamic responsiveness to ANGII was confirmed by the
similar increase in effective renal vascular resistance
during ANGII on both days (Pi 5260(440), Li750 5300(630)
dyne.sec.cm 5).
7.2.3 Sodium and water excretion.
24h sodium excretion was comparable before each
study (PI; Day 178(14) mmol, Night 125(12) mmol, Total
303(13) mmol: Li750; Day 166(15) mmol, Night 142(12)
mmol, Total 308(13) mmol). Absolute and fractional
urinary excretion of sodium were similar at baseline
after both placebo and Li750, and the fall in both
parameters during ANGII was unaffected by lithium (Figure
7.3) .
Urine flow rate was similar at baseline and during
ANGII infusion after Li750 and PI (Li750 15.7(0.6) to
7.0(0.7) ml/min; PI 15.6(0.7) to 6.8(0.9) ml/min). The
fall in free water clearance (C„0/_) during ANGII infusionrlZV
was also unaffected by lithium (Li750 10.6(0.5) to
4.6(0.6) ml/min; PI 10.7(0.5) to 4.3(0.8) ml/min).
Despite the fall in C„__, urinary osmolality (U_ ) roserizU USUI
only slightly above the baseline value during ANGII
infusion on both days. This is discussed in detail in
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Figure 7.3: a) absolute and b) fractional urinary sodium excretion during ANGII
infusion in 15 diabetic patients after placebo and lithium 750mg.
Mean(sem).








7.3 PROBLEMS WITH COMPARISONS BETWEEN DIABETIC AND
CONTROL GROUPS AFTER LITHIUM PRETREATMENT.
The effects of pretreatment with lithium 750mg on
baseline renal haemodynamics and the response to ANGII
infusion are different to the actions of lithium
described in normal man in Chapter 5. This has
implications for comparisons of haemodynamic data
obtained in the two groups after lithium pretreatment.
These will be discussed before examining the validity
of lithium as a tubular marker in diabetes in more
detail.
7.3.1. Effective renal plasma flow.
After placebo pretreatment baseline renal plasma
flow and renal vascular reactivity to ANGII were
identical in the diabetic group and in the normal
subjects, data from whom were reported in Chapter 5
(Control group) (Figure 7.4a). This confirms in a larger
group of subjects the result reported in Chapter 6.
However, comparison of diabetic and control groups after
lithium pretreatment indicated (misleadingly) that
baseline ERPF was elevated in the diabetic patients
(P=0.014)(Figure 7.4b), and that the fall in ERPF during
ANGII infusion was greater in the diabetic patients than
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Figure 7.4: Effective renal plasma flow in 15 diabetic and 10 control subjects
during ANGII infusion after pretreatment with a) placebo and
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Figure 7.5: Glomerular filtration rate in 15 diabetic and 10 control subjects
during ANGII infusion after pretreatment with a) placebo and
b) lithuim 750mg. Mean(sem).
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7.3.2. Glomerular filtration rate.
On the placebo day baseline GFR was slightly but but
not significantly higher in the diabetic group (P=0.096).
There was no difference between diabetic and control
subjects either for the absolute data (F(group)=1*11'
P=0.303) or for the fall in GFR during ANGII (F.' ^ v (group x
time)' P=0.227) (Figure 7.5a). After lithium,
although the difference in baseline GFR between the two
groups was the same as after placebo (P=0.076), the fall
in GFR during ANGII infusion was greater in the diabetic
patients (F(groUp x time)=4"99' p=0-036) (Figure 7.5b).
7.3.3. Effective renal vascular resistance.
After placebo pretreatment the baseline ERVR was
higher in the diabetic group, due entirely to the
slightly higher blood pressure in the diabetic patients
(P<0.05) (Figure 7.6a). This difference was not apparent
after lithium because of the renal vasodilatation which
occurred in the diabetic group. Furthermore, the rise in
ERVR during ANGII was similar in both groups after
placebo, but because of the reduced rise in ERVR in the
control group there was an accentuation of ANGII-induced
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7.3.4. Systemic blood pressure.
After placebo pretreatment mean arterial pressure
was significantly higher in this diabetic group than in
age and BMI-matched controls at baseline (mean 98.5(2.1)
mmHg vs 89.5(1.9) mmHg, F(groUp)=8.55, P=0.007) and
throughout ANGII infusion (F(group)=1°"83' P=0.003),
despite the careful selection of lean subjects without
any evidence of diabetic complications whose blood
pressures were within the normal range for their age.
Because of the consistent rise in MAP after lithium
pretreatment in the control group, the difference in
baseline MAP between the groups was smaller after lithium
(mean 99.1(2.0) vs 93.1(1.9) mmHg, F(group)=4"49'
P=0.04). The rise in blood pressure during ANGII
infusion was reduced after lithium in the controls
(Chapter 5.2.2), but was unaffected in the diabetic
patients, so that although the rise in mean arterial
pressure was similar in both groups after placebo
(F(group x time)=0-52' P=NS) (Figure 7.7a), the pressor
response to ANGII appeared to be accentuated in the












































Figure 7.7: Change in mean arterial pressure (AMAP) during ANGII infusion
in 15 diabetic patients and 10 normal subjects after a) placebo
and b) lithium 750mg. Mean(sem).
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7.4 VALIDITY OF LITHIUM CLEARANCE AS A TUBULAR MARKER
IN DIABETES.
The differing actions of lithium in diabetic and
control groups compromise comparisons of renal and
systemic haemodynamics. This may affect the validity of
lithium clearance as a tubular marker in diabetes in at
least two ways. Firstly, changes in renal haemodynamics
could influence tubular sodium reabsorption by changing
peritubular physical forces or by altering the balance of
cortical and medullary blood flow. Secondly, calculation
of indices of proximal tubular sodium handling from
lithium clearance data involves the glomerular filtration
rate, which may change to a different extent during ANGII
infusion after lithium. As part of the interpretation of
the lithium clearance data in the diabetic subjects it
was therefore necessary to consider how the effects of
lithium 750mg on renal haemodynamic reactivity in
diabetic and control groups might affect lithium
clearance and associated derived data. Measurement of
endogenous lithium in samples from the placebo studies
would have been the ideal way to approach this problem,
but this requires highly specialised atomic absorption
spectrophotometry equipment. A compromise was therefore
reached by examining seven randomly selected diabetic
patients on a third occasion using the same protocol
after pretreatment with a dose of lithium (250mg) which
it was anticipated would not affect renal haemodynamics.
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7.4.1 Results.
Baseline UNaV and FENa in these seven patients were
lower after lithium 250mg than after either placebo or
Li750 (FENa; PI 2.37(0.26)%, Li750 2.53(0.42)%, Li250
1.99(0.23)%). Inspection of individual 24 hour sodium
excretions after Li250 suggested that this difference was
probably caused by two of the subjects not having taken
their sodium supplement as requested (24h excretion of
sodium; 290, 339, 296, 309, 279, 168 , 175 mmol). The
antinatriuretic response during ANGII infusion was
similar on all three days (FENa; PI 2.37(0.26) to
0.95(0.13)%, Li750 2.53(0.42) to 1.06(0.10)%, Li750
1.99(0.23) to 0.81(0.05)%). ERPF was increased at
baseline after Li750, as in the complete group of fifteen
subjects, but baseline ERPF after Li250 did not differ
from placebo (PI 665(51), Li250 695(52), Li750 778(53)
ml.min 11.73m 2; PI vs Li750, P<0.05). The fall in ERPF
during ANGII infusion did not differ on the three study
days.
Tables 7.4 and 7.5 summarise sodium and lithium
clearances and the derived estimates of tubular
reabsorption of sodium for the diabetic patients after
pretreatment with both doses of lithium. There are some
minor differences between the results for the two doses,
which can be expected by chance alone in a small group of
subjects, but the main effects of ANGII on tubular sodium
handling are similar after both doses of lithium. In
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Table 7.4: Sodium (C ) and lithium (C .) clearances, and
derived expressions ?or fractional tuiular reabsorption
of sodium during angiotensin II infusion in diabetic
patients after lithium pretreatment (Li750 data shown as
N=15 and N=7).
ANGII (ng.kg "'"min 1)
B 1.25 2.5 R
C.T Li750 2.4 (0.2) 1.3 (0.2) 0.9 (0.1)a 1.5(0.1)N 3
(N=15)




0 2.6(0.4) 1.5(0.2) 1.0(0.1)a 1.6(0.2)
CT. Li750 28.5(1.6) 19.6(1.4) 17.5(1.5)a 23.5(1.7)Jul
(N=15)




50 32.9 (2.1) 25.8 (2.2) 21.5(0.9)a 31.6(1.7)
v_
Li7 50 25.1(1.6) 19.5(1.1) 19.9 (1.5) 21.3 (1.4)
FE . ,N=15) ,
Li750 28.7(1.9) 22.2(1.3) 22.8(1.7) 22.7(1.6)
(%) (N=7)
Li250 29.8(1.9) 25.3(1.2) 22.4(0.9) 27.3(1.9)
(N=7)
Li750 9.4(0.9) 6.6(0.6) 5.3(0.5) 7.1(0.8)
C / (N=15)
C^a Li750 9.0(1.0) 6.5(0.9) 4.8(0.5) 6.2(0.4)Jul
(N=7) b
(%) Li2 50 8.6(1.1) 5.8 (0.8) 4.8 (0.6) 5.2 (0.5)
(N=7)
Mean(sem). B, baseline, R, recovery period.
FEt., fractional proximal sodium rejection.Jul
C /C ., fractional distal sodium rejection.
in 3 Jul
_ y_
, P<0.001; , P<0.01 vs baseline. The change during
ANGII infusion was not different after either dose of
lithium for any of the parameters.
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Table 7.5: Derived expressions for absolute tubular
reabsorption of sodium during angiotensin II infusion in
diabetic patients after lithium pretreatment (Li750 data
shown as N=15 and N=7).
ANGII (ng.kg "'"min 1)
B 1.25 2.5 R
Li750 11.8(0.5) 11.1(0.5) 9.9(0.6)a 12.0(0.5)
APRNa (N=15) a




min) i 11.1(1.0) 10.5(0.7) 10.5(0.7)° 12.0(1.1)
Li750 3.3(0.2) 2.5(0.2) 2.3(0.3) 3.0(0.2)
ADR (N=15)a
Li750 4.2(0.3) 3.3(0.3) 2.9(0.1) 4.2(0.1)
(mmol/ (N=7) ,
min) Li2 50 4.2 (0.3) 3.3 (0.3) 2.8 (0.1) 4.2 (0.2)
(N=7)
Mean(sem). B, baseline, R, recovery period.
APRNa, absolute proximal sodium reabsorption.
ADRNa, absolute distal sodium reabsorption.
, P<0.05; , P<0.005 vs baseline.
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particular, baseline absolute and fractional lithium
clearances were similar after a 750mg and a 250mg dose of
lithium (Figure 7.8a,b), and the fall in FELi during All
was not different on the two days; the data was
comparable for individual subjects as well as the whole
group (Figure 7.8c). The similar change in fractional
proximal reabsorption of sodium on the two days confirms
that the greater fall in absolute proximal reabsorption
of sodium (APR^a) during ANGII after Li750mg is an
artefact caused by the larger reduction in GFR and
filtered sodium load. It should be noted in passing that
after the 250mg dose of lithium the change in FELi during
ANGII infusion was significantly lower in the diabetic
patients than in the six non-diabetic control subjects
studied after lithium 250mg (data taken from Chapter 5).
7.5 DISCUSSION.
A number of studies have now used the lithium
clearance method while analysing renal haemodynamics and
sodium handling in diabetic patients. The errors due to
'post-proximal' reabsorption of lithium and the effect of
osmotic diuresis on lithium clearance can be minimised by
studying patients when salt replete and euglycaemic, but
the potential for interaction between lithium and
intrarenal hormone systems has not previously been
studied in diabetes. Lithium 750mg caused dose-dependent
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renal vasodilatation, but did not modify the falls in
ERPF or GFR or the whole kidney tubular antinatriuretic
response to exogenous ANGII. Systemic blood pressure and
the pressor response to ANGII were also unaffected by
lithium. The effects of lithium in diabetes proved
sufficiently different from its actions in normal man to
make comparisons of renal and systemic vascular
reactivity data in diabetic and control groups misleading
after lithium pretreatment. Despite this, baseline
lithium clearance and fractional lithium excretion proved
to be similar after both 'inert' and 'active' doses of
lithium, as were the changes in lithium clearance during
ANGII infusion, both on a group basis and within
individual patients.
Lithium in vitro did not interfere with the assay
system for PAH, and the reduced renal vascular resistance
after lithium pretreatment is a real phenomenon. The
reduction in filtration fraction after lithium
pretreatment in the diabetic subjects could be regarded
as indicating a fall in intraglomerular hydraulic
pressure caused by efferent arteriolar vasodilatation,
just as the increased filtration fraction seen in the
diabetic compared to the control group after placebo
pretreatment (IDDM 17.2(0.7)%, Control 15.3(0.4)%;
P=0.043) might be construed as supporting the existence
of intraglomerular hypertension due to relative efferent
arteriolar vasoconstriction. However, the limitations of
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filtration fraction as an index of intraglomerular
pressure have already been mentioned (Smith, 1951;
Carmines et al, 1987).
The renal haemodynamic response to ANGII in this
group of diabetic subjects was not different from that in
a matched control group, confirming the main conclusion
of Chapter 6 in a larger group of subjects with a broader
range of metabolic control. This result differs from a
recent study of normotensive diabetic subjects (Fioretto
et al, 1991) which reported a blunted fall in glomerular
filtration rate and renal plasma flow during ANGII
infusion. The abnormality was reversed by pretreatment
for one week with indomethacin, and this was taken to
indicate that renal vascular hyporeactivity to ANGII was
due to antagonism of the renal vasoconstrictor effect of
ANGII by excessive vasodilator prostaglandins. This
hypothesis could not be substantiated because the acute
changes in prostaglandin synthesis during ANGII infusion
were not reported.
A post hoc power analysis of the data in Chapters 5
and 7.3 shows that the present studies had an 80% chance
(at the 5% significance level) of detecting a difference
in reactivity to ANGII 2.5 ng.kg 1min 1 of 10 ml/min for
glomerular filtration rate and 90 ml/min for renal plasma
flow between diabetic and control groups. The power to
detect the difference in reactivity between diabetic and
control subjects reported by Fioretto et al. (AGFR 15
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ml/min,AERPF 120 ml/min) was 98% for GFR and 96% for
ERPF. It is therefore very unlikely that such large
differences would have been overlooked if present, and
reasons for the discordance between the two sets of data
must be sought.
The inclusion of female subjects and the use of a
-1 . -1
supraphysiological dose of ANGII (4 ng.kg mm ) in the
Italian study are unlikely to be major factors. The
Italian study was performed after blood glucose had been
stabilised overnight using an artificial pancreas, but
the diabetic subjects in Chapter 6 had an unchanged
haemodynamic response to ANGII when studied under similar
conditions. Stabilisation of blood glucose for only
1-1.5 hours before an acute clearance study can be
criticised on the basis of the changes in renal plasma
flow described after acute changes in blood glucose
(Christiansen et al, 1981b; Wiseman et al, 1987) .
However, these changes were small, and other studies have
found no evidence that significant changes in renal
haemodynamics occur during acute changes in blood glucose
(Mogensen 1971c; Jenkins et al, 1989); furthermore, in
the present studies blood glucose levels were comparable
both before and throughout each study, as were the doses
of insulin used to achieve near-normoglycaemia.
It is potentially important that the Italian
patients were studied while on a lower sodium intake than
the present subjects. The week of indomethacin
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pretreatment may itself also have changed total body
sodium and hence vascular reactivity to ANGII within the
diabetic group. No data on renal sodium handling before
or during ANGII infusion was given in the paper, so that
the possibility that the disparate results are a result
of differences in sodium balance between (and perhaps
within) the two study populations due to differences in
the experimental protocols can not be addressed.
In conclusion, despite the problems in interpreting
haemodynamic responses after pretreatment with lithium
750mg, lithium clearance measured after this higher dose
does appear reasonably reliable as an estimate of tubular
sodium handling. The analysis of factors affecting
lithium clearance therefore has internal consistency
within a diabetic group. The validity of comparisons




RENAL TUBULAR SODIUM HANDLING AND
TUBULAR RESPONSES TO ANGIOTENSIN II
IN TYPE 1 DIABETES.
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8.1 INTRODUCTION.
Some of the problems associated with the use of
lithium in diabetic patients were discussed in Chapter 7.
The lithium clearance method does however have some
validity as a tubular marker if interpreted cautiously.
The results in this Chapter are based on analysis of the
lithium clearance data (Table 8.1, 8.2) from the fifteen
diabetic patients and ten control subjects who were
pretreated with lithium 750mg. These tables also include
the same parameters for the diabetic and control subjects
who were pretreated with lithium 250mg, to show that
comparable conclusions regarding tubular sodium handling
in diabetes are drawn after both doses of lithium,
provided that artefacts related to variations in the
filtered load of sodium are recognized. This caveat is
exemplified by the data for absolute proximal
reabsorption rate of sodium (APRNa) (Table 8.2), which
fell to a greater extent in the diabetic than the control
group after Li750 mainly due to the greater fall in the
filtered sodium load resulting from the artefactually
large fall in GFR.
The data on renal sodium reabsorption are followed
by further results showing differences in renal water
handling between diabetic and control groups.
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Table 8.1: Sodium (C ) and lithium (C .) clearances, and
derived expressions for fractional tu&ular reabsorption
of sodium during ANGII infusion in diabetic (D) and














. -1 . -1,kg min ) R
1.25 2.5
2.4(0.2) 1.3(0.2) 0 . 9 (0 . 1) a 1.5(0.1)
2.8(0.2) 1.6(0.2)° 1.2(0.1)3 2.0(0.2)
2.6(0.4) 1.5(0.2) 1.0(0.1)a 1.6(0.2)













































Mean(sem). R, recovery period. FE
proximal sodium rejection; C /ct,' '




a, P<0.001; b, P<0.01; c, P<0.05 vs baseline.
MANOVA(group x time) interactions vs Control: d, P=NS;
e, P<0.05; f, P<0.01.
g, P<0.05 vs C750.
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Table 8.2: Derived expressions for absolute tubular
reabsorption of sodium during ANGII infusion in diabetic
(D) and control (C) patients after lithium 250mg (250)
and 750mg (750).
B/line ANGII(ng. kg "^min "*") R
1.25 2.5
11.8(0.5)a 11.1(0.5) 9.9(0.6)b,C 12 . 0 (0. 5)
9.9(0.7) 10.8(0.8) 10.4(0.7) 12.0(0.5)
11.1(1.0) 10.5(0.7) 10.5(0.7) 12.0(1.1)
10.3(0.5) 10.6(0.3) 10.1(0.2) 10.5(0.5)
3.3(0.2) 2.5(0.2) 2.3(0.3) d 3.0(0.2)
3.8(0.2) 2.7(0.2) 2.3(0.2)d 3.3(0.4)
4.2(0.3) 3.3(0.3) 2 . 8 (0 . 1) d 4.2(0.2)

















Mean(sem). R, recovery period. APR^ and ADR^a;
absolute proximal and distal reabsorption of sodium.
a, P<0.05 vs C750.
, P<0.05 vs baseline.
C, MANOVA(group x time) interaction vs C750, P=0.006.
d, P<0.01 vs baseline.
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8.2 RESULTS.
The serum lithium concentration twelve hours after
the 750mg dose was 0.25(0.01)mM in the diabetic group and
0.29(0.02)mM in the control subjects.
8.2.1 Proximal tubular sodium handling.
Baseline absolute lithium clearance (C .) was not
significantly reduced in the diabetic group (IDDM
28.5(1.6), Control 31.5(1.7) ml/min), and the fall in CL^
during ANGII infusion was similar in both groups (Figure
8.1a). However, because of the small difference in GFR
between the diabetic and control groups, baseline
fractional lithium excretion (FEL^), representing the
proportion of the filtered sodium load rejected by the
proximal tubule, was reduced in the diabetic group
(P<0.05), while the fall in FET. during ANGII infusion,
representing a proximal tubular antinatriuretic response
to ANGII, was blunted in the diabetic group (Figure
8.1b), the result already mentioned in Figure 7.8c.
Baseline absolute proximal reabsorption of sodium
(APRNa) was increased in the diabetic group (P<0.05).
APR^a did not change during ANGII infusion in the control
group, and the apparent reduction in APR^a in the
diabetic patients during ANGII (Table 8.2) was as
already discussed due mainly to artefactual changes in
the filtered load of sodium.




























Figure 8.1: a) absolute and b) fractional lithium clearance in 15 diabetic and 10
control subjects during ANGII infusion after lithium 750mg. Mean(sem).
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Figure 8.2: Correlation of HbA, with a) baseline and b) fall in fractional
lithium excretion during ANGII infusion in 15 diabetic patients after
lithium 750mg. Dotted lines indicate ±2SD from regression line.
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problems associated with the estimation of absolute
sodium reabsorption rate, and was examined by a stepwise
linear regression procedure using glycated haemoglobin,
fractional sodium excretion and duration of diabetes as
possible predictors. The final regression equation shows
that the only independent correlation is between baseline
FE . and the level of chronic glycaemic control (Figure
8.2a). A similar inverse correlation was found between
the fall in FE . during ANGII infusion and HbA- (Figure.LI 1
8.2b). FE . is therefore increasingly reduced as theJ_il
quality of chronic blood sugar control worsens, implying
an increase in fractional proximal tubular sodium
reabsorption, and the change in FEL^, a surrogate measure
of proximal antinatriuretic reactivity to exogenous
ANGII, is increasingly blunted.
8.2.2. Distal tubular sodium handling.
The ratio cNa/cL^' representing fractional distal
excretion of sodium, was similar in both groups at
baseline (Figure 8.3a). Fractional distal excretion
fell in both groups during ANGII infusion, but the size
of the fall was significantly greater in the diabetic
group (P=0.02). Baseline absolute distal sodium
reabsorption (ADRNa) was not different in the two groups
(Figure 8.3b), falling substantially and to a similar
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Figure 8.3: a) fractional, and b) absolute distal tubular reabsorption of
sodium during ANGII infusion in 15 diabetic and 10 control
subjects after lithium 750mg. Mean(sem).
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8.2.3 Renal concentrating capacity and water handling.
During the clearance studies stable positive water
balance was always maintained, resulting in a moderate
but not maximal diuresis at baseline. The minimal
increase in urinary osmolality (uosm^ during ANGII
infusion seen in the majority of the diabetic group
contrasts with the rise in seen in every controlOsm 1
subject. These findings were noted after both placebo
and lithium pretreatment (Figure 8.4a,b), and occurred
despite similar falls in urine flow rate and free water
clearance (C„„) in the two groups on both days (AV:riZ U
IDDM, PI 8.8(0.8), Li750 8.7(0.8) ml/min; Control, PI
7.9(1.0), Li750 8.8(1.1) ml/min: IDDM, PIriZU
6.4(0.6), Li750 6.1(0.7) ml/min; Control, PI 6.4(0.8),
Li750 6.7(1.0) ml/min). The individual changes in u0sm
emphasise how concentrating capacity was impaired in the
diabetic group during ANGII infusion (Figure 8.5a). When
the diabetic group was divided by the lower limit of the
control range into normal 'responders' (R) and abnormal
'non- responders' (NR), glycaemic control in R was better
than in NR (Figure 8.5b, 8.5c). Urine flow rate and free
water clearance were similar at baseline in 'responding'
and 'non-responding' subjects (V; R 16.1(1.2), NR
15.5(0.7) ml/min: Cu^; R 11.4(0.7), NR 10.3(0.7)rlZ U
ml/min); the abnormal response to ANGII infusion was not
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Figure 8.4: Urinary osmolality in 15 diabetic and 10 control subjects during
ANG II infusion after a) placebo and b) lithium 750mg. Impaired

















































Figure 8.5: a) change in urinary osmolality during ANGII infusion in
15 diabetic and 10 control subjects, b) the diabetic
group is divided according to AOsm (see p.205).
c) confirms the result shown in b).
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8.3 DISCUSSION.
Abnormalities of renal tubular sodium and water
handling were apparent in this diabetic group.
Importantly, the severity of both these abnormalities was
correlated with the quality of chronic glycaemic control,
implying that they were an acquired functional effect of
the diabetic state.
The finding of an abnormal urinary concentrating
response in Type 1 diabetes during ANGII infusion is not
unprecedented; reduced concentrating ability has been
described during infusion of the vasopressin analogue
ddAVP in uncomplicated IDDM (Thompson et al, 1990), a
defect which also correlated with the level of chronic
glycaemic control. Infusion of ANGII in water replete
normal humans stimulates the release of endogenous
vasopressin to a very limited extent even at infusion
rates 6-fold higher than those used in the present study
(Phillips et al, 1985). The substantial urinary
concentrating effect of ANGII infusion seen in these
normal men was therefore independent of vasopressin
release, making it difficult to propose an abnormality of
systemic vasopressin release as the cause of the impaired
concentrating response in Type 1 diabetes. The effect is
probably due to a direct medullary action of ANGII,
possibly related to reduced proximal tubular delivery of
sodium and water.
The impaired concentrating ability in response to
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two separate agonists now demonstrated in Type 1 diabetes
seems most compatible with an intrarenal defect, but the
present data can not determine the mechanism involved.
Possibilities include partial washout of the medullary
concentrating gradient following chronic intermittent
glycosuria, or changes in epithelial transport function
due to non-enzymatic glycation.
The positive correlation found in this study between
fractional lithium clearance and glycaemic control, as
judged by HbA^ has not been described in previous
investigations. This may be due to the confounding
effect of the parallel variation of lithium clearance
with dietary sodium intake (Atherton et al, 1987).
Sodium loading before the study presumably facilitated an
increase in proximal tubular sodium rejection towards a
physiological maximum at baseline, and this may have
allowed the underlying influence of chronic glycaemic
control on tubular function to become more evident. The
correlation of glycaemic control with fractional but not
with absolute lithium clearance further suggests that
an abnormality of glomerular filtration rate was of
underlying importance in the expression of the effect.
Since GFR was slightly higher in the diabetic than
in the control group, the increase in baseline proximal
tubular reabsorption of sodium in the diabetic group can
be interpreted as an appropriate response serving to
maintain glomerulo-tubular balance, as already suggested
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(Brochner-Mortensen et al, 1984; Skott et al, 1989b). It
has been proposed that this is supported by
sodium-glucose cotransport in the proximal tubule
(Hannedouche, 1990a). In the present subjects studied at
near-euglycaemia the potential for increased glucose-
linked sodium transport may be too small to detect.
Furthermore, lithium is not transported by the sodium-
glucose cotransporter in vitro (Hopfer et al, 1973), and
lithium clearance data may therefore be intrinsically
unsuitable for detecting such an effect even if present.
The reduction in the fractional proximal anti-
natriuretic response to ANGII infusion suggests an
alternative mechanism by which glomerulotubular balance
may have been preserved. Elevated levels of peptide
hormones usually produce reciprocal down-regulation of
tissue receptor density. The combination of enhanced
baseline sodium reabsorption and blunted reactivity to an
exogenous antinatriuretic agonist is characteristic of
pre-activation of the endogenous agonist. It is
therefore reasonable to speculate that elevation of
intrarenal ANGII could be the mediator of enhanced
fractional proximal sodium reabsorption in Type 1
diabetes. The correlation between tubular sodium
reabsorption and HbA^ would also be not inconsistent with
the positive correlation between glycaemic control and
plasma ANGII levels (Sullivan et al, 1980; O'Hare et al,
1982). However, the complexity of the receptor and
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post-receptor events involved in the proximal tubular
actions of ANGII and the dissociation between plasma and
intrarenal ANGII levels (Mendelsohn, 1979) makes this
postulate difficult to test directly.
Glomerulotubular balance is a substrate-driven
homeostatic process which will not independently induce
an increment in proximal tubular reabsorption exceeding
the increase in the filtered load. Additional factors
must be invoked if tubular sodium retention is to lead to
expansion of total body sodium content in Type 1
diabetes. It is in this role that sodium-glucose
cotransport is potentially more important; glucose-
linked sodium hyperreabsorption during mild or moderate
hyperglycaemia could be superimposed on the 'appropriate'
excess reabsorption needed to preserve glomerulotubular
balance, producing overall sodium retention. It is
therefore especially interesting that ANGII has been
shown to enhance the activity of this transporter
(Garvin, 1990) . The antinatriuretic effect of insulin
may also be relevant, either independently or by
modulating the activity of other systems.
There are several explanations for the fact that
the baseline tubular sodium handling data in these
studies gave no statistically significant evidence that
overall proximal nor distal tubular sodium handling were
inappropriately increased in the diabetic group under
these particular experimental conditions. First, the
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methodological limitations of clearance studies and the
relative insensitivity of the lithium clearance method
have been discussed at length. Second, there may be no
additional abnormality of sodium handling at this stage
of Type 1 diabetes; two studies have failed to find any
significant increase in total exchangeable body sodium
content in carefully selected uncomplicated Type 1
diabetic patients (Hommel et al, 1990; Catalano et al,
1991). Third, the experimental protocol may have
modified the antinatriuretic defect, ie by reducing
proximal sodium-glucose cotransport during euglycaemia.
Finally, the kidney escapes from unphysiological
antinatriuretic stimuli by activating opposing
natriuretic systems, often with only minor changes in the
plasma or urine levels of effector components; this is
the rationale for studying the response to an
intervention which disturbs the baseline situation when
attempting to identify abnormalities in intrarenal
sodium-retaining mechanisms.
The fraction of fluid and sodium delivered from the
proximal tubule to the distal segments, fractional distal
delivery, was reduced in the diabetic group, but the
calculated absolute distal delivery was not significantly
reduced. The increased fall in fractional distal
excretion of sodium during ANGII infusion in the diabetic
group suggests that distal tubular sensitivity to ANGII
is increased, but the data can not establish if this is a
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direct effect of ANGII. The increment in plasma
aldosterone stimulated by ANGII did not differ in
diabetic and control groups. Superimposed insulin-
mediated distal tubular sodium retention is also unlikely
to be a direct cause because baseline fractional distal
excretion of sodium was not reduced in IDDM at the
beginning of the study when the insulin infusion rate was
highest, and the insulin infusion rate was falling during
the ANGII infusion. An interaction between insulin and
ANGII can not be excluded, and this will be discussed
further in Chapter 9.
The discussion above views increased tubular sodium
reabsorption in early diabetes as a secondary response to
changes in glomerular haemodynamics, but a reduced
proportional delivery of sodium to the macula densa in
diabetes is an attractive mechanism by which deactivation
of the tubuloglomerular feedback system could primarily
elicit preglomerular vasodilatation and sustain an
increased glomerular filtration rate (Blantz et al,
1982). The fall in glomerular filtration rate following
the increase in distal sodium delivery (measured by
lithium clearance after a 750mg loading dose) during
acetazolamide infusion in normal man has been used to
support this argument (Hannedouche et al, 1991).
However, it seems dubious to ascribe the effect of this
experimental intervention on glomerular filtration rate
to a TGF response when the data on which this conclusion
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is based is derived from equations which themselves
include GFR as a dependent variable. The correlation
coefficients quoted between qlomerular filtration rate
and proximal tubular rejection are very high
(r=0.94—0. 98) for an in vivo human study, suggesting that
a mathematical artefact is present. The haemodynamic
effects of lithium in diabetes also make it doubtful
whether lithium clearance data can be used to analyse TGF
in this way.
In conclusion, the data in this chapter shows that
defects of tubular sodium and water handling are evident
in uncomplicated diabetic patients. The severity of
these abnormalities correlates with the level of chronic
metabolic control. The alteration in proximal tubular
sodium handling suggests that the kidney in early
diabetes is responding appropriately, at least to some
extent, to the abnormal environment in which it operates.
The data does not exclude the presence of additional
abnormalities of tubular sodium reabsorption, but it is
clear that any hypothesis which attempts to unify the
abnormalities of glomerular and tubular function in
diabetes must acknowledge the central importance of the
level of metabolic control as a factor modulating the
expression of these renal functional abnormalities.
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CHAPTER NINE.
THE EFFECTS OF INSULIN ON RENAL
FUNCTION IN NORMAL MAN.
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9.1 INTRODUCTION.
The interactions described between insulin and other
hormone systems now extend far beyond those involved in
carbohydrate and intermediate metabolism. A positive
association has recently been found in epidemiological
studies between fasting and post-prandial plasma free
insulin levels and blood pressure in Type 2 diabetes
mellitus (Modan et al, 1985; Zavaroni et al, 1987), and
in subjects with normal glucose tolerance with or without
hypertension (Ferranini et al, 1987; Fournier et al,
1986). This has stimulated interest in the importance of
insulin as a vasoactive hormone, but the association
between hyperinsulinaemia and increased blood pressure
can not by itself distinguish genetic co-segregation from
a direct pathophysiological relationship.
The acute cardiovascular effects of insulin include
an increased heart rate in response to postural changes
in uncomplicated Type 1 diabetic patients (Page et al,
1976a), vasodilatation in patients with diabetic
autonomic neuropathy (Page et al, 1976b), and a weak
systemic pressor effect at pharmacological levels in
normal man (Gans et al, 1991a). These effects.are tissue
and species-specific; insulin attenuates vasoconstrictor
responses to ANGII and noradrenaline (NE) in animal
smooth muscle preparations ex vivo (Yagi et al, 1988),
whereas ANGII-mediated contraction of glomerular
mesangial cells is insulin-dependent (Kreisberg, 1982).
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Insulin at physiological concentrations does not modify
either the pressor response to acute ANGII infusion in
normal humans (Vierhapper et al, 1983), or that induced
during chronic ANGII infusion in the dog (Hall et al,
1990), although an interaction between pharmacological
hyperinsulinaemia and the pressor response to ANGII
infusion has been reported in the dog mediated through
facilitation of sympathetic activation (Rocchini et al,
1990).
Acute hyperinsulinaemia reduces renal sodium
excretion in normal man (Miller and Bogdonoff, 1954;
DeFronzo et al, 1975; Skott et al, 1989a; Gans et al,
1991a) and in NIDDM (Skott et al, 1991). This provides a
direct mechanism by which insulin might influence blood
pressure, although in animal models the antinatriuretic
effect appears to be transient (Hall et al, 1990). The
reduction in sodium excretion when insulin is infused
intrarenally (DeFronzo et al, 1976) or into the isolated
perfused kidney (Cohen et al, 1989) indicates a direct
effect on the kidney. However, systemic insulin infusion
increases sympathetic outflow (Rowe et al, 1981), plasma
renin activity and plasma ANGII levels (Trovati et al,
1989). Activation of these systems intrarenally may
augment the sodium-retaining action of insulin. Clearly
an intrarenal interaction between insulin and ANGII in
the control of sodium handling deserves consideration.
The only difference between the experimental
217
protocols used in diabetic and control subjects in
previous chapters was the small amount of insulin infused
in the diabetic patients to maintain euglycaemia. The
first objective of this study was therefore to determine
how the known effect of insulin on renal sodium handling
might affect the interpretation of the lithium clearance
data in Chapters 7 and 8. Secondly, evidence was sought
for an intrarenal interaction between insulin and the
renin-angiotensin system by examining the effect of acute
hyperinsulinaemia on renal sodium handling in normal
humans after blockade of intrarenal ANGII generation with
an angiotensin converting enzyme inhibitor (ACEI).
9.2 PROTOCOL.
Seven normal volunteers (mean age 32(SD 4) years),
weight 76kg (SD 4, range 70 to 83kg), and body mass index
2
23.9(2.4) kg/m ) were studied. All had normal glucose
tolerance (two hour post-prandial blood glucose <6mM,
mean HbA.^ 5.8(0.2)% (normal range 5-8%)) and normal blood
pressure (<140/90 mmHg, diastolic phase V). Enquiry was
made about a family history of diabetes (none) and
essential hypertension (one subject).
Each subject was studied three times in a randomised
order, the studies being at least two weeks apart. One
study served as a time control day (C); before the other
two studies the subjects were treated for one week,
double blind, either with a placebo preparation (Pi) or
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with the angiotensin converting enzyme inhibitor
perindopril 4mg o.d. (Servier Laboratories Ltd, Slough)
(ACEI), a final dose of placebo or ACEI being taken on
the morning of the acute study. Dietary advice was given
with the aim of achieving a daily intake of 150-200 mmol
sodium and 80-100 mmol potassium for one week before each
study. Urine was collected for 24h before each study.
At 2100h in the evening the subjects took 250mg of
lithium carbonate, the dose which was shown to have no
demonstrable pharmacological effects on the kidney in the
studies reported in Chapter 5.
Renal haemodynamic parameters were measured using
the clearance protocol already described. On the two
days when insulin was infused a third cannula was
inserted in a retrograde fashion into a dorsal hand vein
for measurement of glucose concentrations in arterialized
whole blood (oxygen saturation >98%); arterialization of
blood was achieved by heating the right hand to 55°C
(Abumrad et al, 1981). After four baseline clearance
periods, euglycaemic hyperinsulinaemia was established by
starting an infusion of unmodified soluble human insulin
(Actrapid, Novo-Nordisk, Denmark). The insulin was
diluted (0.33 U/ml) into 100ml 0.15M sodium chloride
containing 2ml of the subject's blood to prevent
adsorption of the insulin onto plastic; an initial
-2.-1
infusion rate of 120 mU.m min was reduced every minute
-2 . -1
to reach the maintenance infusion rate of 40 mU.m mm
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after 10 minutes as previously described in detail
(DeFronzo et al, 1979). The pre-infusion fasting blood
glucose level was then maintained by infusing D-glucose
200g/l (1.15 mol/1) at a rate adjusted according to
measurements of whole blood glucose made every 5 minutes
at the bedside with a reflectance glucometer (Reflolux-S,
Boehringer). Samples were collected every 30 minutes for
later confirmation of the values obtained for whole blood
glucose by a glucose oxidase method. Hyperinsulinaemia
was maintained for two hours while four further clearance
periods were completed. Subjects were fed after the
insulin infusion had been stopped to avert the tendency
to develop rebound hypoglycaemia. Insulin vehicle was
infused alone during the time control study, the 20%
D-glucose solution being omitted to avoid stimulating
release of endogenous insulin.
Blood pressure was measured by an automated
sphygmomanometer every 20 minutes, and the mean of all
'baseline' and 'clamp' results on different study days
compared by paired t-test. When analyzing the data, a
significant overall interaction in the data sets from all
three study days was confirmed by three way analysis of
variance before pairs of data sets were compared by two




9.3.1 Dextrose utilisation during insulin infusion.
One subject noticed transient dizziness after
starting perindopril, but continued taking the drug. No
other side effects occurred. Basal fasting plasma free
insulin levels were not affected by ACEI, and comparable
increments in plasma free insulin levels were achieved
during the two euglycaemic clamps in each subject (Table
9.1). Baseline whole blood glucose concentration was
similar on each day, and remained stable throughout both
insulin infusions (Table 9.1 and Figure 9.1). The
dextrose infusion rate needed to maintain euglycaemia
during the first hour of hyperinsulinaemia was higher
after ACEI in five of the seven subjects, but was the
same by the end of the second hour of insulin infusion on
both days (Figure 9.1). The cumulative dextrose
requirement during hyperinsulinaemia was not different on
the two days (PI 719(91) mg/kg, ACEI 824(87) mg/kg).
9.3.2 General.
Pretreatment with the ACEI produced a marked rise in
plasma renin activity (Table 9.1) and a substantial fall
in plasma converting enzyme activity in every subject (C
41(7) u/1, PI 42(7) u/1, ACEI 5(1) u/1; C/Pl vs ACEI both
P<0.01). PRA rose during hyperinsulinaemia compared to
time alone; the insulin-induced rise in PRA was greater
221
Table 9.1: Plasma renin activity (PRA), plasma
aldosterone (ALDO), whole blood glucose (GLUC) and plasma
free insulin levels (INS) during euglycaemic
hyperinsulinaemia (0-120 min) in seven normal subjects.
Baseline Insulin infusion (minutes)
30 60 90 120
PRA C 860(180) - 910(230) - 530(140)
(pmol AI PI 680(180) - 880(150) - 880(240)a
.ml-1h_1 ACEI 2300(260)C - 4080(740) - 3190(590)b
ALDO C 234(55) - 157(30) - 172(26)
(pmol/1) PI 197(39) - 140(27) - 128(22)
ACEI 148(30) - 129(26) - 115(17)
PI 4.30 4.48 4.34 4.62 4.44
GLUC (0.15) (0.19) (0.15) (0.13) (0.14)
(mmol/1)
ACEI 4.24 4.33 4.36 4.30 4.50
(0.24) (0.28) (0.22) (0.26) (0.21)
INS* C 3.8(0.7) - 5.2(0.7) - 4.2(1.0)
(mU/1) PI 5.2(0.5) - 69.9(5.5) - 70.2(5.3)
ACEI 6.7(2.1) - 73.6(6.8) - 79.0(3.4)
Mean(sem). C, Time control; PI, Placebo; ACEI,
Perindopril. a, MANOVA, . . P<0.01; b,^ ' (group x time vs C) ' '
MANOVA, . . . P<0.01, (% change in PRA from(group x time vs PI) ' v ^
baseline, PI 32(9)%, ACEI 50(18)%, P=NS). C, P<0.005 vs
*
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in absolute terms after ACEI than placebo, but the
percentage increases from the baseline value were not
different. Baseline plasma aldosterone was not different
between the three studies, and no significant change in
aldosterone occurred during either insulin infusion.
Mean arterial pressure was reduced after ACEI (PI
96.0(2.9) mmHg, ACEI 89.0(2.1) mmHg,AMAP=7.1(1.2) mmHg,
P<0.005). There was no change in blood pressure during
hyperinsulinaemia on either day (PI, 96.0(2.9) to
97.5(3.2) mmHg; ACEI, 89.0(2.1) to 89.2(2.2) mmHg).
Heart rate did not change during insulin infusion (data
not shown). Venous haematocrit fell during both insulin
infusions (C 41(1.6) to 40.7(1.4)%; PI 39.3(0.6) to
37.4(0.8)%, P<0.05; ACEI 40.2(0.9) to 38.7(0.8)%,
P<0.05).
9.3.3 Renal haemodynamics.
Glomerular filtration rate was similar at baseline
on all three days, and did not change during hyper¬
insulinaemia (Figure 9.2a). Effective renal plasma flow
was significantly increased after ACEI in comparison to C
and PI, but did not change with time alone or during
hyperinsulinaemia (Figure 9.2b). Baseline filtration




































































Figure 9.3: a) absolute and b) fractional urinary sodium excretion in seven





















—i 1 1 1










































—I 1 1 1 1


























Figure 9.4: a] plasma potassium, and b) absolute, c) fractional urinary
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9.3.3 Electrolyte and water excretion.
24h potassium excretion was similar before each
study (C 80(7), PI 74(12), ACEI 79(7) mmol). Sodium
excretion in the 24h before the study was greater after
ACEI (C 176(16), PI 217(28), ACEI 257(23) mmol; C vs
ACEI, P<0.05). Plasma sodium was similar on all three
days, and did not change during insulin infusion. The
urinary excretion rate of sodium rose steadily during the
time control study (Figure 9.3a) due to the infusion of
about 650ml (90 mmol) of 0.15M sodium chloride as vehicle
for Inutest and PAH. After placebo pretreatment a rising
sodium excretion rate during the baseline phase was
followed by a fall in urinary sodium excretion during
hyperinsulinaemia (C vs PI, F, . . =7.93,v ' (group x time)
P<0.0001). Baseline sodium excretion was higher after
ACEI than on either of the other two days (C vs ACEI,
F, ,=8.72, P=0.026), but antinatriuresis was still(group) ' ' '
apparent during insulin infusion (C vs ACEI, F(gr0up x
time)=6*69' P<0.0001). There was a significant
interaction between PI and ACEI when all eight time
points were analyzed (F. . . ,=3.58, P=0.004);c 1 v (group x time) ' '
however, this result was caused by the higher sodium
excretion rate during the early baseline periods after
ACEI because analysis of clearance periods 3 to 8 (the
second hour of baseline and the period of insulin
infusion) showed that the antinatriuretic potential of
insulin was unaffected by ACEI (F. . . =1.58,1 v (group x time)
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P=NS). The results for fractional sodium excretion
showed the same pattern as the absolute sodium excretion
data (Figure 9.3b).
Baseline plasma potassium was the same on each day,
and a fall in plasma potassium concentration occurred
during both insulin infusions which was not affected by
ACEI pretreatment (Figure 9.4a). Baseline urinary
potassium excretion (UKV) (Figure 9.4b) was similar on
all three days. The fall in UKV during hyperinsulinaemia
after PI and ACEI exceeded the small fall with time alone
(C vs PI, F. . . =5.75, P<0.001; C vs ACEI,v ' (group x time) ' ' '
F, . . =14.93, PC0.0001); the antikaliuretic(group x time) ' ' '
effect of insulin did not differ after ACEI (PI vs ACEI,
F. . . =0.45, P=NS) . The same conclusion emerged(group x time) ' ' ^
when changes in fractional potassium excretion were
analyzed (Figure 9.4c) to take account of the reduced
filtered load of potassium resulting from the fall in
plasma potassium during hyperinsulinaemia. The urinary
Na+:K+ ratio (Figure 9.5) increased to a greater extent
during hyperinsulinaemia than with time alone (C vs PI,
F, . . .=4.43, P=0.001; C vs ACEI, F,(group x time) ' ' ' (group x
. . .=3.94, P=0.002) with no interaction attributable totime) ' '
ACEI. Urine flow rate (Figure 9.6a) and free water
clearance (Figure 9.6b) fell with time on all three days,
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Figure 9.6: a) urine flow rate and b) free water clearance in seven
normal subjects during euglycaemic hyperinsulinaemia.
Mean(sem).
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9.3.4 Lithium clearance data.
The serum lithium concentration at the beginning of
the study was similar on all three days (C 0.104(0.01),
Pi 0.107(0.01) , ACEI 0.117(0.005) mmol/1). There was no
change in either absolute or fractional lithium clearance
with time alone or during insulin infusion (Figure
9.7a,b). The ratio C /C . (Figure 9.7c), representingNd i_il
fractional distal sodium excretion, fell during
hyperinsulinaemia; the response of CNa^CLi to insulin
infusion was not different after ACEI.
9.4 DISCUSSION.
This study confirms that an acute increase in plasma
free insulin to levels within the pathophysiological
human range reduces renal excretion of sodium and
potassium. The time control day, which allowed for the
circadian variation in sodium excretion and the
natriuretic effect of the isotonic fluid infused during
the study, showed that the antinatriuretic potential of
insulin is greater than would otherwise have been
concluded. The dose of insulin infused was low enough to
avoid the systemic haemodynamic effects previously
reported during higher infusion rates (Gans et al,
1991a). The lack of a measurable effect of
hyperinsulinaemia on glomerular haemodynamics confirms a
recent report (Vierhapper et al, 1991), and suggests that
the antinatriuretic and antikaliuretic effects of insulin
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involve changes primarily in the renal tubular handling
of these ions. However, increased sodium reabsorption
which is independent of sodium-glucose co-transport has
been demonstrated following glucose exposure in the
isolated perfused kidney (Frega et al, 1977). Glucose
was deliberately not infused during the time control
experiment to avoid stimulating endogenous release of
insulin. Conseguently, sodium retention due to
increased utilization of glucose rather than to insulin
infusion per se can not be completely excluded.
Insulin increases reabsorption of tubular fluid in
isolated perfused rabbit proximal tubules (Baum, 1987) ,
and stimulates Na+-H+ exchange in proximal tubule brush
border membrane vesicles (Fine et al, 1985). There is
however disagreement in human studies as to whether the
antinatriuretic effect of insulin seen in human studies
occurs in a distal (DeFronzo et al, 1975; Skott et al,
1989a) or a proximal tubular segment (Trevisan et al,
1990). In the present investigation the absence of a
change in lithium clearance during hyperinsulinaemia, and
the fall in the fractional distal rejection of sodium
inferred from the change in the ratio C /CT. bothMd l_ll
suggest that the antinatriuretic action of insulin
occurred in a segment distal to the proximal tubule.
This interpretation is consistent with the reduction in
fractional urinary potassium excretion during
hyperinsulinaemia, since changes in urinary potassium
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excretion are modulated predominantly in distal tubular
segments. It can not be determined whether insulin was
acting in the loop of Henle or the distal tubule, which
is the tubular segment with the highest density of
insulin receptors (Rabkin et al, 1984), but the absence
of a rise in plasma aldosterone, the occurrence of
antikaliuresis, and the rising urinary Na+:K+ ratio all
indicate that insulin was acting directly and not through
stimulation of aldosterone dependent Na+-K+-ATPase as
previously suggested (Katz, 1982).
The potential relevance of insulin-stimulated
release of renin and increased ANGII generation to the
sodium retaining effect of insulin was examined by
restudying the subjects in a new steady state after
pretreatment for one week with an inhibitor of
angiotensin converting enzyme. Plasma ANGII levels
were not measured, but the in vitro effectiveness of the
ACEI was mirrored in vivo by the increased renal plasma
flow and the decreased filtration fraction which together
are consistent with intrarenal vasodilatation following
reduction of endogenous ANGII.
Because the antinatriuretic effect of euglycaemic
hyperinsulinaemia persisted after ACEI pretreatment,
increased intrarenal ANGII generation probably plays
little if any part in mediating the renal response to
insulin. Interpretation of this part of the study is
complicated by the increase in baseline sodium excretion
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after ACEI. Sodium intake before each study could not be
rigidly controlled in an outpatient setting, making it
uncertain whether the increased 24h sodium excretion
after ACEI was due to a natriuretic effect of the drug
following renal vasodilatation, an increase in dietary
sodium intake, or a combination of these factors. It
could be argued that the antinatriuresis during
hyperinsulinaemia after ACEI was a purely time-related
phenomenon occurring in subjects who were relatively
sodium depleted in comparison to the placebo study by the
natriuretic effect of the ACEI. This is unlikely because
effective converting enzyme inhibition was present
throughout the acute study at a time when the subjects
were receiving an infusion of sodium, so that insulin
still caused antinatriuresis despite the presence of
these two natriuretic influences. Quantitative
comparison of the antinatriuretic potential of insulin
with and without prior ACEI must nonetheless be cautious,
and a time control study after ACE inhibition would be
desirable to address this point more fully. However,
despite the differing baseline sodium excretion rates,
the data strongly suggests that the antinatriuretic
potential of insulin is not affected by a period of ACE
inhibition.
How do these results bear upon the studies described
in previous chapters? The study was planned bearing in
mind the much greater antinatriuretic potential of ANGII
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compared to insulin, which would have resulted in a very
low power to detect modulation of the renal effects of
ANGII infusion by insulin. The design used was intended
to test first whether insulin infusion affected lithium
clearance, and second whether the antinatriuretic effect
of insulin infusion was mediated or modulated by
intrarenal ANGII generation. The insulin infusion rate
(about 4.5 u/h) and the plasma free insulin levels in
these normal subjects during insulin infusion far exceed
those measured in the diabetic patients reported in
Chapter 6. Plasma insulin levels are not available for
the studies described in Chapters 7 and 8, but the usual
insulin dosage of this group of patients and the insulin
infusion rate used to maintain stable glycaemia during
the acute study were both similar to those of the
diabetic patients described in Chapter 6. It is
therefore likely that plasma insulin concentrations in
all the studies involving diabetic patients were much
lower than the levels produced in these normal men.
There is no a priori reason to expect the site of
action of insulin within the nephron to be qualitatively
different in diabetic subjects, and it is reassuring with
regard to Chapter 8 that insulin infusion does not affect
lithium clearance, as the correlation between fractional
lithium excretion and glycaemic control could not have
been biased by differing plasma free insulin levels in
the diabetic subjects. However, because the
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antinatriuretic effect of insulin apparently involved a
distal tubular segment, the ratio CNa^CLi Inore
susceptible to interference and should be interpreted
correspondingly cautiously; the experiment as designed
can not determine whether insulin was in any way
responsible for the accentuated fractional distal
antinatriuretic effect of ANGII seen in the diabetic
group. One unexplained feature of the studies in both
Chapters 6 and 7 is that despite comparable levels of
sodium intake, as judged by 24h sodium excretion,
baseline fractional sodium excretion during the acute
study was always lower in the diabetic patients than the
controls, particularly after overnight insulin infusion.
It is tempting to speculate that insulin-mediated
antinatriuresis at a distal tubular site in the diabetic
patients might have contributed to this phenomenon. This
argument is compatible with the finding that the
antinatriuretic potential of insulin is preserved in Type
2 diabetic patients (Skott et al, 1991; Gans et al,
1991b), but the effect of insulin on sodium handling in
Type 1 diabetes has not hitherto been reported.
The euglycaemic hyperinsulinaemic clamp technique
was used primarily to look at the effects of insulin on
the kidney, and a two hour insulin infusion is not long
enough to be absolutely confident about interpreting
insulin-mediated glucose disposal as an index of insulin
sensitivity. However, since the dextrose infusion rate
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at the end of the second hour of insulin infusion
appeared to be close to or at a plateau, the comparable
final dextrose requirement after both placebo and ACEI in
the face of identical plasma free insulin levels suggests
that pretreatment with perindopril for one week had not
appreciably altered peripheral insulin sensitivity.
Chronic converting enzyme inhibition with enalapril also
has little or no effect on insulin sensitivity in normal
man (Gans et al, 1991c) or in uncomplicated Type 1
diabetes (Seefeldt et al, 1990). It is not surprising
that ACEI has no effect on insulin-mediated glucose
disposal in nonobese normotensive young men in whom
insulin sensitivity is likely to already be high, and
this finding is not inconsistent with the potentially
beneficial effects of converting enzyme inhibition on
insulin-mediated glucose disposal into muscle in
insulin-resistant states such as hypertension, heart
failure, and obesity (DeFronzo and Ferranini, 1991).
In conclusion, this study shows that acute
hyperinsulinaemia has a significant antinatriuretic and
antikaliuretic effect in normal man, manifested
predominantly at a tubular segment(s) distal to the
proximal tubule. The antinatriuretic effect of insulin
is not modified by pretreatment with an angiotensin
converting enzyme inhibitor, implying that insulin-







Coordinated interactions between many physical and
humoral systems allow the kidney to maintain sodium
homeostasis by modulating renal haemodynamics and tubular
sodium handling in response to changing environmental
stresses. In defining the causes of abnormal renal
function, the assumption that plasma or urinary
activities of humoral mediators reflect the balance
between vasoconstrictor/antinatriuretic stimuli and
vasodilator/natriuretic forces has several limitations.
Dynamic measures of renal response are potentially much
more informative. For most systems the definition of
normality includes some consideration of the prevailing
state of sodium balance; this is particularly true of the
actions of the renin-angiotensin system examined in this
work.
The aim of the studies was to examine the renal
response to exogenous angiotensin II in Type 1 diabetes
under conditions of controlled sodium intake, in order to
resolve some of the conflicting evidence from previous
studies in animal models and human patients. As well as
the conceptual deficiencies of this experimental approach
already mentioned, the technical limitations of the
methods used for analyzing renal function in vivo must
also be acknowledged, especially in out-patient studies
when the precise state of whole body sodium balance is
unknown, interindividual variation is often large, and
extraneous influences may not be identifiable or
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controllable. Measurement of total exchangeable body
sodium might have helped in interpreting some of the
results, but was not attempted because of the large
technical errors involved in estimating this parameter in
small groups of subjects who were being studied after a
change in sodium balance without the benefit of metabolic
ward facilities. Furthermore, since the results obtained
in a clearance study represent the final outcome of
numerous events in compartmentalised regions of the
kidney, the pathophysiological significance of any
abnormality should be interpreted cautiously. Exogenous
angiotensin II for instance has access to pre- and
postglomerular arterioles and to proximal and distal
tubular epithelia from the luminal and the basolateral
surface, and the present data can not add to the debate
on the possible changes in tubuloglomerular feedback
sensitivity in diabetes. Another problem with reactivity
studies is that following an experimental intervention
the compensatory adjustments in other mechanisms may
modify the expression of changes in the index system,
particularly if physiological manipulations leading to
subtle changes are examined.
Increased systemic pressor reactivity to exogenous
ANGII in diabetes has been regarded as sodium-dependent,
as vascular reactivity is restored to control levels by
diuretic treatment (Weidmann et al, 1979). In the
present studies an increased systemic pressor response to
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ANGII occurred only as an artefact following lithium
pretreatment, the small difference in response between
diabetic and control groups after placebo treatment not
being statistically significant. This is not necessarily
inconsistent with the previous evidence, because the
current studies were performed after a period of high
sodium intake. A comparison of the dose response curves
for blood pressure in the present work with published
data (Drury et al, 1984) obtained using very comparable
infusion rates of ANGII in subjects taking a normal
sodium intake is shown in Figure 10.1. This figure
suggests that the different conclusion of the two sets of
data lies in the control studies. The pressor response
to ANGII is increased in the present control studies
compared to the normal sample studied by Drury et al.,
indicating normal modulation of pressor reactivity to
ANGII with increasing sodium intake. In contrast, the
pressor response in the diabetic patients appears
relatively fixed irrespective of the differing sodium
intakes of the two study samples. It appears that
systemic pressor reactivity is not modulated normally
by sodium intake in diabetic subjects. The present
data is incomplete because of the absence of measurements
during both normal and low sodium intake to confirm this
postulate, but failure of sodium restriction to modulate
pressor responsiveness to ANGII has recently been
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hypertension (Tuck et al, 1990).
A rise in blood pressure (and renal perfusion
pressure) is a central factor in permitting renal escape
from various antinatriuretic stimuli, including chronic
ANGII infusion. This has been used to support the
existence of a primary renal defect in some hypertensive
states, and may be a contributory factor to the
intractable sodium retention in conditions where blood
pressure is inappropriately low such as severe cardiac
failure, cirrhosis and nephrotic syndrome. The selection
criteria for the diabetic patients described in Chapter 7
included a blood pressure within the normal range for
their age and sex, but a small increase in mean arterial
pressure was nevertheless seen in comparison to a matched
control group. This increase has been noted previously
(Hommel et al, 1989). The higher blood pressure was not
directly caused by sodium loading, as mean arterial
pressure measured by the same semi-automated method while
the patients and control subjects were taking their
normal diet was not different, and remained higher in the
diabetic group (IDDM 95.3(2.2) mmHg, control 88.6(2.1)
mmHg; P<0.05). An increased blood pressure could be
interpreted as a normal pressure-natriuresis response to
an increase in total exchangeable sodium secondary to
defective renal sodium handling, and is compatible with
the correlation which exists between total exchangeable
sodium and systolic or mean arterial pressure (Ferriss et
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al, 1985; Feldt-Rasmussen et al, 1987; Hommel et al,
1990). However, this can not be tested because total
exchangeable sodium was not measured. Additionally,
several conflicting lines of evidence must also be
considered. First, the fall in blood pressure which
accompanies dietary sodium restriction in a proportion of
Type 2 diabetic patients does not correlate with the rise
in blood pressure during sodium loading in the same
subjects (Tuck et al, 1990), indicating that different
mechanisms may operate within the same patient depending
on sodium intake. Second, large scale epidemiological
evidence shows that the distribution of blood pressure in
uncomplicated diabetic patients does not differ from the
normal population (Norgaard et al, 1990), an increase in
blood pressure only following the development of
incipient nephropathy. Thirdly, total exchangeable
sodium increases at a time when blood pressure is falling
when glycaemic control is improved (O'Hare et al, 1982).
Sodium retention may thus account for changes in
cardiovascular responsiveness in diabetes, but is not the
only factor modulating the final blood pressure.
There are also inconsistencies in existing data
concerning the effect of changing glycaemic control on
body sodium content. O'Hare et al (1982) studied a
highly selected group of Type 2 diabetic patients who
were being admitted to hospital for stabilisation of
poorly controlled (mean HbAl 12.4%) but non-ketotic
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diabetes. After a period of improved glycaemic control
plasma volume and total exchangeable sodium increased
above control levels, and there was a fall in plasma
angiotensin II concentrations. A similar increase in
extracellular fluid volume during short-term improved
control occurs in normoalbuminuric Type 1 diabetes
(Mathiesen et al, 1989). In contrast however, in Type 1
diabetic patients plasma atrial natriuretic peptide
levels were higher and plasma renin activity lower in
patients with poor glycaemic control (HbAl >9%) (Bell et
al, 1989), suggesting that extracellular volume expansion
worsened with deteriorating glycaemic control. These
reports vary in the populations studied and in the range
of glycaemic control examined, only three subjects in the
last study having a HbAl greater than 11%. The greatest
difference however is that the first two studies improved
diabetic control by increasing exogenous insulin doses or
by stimulating endogenous insulin production using oral
sulphonylureas, and the results may simply reflect an
acute antinatriuretic effect of insulin. Taken together
the three sets of data are not inconsistent with a
progressive expansion of extracellular volume as
glycaemic control worsens up to an HbA.^ of 10%-11%, when
sodium-glucose cotransport theoretically is at a maximum,
followed by a reduction in total body sodium towards
control levels if a marked deterioration in diabetic
control (which is usually caused by insulinopenia)
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produces glycosuric diuresis and distal tubular sodium
losses.
Systemic factors may also promote sodium retention
in some diabetic patients. Poor metabolic control,
hypertension, and the presence of microangiopathy all
independently increase the transcapillary escape rate of
albumin in diabetic patients (O'Hare et al, 1983). In
early diabetes improved metabolic control for one week
normalises this microvascular leakage (Parving et al,
1976). This functional capillary defect may be caused by
intracapillary hypertension, which is also aggravated by
poor glycaemic control (Sandeman et al, 1991). Enhanced
capillary permeability theoretically promotes movement of
sodium and water from the intravascular to the
interstitial space, leading to relative plasma volume
depletion. Renal sodium retention is then an appropriate
compensatory response restoring plasma volume to a normal
level, the end result being plasma oncotic dilution and
an increase in interstitial volume. There is no positive
evidence that this sequence of events occurs in
uncomplicated diabetes because plasma oncotic pressure is
not reduced. However, plasma protein dilution and
reduced intravascular oncotic pressure have been found in
diabetic patients with established nephropathy and
generalized oedema (Hommel et al, 1990). In these
patients combination of a functional leak (capillary
hypertension) with structural damage (microangiopathy)
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may make the effect more relevant. A novel intrarenal
mechanism has also been proposed (Pinter and Atkins,
1991), by which increased peritubular protein leakage may
increase renal interstitial pressure, contributing to
interstitial fibrosis (Thomsen et al, 1989) and
glomerular injury.
The work in this thesis confirms that proximal renal
tubular reabsorption of sodium is increased from an early
stage of Type 1 diabetes. The abnormality is a
functional effect of the diabetic state, directly related
to the level of chronic diabetic control, and is not a
secondary response to structural renal damage. The data
are also consistent with the hypothesis that relative
activation of the intrarenal renin-angiotensin system may
play some part in causing this sodium retention. There
is no direct evidence that the increase in renal sodium
reabsorption during these experiments was not an
appropriate response which maintained glomerulotubular
balance in the face of a small increase in glomerular
filtration rate, albeit still within the normal range.
Because the majority of the diabetic patients had a
normal glomerular filtration rate and renal plasma flow,
the corollary is that abnormal renal sodium handling is
unlikely to directly determine the development of
glomerular hyperfiltration. However, the methods
available in humans may not be sufficiently sensitive to
detect small 'inappropriate' increases in tubular sodium
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reabsorption due to for instance enhanced sodium-glucose
cotransport or to hyperinsulinaemia, and the potential
importance of these processes should not be discounted.
It is relevant at this stage to briefly reiterate
the effects of glucose-mediated sodium retention at the
cellular level. The induction of insulin-dependent
diabetes in the rat is rapidly followed by an increase in
the intracellular sodium content ([Na]^) of proximal
tubular cells, and a proportionate increase in
Na+-K+-ATPase (Kumar et al, 1988). Furthermore, the
tubules of chronically diabetic animals are adapted so as
to maintain this higher [Na]^ even in the presence of a
normal extracellular glucose concentration. Thus changes
in the intracellular electrolyte environment provide
another pathway by which the diabetic state may influence
protein kinase C activation and second messenger pathways
to alter cellular reactivity, the regulation of cell pH,
and the control of cellular hypertrophy.
The development of clinical nephropathy in Type 1
diabetes is a multifactorial process determined by the
renal response to genetic and environmental factors. In
the presence of as yet unidentified inherited influences
(Seaquist et al, 1989), it is naive to automatically
ascribe pathogenetic importance to individual functional
abnormalities in early diabetes, unless this is also
justified by evidence from long-term prospective studies.
The abnormality in renal sodium handling in the present
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studies correlated with the quality of chronic glycaemic
control, but it is clearly illogical to suggest that the
correlation between poor glycaemic control and the
long-term risk of nephropathy de facto makes abnormal
proximal renal sodium handling a risk factor for the
development of diabetic nephropathy.
It is also important to recognise that the
determinants and consequences of renal sodium retention
are unlikely to be the same in different sub-groups of
diabetic patients. The practical consequences of sodium
retention in Type 1 diabetes are greatest in those
patients who develop incipient or overt nephropathy, in
whom the pathophysiological effects of microangiopathy
and a falling nephron mass are superimposed on the
functional defects already discussed. In these patients
the secondary abnormalities which follow expansion of the
extracellular sodium space, such as enhanced vascular
reactivity and changes in intracellular electrolytes,
will perpetuate the vicious cycle of oedema formation and
volume-dependent hypertension which accelerates nephron
loss and the progression to end stage renal failure.
Therapeutic strategies which modify or abrogate the
pathophysiological effects of sodium retention in this
situation (Dodson et al, 1989) may therefore be of value
in the management of diabetic hypertension and
established chronic renal disease.
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